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 Biologic drugs have gained enormous research attention in recent years as reflected 
by the development of multiple candidates to the clinical pipelines and an increased 
percentage of FDA approval. This is reasoned by the fact that biologics have been proven 
to deliver more predictive and promising benefits for many hard-to-cure diseases by 
‘drugging the undruggable’ targets. However, the challenges associated with biologic drug 
development are multi-fold, viz, poor encapsulation efficacy, systemic instability, low 
cellular internalization and endosomal escape capability. Thus, it is essential to develop 
new molecular strategies that can not only address the associated drug delivery challenges, 
but also help strengthen the fundamental chemical understanding to meet the future need 
of this rapidly evolving field. 
 Designing a supramolecular container that is capable of stably holding sensitive 
active and releasing them at target site upon environmental changes is a promising solution 




Addressing this requires a basic understanding of the structural and functional factors to be 
engineered into the delivery vehicle. To this end, we have explored the interactions 
between synthetic polymers with various biologics to form well-defined self-assembled 
structures, wherein the function of the encapsulated active is only revealed upon specific 
structural modulation of the polymer surrounding it. In this dissertation, we have discussed 
the development of three distinct self-assembly strategies to reversibly capture sensitive 
biologics, viz. protein, nucleic acid and antibody. A covalent self-assembly strategy is 
employed for proteins irrespective of their isoelectric points (chapter 2). Our second 
strategy utilizes non-covalent interactions (electrostatic and hydrophobic) for 
complexation with negatively charged nucleic acids (chapter 3). Finally, we studied a 
combination of covalent and non-covalent interactions for encapsulating large proteins and 
antibodies (chapter 4 and 5). This dissertation will focus on the inherent challenges 
associated with functional delivery of proteins and nucleic acids. It will highlight the 
advantages of rational designs to control the complex interplay between the structural 
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1.1 Biologics as potential therapeutic agents 
In the post-genomic era, development of bio-therapeutics has gained an enormous 
momentum due to their potential in controlling the human disease portfolio. Since the 
approval of first recombinant human insulin by FDA in 1982, research interests have 
surged to utilize bio-therapeutics for clinical applications.1 A tremendous growth in the 
biotechnology sector have placed over 7000 biopharmaceuticals in the development 
pipeline, 74% of which are first-in-class medicines.2 Although small molecule drugs are 
still dominating the pharmaceutical sector, Biologics License Approval (BLA) rates are 
rapidly increasing, with 21-22 approved drugs each year between 2017 and 2019.3 Based 
on a recent analysis, biotherapeutics are expected to capture more than one fourth of the 
pharmaceutical industry by 2020.4 
Protein, peptide, antibody, and nucleic acids (siRNA, micro-RNA, mRNA and 
DNA) are classical examples of biomacromolecules studied under the class of biologics 
(Figure 1.1). The recent success of biologic drug products can be attributed to their higher 
specificity and potency compared to small molecule therapeutics. Biologics can lead to 
more predictive and promising therapeutic benefits in case of many hard-to-cure complex 
diseases, with potential to drug the undruggable scenarios. The origin of such selectivity 
comes from the macromolecular architecture of biologics with multivalent binding sites 
2 
that dictate precise target recognition leading to exclusive binding events. However, owing 
to the dynamic structural features, biologics are ultra-sensitive to external environment and 
inherently unstable. Consequently, it is hard to keep these molecules stabilized in 
pharmaceutical formulations and deliver into the target tissues in biologically active forms. 
The loss of structural integrity and denaturation during systemic circulation presents some 
of the major hurdles in functional delivery of biologics. Apart from this, high molecular 
mass and polar surfaces of biologics contribute to their poor cellular permeability.1 
Moreover, characterization, manufacturing and handling of biologic drugs are rather 
stringent and complicated compared to the traditional small molecule medicines. All these 
challenges cumulatively prolong the drug discovery timeline leading to an increased 
burden for successful development of bio-therapeutics. Thus, it is essential to develop 
strategies guided by simple design rules to address the fundamental challenges in non-
destructive encapsulation and on-demand targeted release for these complex 
biomacromolecules. 
 This chapter aims to provide an overview of the challenges associated with the 
successful delivery of biologic drugs and the current state-of-the-art technologies 
developed to address these challenges. The first part of this chapter will specifically focus 
on the hurdles related to systemic stability, cellular uptake, endosomal escape, cytotoxicity 
and immunogenicity issues of the biologics. The second part will discuss engineered 
delivery platforms to address these challenges with a particular focus on three key classes 
of biologics, e.g., protein, antibody and nucleic acid therapeutics. 
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Figure 1.1 Comparison between small molecule and different forms of biologic drugs 
(reprinted with permission from reference 5 and Amgen). 
 
1.2 Salient features and key determinants for efficient delivery of biologic drugs 
 Developing effective strategies for biopharmaceuticals requires understanding the 
key constraints associated with the delivery of biologic drugs. The following sections will 
discuss the major challenges associated in dealing with delicate biologics. 
1.2.1 Stability of biomacromolecules under in vitro and in vivo conditions   
 Most biologics suffer from poor stability owing to several modes of degradation 
pathways. Proteins are prone to denaturation, aggregation, chemical and proteolytic 
degradation when exposed to normal in vitro and in vivo environmental conditions.6 
Nucleic acids considered to be relatively stable, can also undergo chemical and proteolytic 
degradation in presence of certain enzymes and low pH, respectively.7 Owing to these 
stability challenges, different routes of administrations were investigated, e.g., oral, 
transdermal, mucosal, pulmonary, nanoparticle-based, and depot injections.1 Amongst  
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Figure 1.2 (a) Physicochemical properties of nanoparticles relevant for cytotoxicity; (b) 
Inducing cytotoxicity through various cellular interactions with nanoparticles (reproduced 
with permission from reference 8). 
 
these, oral delivery is the most favored one for the ease of administration and high patient 
compliance. However, proteolytic and enzymatic degradation of the biopharmaceuticals in 
stomach and liver, along with low bioavailability due to the hydrophilic macromolecular 
structures, have plagued the scope of oral administration. Moreover, pre-systemic 
metabolism or ‘first-pass effect’ in liver greatly diminishes the bioavailability of the drug 
released into systemic circulation. Finally, rapid clearance through kidney shortens the 
biological half-life of the drug reducing the possibility to reach its target site to impart 
desired therapeutic action. 
1.2.2 Cytotoxicity mediated by nanoparticle-based systems 
 To address the stability concerns and intracellular trafficking, various delivery 
vectors are proposed consisting polymer, lipid, peptide and inorganic nanoparticle based 
systems.9 However, a relatively low number of nanoparticle based drug delivery 
formulations are actually considered for clinical development and finally get cleared by 
U.S. Food and Drug Administration (FDA). A recent analysis shows that the technology 
translational efficacy is 5% between global clinical trials to publication numbers and, only 
10% of the clinical trials give rise to successful products in market.10 One of the major 
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reasons associated with such limited number of clearance is the cytotoxicity issues of the 
designed delivery agents. 
 For nanoparticle-based drug delivery systems, cytotoxicity is majorly governed by 
four prime factors: (a) material composition; (b) morphological parameters, e.g., size and 
shape; (c) surface charge; and (d) hydrophobicity (Figure 1.2).11 Nanoparticles with diverse 
chemical functionalities can bind to extracellular regions like plasma membrane, ion-
channels, cell surface receptors, and either damage or block the machineries from 
functioning normally.11 Upon penetration into the cells, nanoparticles can even interfere 
with the intracellular organelles like mitochondria, lysosome, cytoskeleton and nucleus via 
changing metabolic pathways, generating reactive oxygen species and inhibiting protein 
functions. The effect of nanoparticle size on toxicity is dependent on several other factors 
like the choice of materials, physicochemical properties, and cell types. A consensus in this 
aspect is to utilize 50-200 nm particle to be able to minimize cytotoxic effect exerted by 
the delivery system.11-12 Shape of nanoparticles also has profound effect on toxicity 
induced by increased reactivity and exposure in circulation. Generally, spherical particles 
were reported to be less-toxic compared to non-spherical ones.12 Hydrophobic particles, 
with identical surface charges, were found to be more cytotoxic when compared to the 
hydrophilic particles due to the increased interaction with hydrophobic cellular 
membrane.13  
 The most influential parameter might be the nanoparticle surface charge mediated 
cytotoxicity. Several reports had suggested that cationic nanoparticles can change the 
plasma membrane and mitochondrial membrane potential (MMP),14-16 thereby creating 
punch-holes, increasing the production of ROS and activating caspases and cytochrome C 
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to induce apoptosis.14 Whereas anionic and neutral nanoparticles are considered to 
relatively non-toxic owing to the diminished interaction with the negatively charged lipid 
bilayer of the plasma membrane.17-18  
1.2.3 Immunological effects of designed nanoparticulate drug delivery vehicles  
 A growing concern in therapeutic biologics development is the induced 
immunogenicity mediated by particulate material in the delivery formulation or drug 
aggregates due to instability under in vivo conditions.19 Recognition of nanoparticles as 
foreign objects by immune system could be deleterious, initiating immunosuppression or 
immunostimulation leading to inflammatory responses, acute toxicity and loss of 
therapeutic efficacy of the biologic drug.20-21 Immunostimulatory responses can be derived 
by antigenicity of the biopharmaceuticles, causing the production of neutralizing antibody 
that is capable of dually recognizing endogenous target and exogenous delivery vector. 
Also, nanoparticulate systems can invoke inflammatory responses upon recognition as 
foreign substances and release of cytokines by immune cells to trigger destruction of the 
substance.21 Note that, in vaccine development applications nanoparticulate materials can 
act as adjuvants which are taken up by dendritic cells and macrophages, leading to 
favorable immune response.22 However, downregulation of immune responses 
(immunosuppression) can alter the therapeutic effect and promote infection as harmful 
foreign substances are undetected by the immune system.21    
1.2.4 Challenges involving endosomal escape 
 One of the major bottlenecks in biologics delivery is entrapment of the cargo into 
a vesicle like structure, endosome or early endosome, upon internalization into the cell 
through various endocytosis mechanisms. While early endosome matures into late 
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endosome and lysosome, the pH of the vesicles decreases to ~6.5, ~6.0 and finally to ~5.0, 
respectively.23 Interestingly, the biologics encapsulated in the nanoparticle cargo should be 
able to evade from the early or late endosome stage. Entrapped cargo eventually gets 
degraded inside lysosome losing the therapeutic efficacy.24 As endosomal escape is often 
considered as the rate-limiting step for the delivery of biologics, several studies have 
elucidated probable escape pathways with the help of specific molecular designs.23 The 
key to endosomal escape is dictated by the interaction of the nanoparticle with the 
endosomal membrane, leading to four reported pathways: (i) membrane fusion; (ii) osmotic 
rupture, (iii) swelling of nanoparticle; (iv) membrane destabilization (Figure 1.3).23 Fusion  
 
Figure 1.3 Various proposed pathways for endosomal escape (reproduced with permission 
from reference 23). 
 
of nanoparticles with the endosomal membrane can be guided by hydrophobic 
compatibility, fusogenicity and pH.15, 25-26 Whereas osmotic pressure effect, also known as 
‘proton sponge’ effect, is executed by the influx of protons, counter anions and water 
molecules into the endosomal vesicle due to buffering effect exerted by the nanoparticle 
leading to enlargement and lysis of the endosomal membrane.27-29 Crosslinked polymeric 
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nanoparticles were also reported to have tunable swelling property introducing mechanical 
strain beneficial for evading endosome.30-31 Similarly, pH sensitive polymers with specific 
architectures (hyperbranched and dendritic polymers) showed efficient destabilization of 
endosomal membranes.32-33 Although the endosomal escape process is grossly classified 
into the four mechanisms mentioned above, it is likely that more than one mechanism might 
be acting simultaneously to impart the overall fate of the endocytosis process. 
1.3 Responsive polymers as suitable candidates for therapeutics delivery 
 To address the above-mentioned critical issues involved in the delivery of 
biologics, several drug delivery strategies have been proposed. As the primary goal of this 
thesis is to address the delivery issues with three key biologics, viz., protein, nucleic acid 
(siRNA) and antibody therapeutics, the following sections are devoted to discuss the state 
of the art technologies in each specific case. 
1.3.1 Protein: non-covalent vs. covalent encapsulation strategies 
 Protein therapeutics is considered to be one of the most promising areas of recent 
times in the field of pharmaceutical drug development.34-35 Being directly involved in 
various biochemical pathways, proteins perform the pivotal role to dictate the overall fate 
of major cellular processes.36 Thus, regulating specific protein expressions, by either 
attenuation or enhancement, should furnish significant control over such cellular signaling 
mechanisms. Being more specific and possessing less cytotoxicity risks compared to non-
targeted small molecule drugs, direct delivery of functional proteins into cells is expected 
to provide exquisite benefit towards many challenging diseases.  
 To this end, a wide array of brilliant approaches has been attempted to design 




Figure 1.4 (a) Liposomal drug delivery systems; (b) Lysine head-group containing cationic 
liposomes for intracellular protein delivery (c) Biocompatible hydrogels for oral delivery 
of proteins (reproduced with permission from references 37-39). 
 
quantum dots.6, 40-43 Here, we will majorly focus on examples of liposome and polymer 
based approaches relying on non-covalent and covalent interactions. 
 Liposome is considered to be an excellent biocompatible nanocarrier for the 
delivery of both hydrophobic drugs (in bilayer) and hydrophilic protein (inside aqueous 
lumen) therapeutics (Figure 1.4).37 β-galactosidase (β-gal, ~465 kDa, with four subunits of 
116.3 kDa) enzyme has been efficiently encapsulated with the help of a cationic 
guanidinium-cholesterol lipid (bis (guanidinium)-tren-cholesterol, BGTC) and helper 
dioleoyl  phosphatidylethanolamine (DOPE) lipid, and found to be active after intracellular 
10 
 
Figure 1.5 (a) Protein PEGylation and subsequent formation of nanoparticles; (b) Recent 
approaches for modified PEGylation methods (reproduced with permission from references 44-47). 
 
delivery.40 In another study (Figure 1.4b), a lysine headgroup containing cationic liposome 
was utilized to deliver bovine serum albumin (BSA, 66 kDa).38 Several apoptotic mediator 
enzymes (caspase 3, caspase 8 and granzyme B ) were encapsulated in a cationic lipid 
based formulation consisting trifluoroacetylated lipopolyamine (TFA-DODAPL) and 
DOPE. Upon intracellular delivery, the enzymes remained functional and induced 
apoptosis.48 However, these systems generally suffer from poor encapsulation efficacy due 
to the lack of driving force for hydrophilic proteins to preferentially encapsulate from bulk 
media to the interior aqueous pool of liposome. This issue can be partly addressed by 
hydrogels based on natural (polysaccharides, protein and DNA based) and synthetic 
(polyesters, polyamides, poly(ethylene oxide), polyorthoester and polyphosphazene) 
polymers for protein encapsulation.6 Nonetheless, application of hydrogel based systems 
are limited by the localized delivery of therapeutic biologics. 
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Figure 1.6 (a) A covalent self-assembly strategy for encapsulation of an apoptosis inducing 
protein, caspase 3; (b) A traceless reversible thioester chemistry for protein PEGylation 
(reproduced with permission from references 49-50). 
 
 In this context, covalent protein delivery strategies with polymers would be 
beneficial for rendering high encapsulation efficacy owing to the covalently attached 
proteins with the delivery vehicle and for imparting structural and in vivo stability from 
the polymer backbone. PEGylation is one of the FDA approved techniques heavily used in 
biopharmaceutics development (Figure 1.5).51 Attachment of PEG chain shows prolonged 
circulation half-life, reduced immunogenicity and cytotoxicity.52-53 In other scenarios, 
covalent ligation techniques have been employed via polymeric nanocarriers to effectively 
improve encapsulation efficacy and in vivo stability (Figure 1.5). However, many of these 
methods require organic solvents and harsh synthetic conditions that tend to irreversibly 
modify the protein cargo, resulting in denaturation the sensitive cargo and diminished 
activity.54-55 
 To address these issues, reversible covalent strategies (Figure 1.6) are being 
explored that can not only provide high fidelity protein encapsulation, but also help 
preserve structure and activity through ‘traceless’ release of protein in native form.50, 55-56 
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1.3.2 Nucleic acid: state of the art approaches in RNAi 
 Nucleic acid based gene silencing, specifically RNA interference (RNAi), has 
created an enormous opportunity in therapeutics development.57 Despite many promising 
advantages, RNAi technology possesses several limitations that have hindered its 
applicability and therapeutic potential.7 Poor cellular internalization and systemic 
instability of naked siRNA in presence of serum nucleases followed by fast renal clearance 
are two major biological barriers for efficient intracellular delivery of siRNA.58 In addition, 
undesirable toxicity from chemical modifications of siRNA or transfection agents increases 
the barrier for its successful implementation.59 Ever since its inception, these hurdles are 
reflected in the commercial development of RNAi based therapeutics with only one recent 
FDA approval in this drug category.60 Thus, designing an efficient and safe siRNA delivery 
strategy still remains a grand challenge to realize the fullest potential of such powerful 
technology. 
 To address the critical pitfalls of siRNA-based therapeutics, several approaches 
have been proposed which can be classified into two major categories: (a) chemical 
modification of siRNAs and (b) siRNA carriers.58, 61 In the first case, siRNAs are 
chemically modified to enhance its systemic stability by providing nuclease resistance (e.g. 
phosphorothioate, boranophosphate, 2’OMe modifications; see Figure 1.7 for a general 
overview of oligonucleotide modifications) and to increase the biological half-life 
(PEGylation, hydrophobic modifications with cholesterol, bile or fatty acid).58 These 
approaches bring in complexity within siRNA molecules typically resulting in increased 
toxicity and reduced silencing ability of the delivered siRNA.62 On the other hand, potent 
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siRNA carriers like viral vectors impart high transfection efficacy; albeit introduces 
elevated risk of immunogenicity and undesired mutagenesis.7 In this scenario, non-viral  
 
 
Figure 1.7 Chemical modifications on oligonucleotides along with their operating 
mechanisms (reproduced with permission from reference 61). 
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delivery vehicles63-66 like cationic lipids, peptides and polymers provide rather clean and 
straight-forward but efficient choices, wherein electrostatic forces between cationic 
delivery agents and negatively charged siRNA molecules result in a condensed complex 
(Figure 1.8a). The stability of such complexes in biological milieu is essentially 
proportional to the electrostatic attractions between the siRNA and the siRNA-binder, 
which is dictated by (i) the amount of cationic charge in play and also by (ii) the ability of 
these molecular systems to optimize the interactions (e.g. controlled by factors such as  
 
Figure 1.8 (a) Non-viral vectors for nucleic acid delivery (reproduced with permission 
from reference 67); (b) Molecular design strategy of guanidinium ion appended telechelic 
dithiol monomers for siRNA delivery (reproduced with permission from reference 68). 
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molecular flexibility, etc.). Typically, a high positive charge, dictated by the high N/P ratio 
(molar ratio of cationic nitrogen in delivery agent to phosphate groups in siRNA), is found 
to be critical for complete complexation and protection of siRNA (Figure 1.8b).68 
Interestingly, complexes with high cationic charge, under in vivo conditions, poses 
increased toxicity and adverse side effects (plasma membrane damage, release of 
cytochrome C from mitochondria and alteration in membrane potential).14 As a remedy, 
reduction of positive charge at lower N/P ratio in the complex was investigated to attenuate 
toxicity.69 However, this approach might compromise the complex stability under in vivo 
conditions and does not address the inherent problem of cationic charge driven toxicity. 
Moreover, competitive binding with negatively charged serum proteins becomes an 
important parameter at lower N/P ratio which can even result in the leakage of siRNA 
impeding the therapeutic efficacy. PEGylation of cationic vectors, another promising 
strategic solution to this problem, enhances steric crowding in the system diminishing the 
binding efficacy with cationic vectors and retards efficient cellular uptake of siRNA 
carriers.70 In essence, the paradox with cationic charge vs. toxicity vs. binding affinity and 
stability of siRNA delivery vectors demands a new potent self-assembly strategy for 
efficient complexation and delivery of siRNA cargo.   
1.3.3 Antibody: emerging opportunity to target intracellular proteins 
 Probing various cellular processes by specific targeting of proteins is immensely 
important in developing therapeutic candidates.71 Antibodies, being the key 
biomacromolecule utilized for targeting purposes, have so far served the diagnostic need 
via targeting extracellular proteins. On the other hand, intracellular targeting of specific 
proteins has only been possible with techniques like microinjection and electroporation, 
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owing to the membrane impermeable nature of large hydrophilic antibody.71-72 However, 
given the concerns regarding cell membrane damage, cytotoxicity and low throughput 
methods, those process are limited to in vitro applications.71 
  
Figure 1.9 (a) Molecular design strategy for the endosomolytic peptide based delivery of 
antibody; a peptide based fast intracellular delivery strategy for (b) fluorescent IgG 
antibody; and (b) anti-nuclear pore complex antibody (reproduced with permission from 
references 73-74). 
 
 To expand the enormous opportunity associated with intracellular targeting, 
molecular designs for encapsulation of antibodies have been proposed.71, 75-79 An 
endosomolytic peptide is developed by substituting leucine with glutamic acid of a 
cationic-lytic peptide, M-lycotoxin (Figure 1.9a).73 Cytosolic localization of IgG is 
observed after rupture of endosomal membrane. On the other hand, liposome made with a 
combination of aminoglycoside lipid dioleyl succinyl paromomycin (DOSP) and 
imidazole-based helper lipid MM27 has been identified as superior for the intracellular 
delivery of anti-cytokeratin8 antibody (anti-K8).40 Harnessing the strengths of lipid and 
peptide based systems, a high-speed antibody delivery strategy has been reported with 
liposomes modified with cell penetrating peptide, octaarginine (R8) and pH-sensitive 
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fusogenic peptide, GALA.74 Within 30 min of incubation, ~98% of cells are transfected by 
IgG containing liposomes with endosomal escape and predominant cytosolic localization 
(Figure 1.9b). 
Figure 1.10 Formation of PIC micelles and intracellular delivery of antibody (reproduced 
with permission from reference 80). 
 
 Further, delivery of nuclear pore complex (anti-NPC) antibody proved the retention 
of structural and functional features of the delivery antibody (Figure 1.9c). In another 
elegant approach, anionic polypeptide fused IgG is encapsulated within cationic liposome 
to inhibit two intracellular targets - multidrug resistance-associated protein 1 (MRP1) and 
the transcription factor NF-κB.72 Polymeric nanoparticles based on polyethyleneimine 
(PEI), poly(lactic-co-glycolic acid) (PLGA), poly(ethylene glycol)-block-poly[N-(N′-(2- 
aminoethyl)-2-aminoethyl)aspartamide]) (PEG-b-PAsp(DET)) and MePh13-b-dG5 
18 
polyoxanorbornene diester copolymer (dG: dense guanidinium functionality) have also 
been explored for intracellular trafficking of antibodies.80-83 Polyion complex (PIC) 
comprising copolymers (PAsp: poly[N-(N′-(2-aminoethyl)-2-aminoethyl)aspartamide]) 
have been shown to successfully deliver IgG and anti-NPC antibody (Figure 1.10).80, 84 
However, given the enormous possibility of antibody therapeutics, there is still a dearth of 
design strategies for intracellular targeting of disease relevant proteins. 
1.4 Summary & dissertation overview 
 In this chapter, the importance of biologic drugs and the challenges associated with 
the delivery via biopharmaceutical products are discussed. Along this line, recent state of 
the art drug delivery strategies for three key important biologic candidates, viz., protein, 
nucleic acid (siRNA) and antibody therapeutics, are discussed. For protein therapeutics, 
non-covalent and covalent approaches comprising lipid and polymeric delivery vehicles 
have been discussed describing the advantages and pitfalls. Being negatively charged, 
nucleic acids like siRNAs have been encapsulated via cationic nanoparticles, which in turn, 
raises toxicity issues in proportion with gene silencing. Recent state of the art techniques 
and existing issues have been discussed have been discussed. Delivery of antibody drugs 
for intracellular targets is gaining recent attention and has been discussed. However, a 
dearth of strategies reveals significant challenges associated with the antibody delivery and 
a dire need of novel drug delivery vehicles. 
 Targeting the need for advanced molecular designs of delivery vehicles, this 
dissertation will discuss the design principles of developed strategies that target the existing 
challenges in the delivery of protein, siRNA (nucleic acid) and antibody therapeutics. 
Chapter 2 describes a templated self-assembly strategy with a self-immolative polymer to 
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shrink-wrap protein cargoes and their intracellular trafficking. For siRNA delivery, a 
tricomponent symbiotic self-assembly strategy has been described in chapter 3 comprising 
siRNA, polymer and lipids, that address the toxicity challenges from cationic particles. In 
chapter 4, a rigorous structure-activity study has been reported to improve the conjugation 
efficacy of protein with the designed activated ester containing self-immolative polymer. 
Chapter 5 describes engineering of the developed polymer platform to incorporate an 
electrostatic handle for boosting conjugation efficacy of larger proteins and antibody 
therapeutics. Summary is described in chapter 6 along with future directions focusing on 
some ongoing research efforts and prospective ideas as a corollary of the developed drug 
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cellular Protein Delivery and Traceless Release” J. Am. Chem. Soc. 2017, 139 (16), 5676–
5679. Copyright © 2017 American Chemical Society. 
 
2.1 Introduction 
 Using proteins as a therapeutic is attractive, as this promises to directly address 
genetic deficiencies and there-fore mitigates side-effects that plague many small molecule 
drugs.1 Potential side-effects from small molecule binders are understandable, as these 
molecules must be designed to target a specific protein in our complex biological system, 
highlighted by the nearly 20,000 protein-encoding genes. On the other hand, proteins can 
directly compensate for a specific deficiency and therefore the drug development is less 
heuristic. However, realizing the full potential of protein-based therapeutics has been 
difficult, mainly due to their in vivo instability and immunogenicity. To overcome these 
issues, approaches to modify protein surfaces have been taken, starting with PEGylation 
that has been shown to enhance protein circulation lifetimes.2-4 More recently, strategies 
that allow for attaching other polymers to proteins have been developed in order to endow 
these conjugates with stimulus-responsive characteristics or to realize new self-assembled 




enhanced circulation lifetimes and thus have impacted the utility of proteins that function 
in the extracellular environment.9 
 The next level of challenge involves the ability to develop systems that can handle 
intracellular proteins, where trafficking the cargo across a cellular membrane is a major 
hurdle. Two limiting approaches have been taken to address this need, both of which 
involve non-covalent self-assembly. First involves electrostatic binding of proteins to 
complementarily charged polymers and nanoparticles.10-12 The second approach includes 
encapsulating proteins in water-filled compartments, such as liposomes.13 A limitation of 
the former approach comprises non-specific fouling of the complex surfaces due to 
electrostatic interactions and the associated toxicities.14 The latter approach has the 
potential to address the fouling issues, but is fraught with low loading capacities, especially 
when charge-neutral lipids are used. 
 
Figure 2.1 Schematic representation of the formation of a covalent polymer network using 





  We envisaged that a covalent self-assembly approach, where the protein cargo 
itself acts as the template for the polymer to self-assemble around it, has the potential to 
encapsulate proteins with high fidelity and present charge-neutral surface functionalities 
(Figure 2.1). The key design hypothesis here is that an initial reaction between the side 
chain functionalities of a random copolymer and multiple surface-exposed functional 
groups of a target protein would cause a few polymer chains to organize around the protein. 
This covalent capture then can act as a template to form a polymer sheath around the protein 
through a polymer side-chain crosslinking step, as schematically illustrated in Figure 2.1. 
We envisaged that the high-fidelity protein encapsulation within this sheath would be aided 
by: (a) convex sur-face of globular proteins on which the reactive functional groups are 
presented, and (b) high-yielding and multivalent reactions are presented; and (b) high-
yielding and multivalent reactions between the protein and polymer side chains. 
2.2 Results and discussion 
2.2.1 Design and synthesis of a self-immolative polymer for lysine conjugation 
 Cysteine and lysine are two popular handles for conjugating polymers with 
proteins, because of their nucleophilicity.15-22 Because of the surface availability in larger 
number of proteins, lysines are generally preferred. However, this amino acid presents a 
challenge in that it is more difficult to functionalize them in a form, whereby they can be 
tracelessly liberated in the intracellular environment. We hypothesized that placing reactive 
side-chain functionalities in a polymer, with responsive self-immolation characteristics,23 
would result in a novel and general system that is capable of encapsulating proteins with 




 The structure of the target polymer P1 (Scheme 2.1), which satisfies all the design 
requirements, was synthesized by RAFT polymerization. Reaction of an amine with the p-
nitrophenylcarbonate (NPC) moiety in P1 will produce the corresponding carbamate, as 
 
Scheme 2.1 Chemical structures of polymers and the reaction scheme for protein 
conjugation, crosslinking to generate the nano-assembly and its release in the presence of 
a reducing agent. 
 
shown in P2. The polymer is first treated with the protein, where multiple lysine moieties 
are reacted with the NPC groups in the polymer chains. The remaining NPCs are reacted 
with a diamine crosslinker to complete the sheath formation around the protein (Figure 2.1 
and Scheme 2.1). Note that a disulfide moiety is placed at the β-position, relative to the 
carbamate oxygen, which serves to render the polymer responsive to the more reductive 
intracellular environment, compared to the extracellular space.18 Reductive cleavage of the 




cause both the polymer being uncrosslinked and the protein being tracelessly liberated from 
the polymer. 
 
Figure 2.2 (a) Top: Bright Field Cryo-TEM image of NA-CytCPEG showing both 
individual and small clustered particles. Inset shows a cluster of 3 protein nanoassemblies, 
Bottom: HAADF image of a NA-CytCPEG nanoassembly. The bright spots with diameters 
of 2-3 nm are caused by the Fe-content of Cyt C, inset is NA-EmptyPEG particle with no 
detectable Fe from EDS (~50 nm); (b) MALDI-MS analysis of the trypsin digest from 
encapsulated and naked Cyt C; (c, d) SDS-PAGE of the NA-CytCPEG under non-reducing 
and reducing conditions (10 mM DTT, 37 °C for 4 h). 
 
2.2.2 Conjugation studies and characterization of protein-polymer nanoassemblies  
 To test our design strategy, we chose cytochrome C (CytC, pI 9.6) as a model 
protein, because of its distinct cellular readout in the form of apoptotic cell death. After 
initially reacting CytC with P1, the polymer-protein conjugate was further secured by 
crosslinking with ethylenediamine (ED) or tetraethyleneoxide-bis-amine (PEG) to afford 
nano-assemblies NA-CytCED and NA-CytCPEG, respectively. Note that the reaction 
between the NPC moiety and an amine produces p-nitrophenol as a by-product, the distinct 




quantified using the evolution of the absorption spectrum. Encapsulation efficiency and 
loading capacity were found to be 64-67% and 5-7%, respectively. Dynamic light 
scattering (DLS) measurements revealed the hydrodynamic diameters of native CytC and 
the protein-containing nanoassembly to be ~4 nm and ~8-10 nm, respectively. Moreover, 
zeta potential measurements revealed that the surface of the complex is charge-neutral, 
suggesting that the complex surface is dominated by the PEG moieties from P1. Figure 
2.2a (top) shows a Cryo-EM image of NA-CytCPEG. The average individual particle size is 
in the 10-30 nm range which is in agreement with DLS data. To obtain a more detailed 
insight into the protein distribution within the nano-assemblies we employed High Angle 
Annular Dark Field Microscopy (HAADF) and Energy Dispersive X-Ray Spectroscopy 
(EDS) at cryo temperatures. Figure 2.2a (bottom) shows a HAADF image of an individual 
nano-assembly. The whole assembly has a diameter of about 20 nm and the bright spots in 
the 2-3 nm range are caused by the Fe-content of discrete Cyt C molecules (compare with 
the empty assemblies in the inset) and EDS analysis con-firmed the presence of Fe.  
 An important objective of this work is to use the polymer sheath to protect the 
protein from protease degradation. To rigorously test for this, we subjected the polymer-
protein conjugate to protease digest with trypsin and analyzed the products using MALDI 
mass spectrometry. While the unprotected Cyt C afforded characteristic peptide frag-ment 
peaks, the conjugate at the same protein concentration did not afford any discernible 
fragments (Figure 2.2). These results show that assemblies do indeed protect the protein. 
The conjugates also seem to be generally stable in serum. 
 Next, we were interested in testing whether the encapsulated protein can be released 




PAGE). As anticipated, when the protein is conjugated to the protein, no bands 
corresponding to the protein was found (Figure 2.2). When the same SDS-PAGE gel was 
run under reducing conditions, appearance of protein bands clearly indicated that the 
encapsulated protein can be re-leased. This is the first indicator, suggesting that the protein 
release using the reductive self-immolative linker is feasible. We utilized SDS-PAGE 
experiments to quantify the amount of proteins inside our nanoassemblies. After treating 
the nanoassemblies with excess dithiothreitol (DTT), the intensity of the protein band in 
the gel is compared with native proteins of different concentrations to estimate the amount 
of proteins present inside the nanoassembly (Figure 2.2).  
 
Figure 2.3 Structure and function of released Cyt C from the NA-Cyt CPEG, evaluated by 
(a) CD spectroscopy; and (b-c) ABTS activity assay: b- assay kinetics, c- % activity of 





2.2.3 Structure and activity studies of released protein 
 The protein encapsulation and release process would be a futile exercise, if the 
methodology does not preserve the structure and function of the protein upon release. To 
this end, the secondary structure of the released protein was examined by circular 
dichroism (CD) spectroscopy, the spectrum of which was found to be identical to that of 
the native Cyt C (Figure 2.3). This suggests that the conjugation and release processes did 
not alter the secondary structure of the protein. We also claim that the strategy leads to a 
traceless release of the protein in reductive environment. To test this hypothesis, the 
released protein was analyzed by mass spectrometry. The m/z for the released protein 
matched the native Cyt C, suggesting that there are no remnants of the polymer after the 
protein’s reductive release. 
 Next, we investigated whether the function of the protein is maintained by 
quantifying the released protein’s activity using an ABTS assay (based on 2,2’-azino-bis(3-
ethylbenz-thiazoline-6-sulfonic acid) (Figure 2.3b-c).2410a While the nanoassembly did 
not exhibit any enzymatic activity, the activity recovery was nearly quantitative when the 
assembly was treated with 10 mM DTT (compare the activities of native Cyt C and released 
Cyt C in the presence of 10 mM DTT in Figure 2.3). This activity recovery was also found 
to be dependent on the concentration of DTT and thus the extent of protein release. These 
results show that the polymer shell can act to ‘turn-off’ the protein function, until it is 
released in its target environment. Both structure and function recoveries were found to be 






2.2.4 Intracellular delivery and cellular activity studies  
 The ultimate goal of the proposed research is to utilize this polymer coating to 
traffic the protein across the cellular membrane and release it in the cytosol. It is the higher 
redox potential of the cytosol that is being targeted for selective release. To track the 
location of the protein under con-focal laser scanning microscopy (CLSM), Cyt C was 
labeled with rhodamine B and the cell nucleus was stained with hoechst 33342. After 4 h 
 
Figure 2.4 HeLa cells treated with NA-Cyt CPEG conjugates to study cellular uptake: (a) 4 
h post-incubation; (b-c) endosomal co-localization and escape at 4 h and 24 h, respectively; 
(green: lysotracker; red: rhodamine B; blue: hoechst); (d) cell viability after 72 h (dosage 
represents amount of NA-Protein conjugate); (e) detection of activated caspase-3/7 after 
72 h using the Cy5-tagged assay reagent; scale bar: (a) 50 µm, (b, c, e) 10 µm. 
 
incubation, well-distributed red fluorescence from labeled proteins was observed (Figure 
2.4a), while negligible fluorescence was observed from cells that were treated with an 
identical concentration of naked proteins. These results suggest that the polymer conjugate 




cellular internalization process was also monitored under CLSM for this conjugate. Since 
the most likely pathway for uptake is endocytosis, we were next interested in evaluating 
whether the proteins are stuck in the endo-some or they escaped the endosome to get into 
the cytosol. For a cytosolic delivery, the latter is desired. Accordingly, the endosomes were 
labeled with lysotracker green. The data clearly indicate that the nanoassemblies enter the 
cells through the endosomes (see co-localization of lysotracker green and rhodamine-B 
label after 4 h incubation (Figure 2.4b)), but the proteins escape the endosomes over time 
as seen by the dominant red color in the cell in the 24 h image (Figure 2.4c).  
 To evaluate whether the delivered Cyt C is active, we evaluated the apoptotic cell 
death in response to the protein delivery. Cyt C is known to induce apoptosis through inter-
action with apoptotic protease activating factor 1 (Apaf-1) in cytosol and activation of pro-
caspase-9, which in turn initiates pro-caspase-3 leading to activation of caspase dependent 
apoptotic pathways.25-26 The dose-dependent decrease in cell viability of the nanoassembly 
(Figure 2.4d), combined with the lack of toxicity for the corresponding concentration of 
the free nanoassembly or naked Cyt C, indicate that the cytosolically delivered Cyt C is 
causing apoptosis. Further-more, the mechanism of action of Cyt C allows the direct 
interrogation whether the caspase-dependent pathway is activated in the cytosol. A 
fluorimetric immunoassay that causes a caspase product to be intercalated the DNA in the 
nucleus was utilized to assess this possibility. The co-localization of the caspase-processes, 
cy5-tagged reagent (red) and the nuclear stain (blue) confirmed the apoptotic nuclei in the 
cells (Figure 2.4e).  Control experiments show that the nanoassembly without the Cyt C 





2.2.5 Versatility of the protein encapsulation approach 
 The true testament to the versatility of this strategy is the applicability to a broad 
range of proteins. To test this, we used two other proteins, viz. lysozyme (Lys) and 
ribonuclease A (RNase A). Both proteins were found to be success-fully conjugated with 
the polymer P1. SDS-PAGE, CD, and activity studies also show that the encapsulated 
protein can be released with high fidelity under reducing conditions with high retention in 
both structure and function (Figure 2.5a-b). It is interesting to note that the overall kinetics 
 
Figure 2.5 SDS-PAGE showing protein release (reducing conditions), cellular uptake (4 
h) and viability (72 h) in HeLa cells for (a) NA-Lys and (b) NA-RNase A conjugates, scale 
bar: 50 µm. 
 
of proteins release was observed to have the order: Cyt C<RNase A<Lys. The release 
kinetics seems to correlate with the number of sur-face exposed lysines in each protein 
(Cyt C: 19, RNase A: 10, Lys: 6).27-28 This is understandable, since the higher number of 
anchoring points requires more sites for the reducing agent to process during release. 




Figure 2.5). While lysozyme is expected to be innocuous to cells, RNase A with access to 
cytosolic RNA can initiate cell death.29-30 Although both proteins were taken up by the 
cells as assessed by CLSM studies, the lysosome-containing nanoassembly did not induce 
any cell death, whereas the RNase A-bearing nanoassembly had a profound effect on cell 
viability (Figure 2.5).  The proteins studied so far are basic (pI >8.5) with a MW of 12-15 
kDa. To further test this system, we also investigated the encapsulation and release 
properties of eGFP with higher MW and lower pI (MW ~27 kDa, pI 5.5). SDS-PAGE and 
cellular uptake studies show that this protein, too, can be successfully encapsulated and 
delivered.  
2.3 Summary 
 In summary, we have developed a versatile strategy for the encapsulation of 
proteins and their traceless release in response to a specific trigger.  The encapsulation is 
templated by the lysine handles in the protein itself, which are then used to wrap the protein 
with a polymer sheath in a secondary crosslinking step. The versatility of the approach is 
high-lighted by the fact that: (i) it utilizes a functional handle that is abundantly available 
on the surface of >85% the globular proteins, which renders the strategy broadly appli-
cable; (ii) the target protein is encapsulated with high fidelity, i.e. high loading capacity; 
(iii) the cargo is protected from degradation by proteases; (iv) the protein activity is masked 
in the encapsulated state; (iv) the polymer sheath is re-moved tracelessly with high 
efficiency in response to a tar-get intracellular environment; (v) the native structure and 
function are retained upon release; (vi) the protein can be delivered with high fidelity into 




this simple and general strategy will serve to produce a potent protein therapeutic delivery 
platform for a broad range of proteins. 
2.4 Experimental 
2.4.1 Materials 
 All chemicals, polyethylene glycol monomethyl ether methacrylate (PEGMA; MW 
500), 2,2′-dithiodipyridine, 4-cyano-4-(phenylcarbonothioylthio)pentanoic acid (chain 
transfer agent), D,L-dithiothreitol (DTT), lysozyme, RNase A, cytochrome C and 
rhodamine B isothiocyanate were obtained from Sigma-Aldrich and were used without 
further purification unless otherwise mentioned. 2,2′-azobis-(2-methylpropionitrile) 
(AIBN) was procured from Sigma-Aldrich and purified by recrystallization before usage. 
Pyridyl disulfide ethyl methacrylate (PDSMA) was synthesized using previously reported 
procedure.31  
2.4.2 Synthesis of p(PEGMA-co-PDSMA), PPcP 
 PDSMA (0.511 g, 2 mmol), PEGMA (1 g, 2 mmol) and 4-cyano-4-
(phenylcarbonothioylthio) pentanoic acid (55.7 mg, 0.2 mmol) were weighed and 
dissolved with 2 mL THF in a 25 mL Schlenk flask. To the reaction mixture, 1 mL AIBN 
(6.7 mg, 0.0408 mmol) solution in THF was added and mixed for 5 min. The flask was 
purged with argon and performed three freeze-pump-thaw cycles. After that the reaction 
vessel was sealed and transferred to an oil bath preheated at 70 °C. The polymerization was 
quenched after 24 h by cooling down the reaction flask with cold water and the solvent was 
evaporated. The viscous reaction product was purified by repeated washing with cold 
diethyl ether and finally dried in high vacuum at room temperature for 24 h. Yield: 96%, 




3.64−3.37, 3.03, 1.93-1.82, 1.03−0.87. From 1H NMR, integration of the methoxy proton 
(in PEG unit) and the aromatic proton (in pyridine unit) provided the molar ratio of two 
monomers to be 1:1 (PEG/PDS). 
2.4.3 Modification of synthesized p(PEGMA-co-EDSMA) polymer, PPcE 
 PDS polymer (1 g, 1.32 mmol PDS repeat unit) was weighed in a 20 mL glass vial 
and dissolved in 8 mL DCM. Catalytic amount (100 µL) of glacial AcOH was added to it 
and stirred for 5 min. Afterwards, 2-mercaptoethanol (0.9 mL, 13 mmol) was added 
dropwise to the reaction mixture and the solution was stirred for 24 h at room temperature. 
After that, the modified polymer was purified by dialyzing against methanol using a 
membrane of MWCO: 3.5 kDa. After dialysis, the solvent was evaporated and the polymer 
was dried under vacuum for 24 h. Yield: 90%, GPC (THF) Mn: 26 K. Đ: 1.2. 1H NMR (400 
MHz, CDCl3): δ 4.24−4.09, 3.87, 3.65−3.53, 3.37, 2.95-2.90, 1.93-1.84, 1.04-0.89. 
2.4.4 Synthesis of p(PEGMA-co-NPC) (NPC: p-nitrophenylcarbonate), P1 
 Modified polymer P2 (1 g, 1.39 mmol) and 4-Nitrophenyl chloroformate (325 mg, 
1.61 mmol) were dissolved in 5 mL DCM taken in a 20 mL glass vial. The reaction mixture 
was cooled in ice bath for 10 min. To the cold mixture, pyridine (130 µL, 1.61 mmol) was 
added dropwise under vigorous stirring. Finally, the reaction mixture was stirred at room 
temperature for 24 h and the self-immolative polymer was purified by dialyzing against 
DCM/MeOH 1:1 mixture using a MWCO 3.5 kDa membrane. Yield: 98%, GPC (THF) 
Mn: 32 K. Đ: 1.2. 1H NMR (400 MHz, CDCl3): δ 8.29-8.27, 7.41-7.42, 4.54, 4.23-4.08, 






2.4.5 1H-NMR spectra for polymer samples PPcP, PPcE and P1 
 1H-NMR spectra of the samples were recorded on a 400 MHz Bruker NMR 
spectrometer using residual proton resonance of the solvent as the internal standard and 
chemical shifts were reported in parts per million (ppm). 
 
Figure 2.6 1H-NMR spectra of p(PEGMA-co-PDSMA), PPcP 
 









































Figure 2.8 1H-NMR spectra of p(PEGMA-co-NPC), P1 
 
2.4.6 Gel permeation chromatography (GPC) for PPcP, PPcE and P1 
 Molecular weights of all synthesized polymers were estimated by GPC in THF 
using poly(methyl methacrylate) (PMMA) standards with a refractive index detector. 
 














































2.4.7 Preparation of polymer-protein nanoassemblies 
2.4.7.1 NA-EmptyED and NA-EmptyPEG 
 The self-immolative polymer P1 (10 mg) was dissolved in 2.5 mL phosphate buffer 
(adjusted to pH 8.5) at 20 ºC. A calculated amount (~0.005 mmol) of ethylenediamine (for 
NA-EmptyED) or (PEO)4-bis-amine (for NA-EmptyPEG) was added to the solution and kept 
stirring for 24 h for cross-linking. The resulting nanoassembly was purified by repeated 
washing (five times) with phosphate buffer pH 7.4 Amicon Ultra Centrifugal Filters 
MWCO 30 kDa. The final volume of empty nanoassembly was adjusted to 500 µL with 
phosphate buffer of pH 7.4. 
2.4.7.2 NA-LysED, NA-LysPEG, NA-RNaseAED, NA-RNaseAPEG, NA-CytCED and NA-
CytCPEG 
 Initially, polymer P1 (10 mg) was dissolved in 1.5 mL phosphate buffer (adjusted 
to pH 8.5). To this solution, 1 mL solution of a specific protein (1 mg lysozyme or RNase 
A or cytochrome C in phosphate buffer, pH 8.5) was added dropwise and stirred for 24 h 
at 20 ºC to generate P2. Then, calculated amount (~0.005 mmol) of ethylenediamine (for 
NA-ProteinED) or (PEO)4-bis-amine (for NA-ProteinPEG) was added to each solution for 
cross-linking and mixed for another 24 h at 20 ºC. Finally, the reaction mixture was washed 
(five times) with phosphate buffer (pH 7.4) using Amicon Ultra Centrifugal Filters MWCO 
30 kDa to get purified nanoassemblies (NA) encapsulated with proteins. The final volume 






2.4.8 Monitoring protein-polymer conjugation, degree of NPC group modification 
by protein and crosslinking density 
 The conjugation process and cross-linking density for the protein-polymer 
conjugates can be evaluated by UV-Vis spectroscopy. The amount of released 4-
nitrophenol was monitored at its λmax 400 nm (measured molar extinction co-efficient 
≈12.14*103 LM-1cm-1 at 400 nm). Absorbance of each solution was measured after the 
conjugation and cross-linking processes. For each absorbance measurement, 25 µL of 
sample was withdrawn and diluted to 1 mL with distilled water. Cross-linking density was 
calculated by assuming that the formation of a single chain crosslinking bond would 
require cleavage of two NPC units and produce two 4-nitrophenol molecules.   
The molar ratio of NPC:PEG in the polymer, P1= 50:50 (x mol : y mol, from NMR) 
NPC molecular weight = 387 g/mol, PEG molecular weight = 500 g/mol 
So, x mol * 387 g/mol + y mol * 500 g/mol= 0.1 mg  
x mol = 50/50 y mol 
Amount of polymer used = 0.1 mg/mL for each absorbance measurement 
Moles of NPC-unit (x mol) in the solution= (0.1/887)/1000= 1.13 * 10-7 mol 
Example for NA-LysED: 
From Beer-lamber’s law: A = ε.c.l and path-length=1 cm 
So, concentration of 4-nitrophenol, [c]= 0.3692/ (12.14 * 103) = 3.04 * 10-5 M 
Thus, moles of 4-nitrophenol in 1 mL solution= 3.04 * 10-8 mol 
This represents 27 mol% of total NPC unit. As we assume that two 4-nitro phenol are 
released per crosslinking bond formation and NPC unit is 50 mol% of total polymer. 




Table 2.1 NPC modification and crosslinking density of nanoassemblies 
3  
* Amount of reacted NPC group, calculated based on amount of 4-nitrophenol released 
and original content of the same in the reactant polymer.  
#  moles of lysine/moles of NPC * 100; calculated based on initial polymer dosage (10 




Figure 2.10 (a) Time-course of absorbance profile for released 4-nitrophenol as a fate of 
conjugation of lysozyme with polymer P1; Absorbance spectra of polymer-protein 
conjugates- before and after crosslinking for (b) lysozyme; (c) RNase A and (d) 




























































 NA-CytED (before cross-linking)
 NA-CytPEG (before cross-linking)
 NA-CytED (after cross-linking)
 NA-CytPEG (after cross-linking)












 NA-RNaseAED (before cross-linking)
 NA-RNaseAPEG (before cross-linking)
 NA-RNaseAED (after cross-linking)




cytochrome C. UV−visible absorption spectra were recorded on a PerkinElmer Lambda 35 
spectrophotometer. 
 
2.4.9 Encapsulation efficacy and loading capacity 
All nanoassemblies were evaluated for amount of protein encapsulation after conjugation 
and cross-linking process. Protein concentration in each sample was measured from the 
filtrate after crosslinking reaction and the amount of protein was back-calculated in the 
conjugate. An absorbance based assay (with PierceTM 660 nm Protein Assay Reagent) was 
utilized to quantify the protein amount. The encapsulation efficiency (EE) and loading 
capacity (LC) were calculated based on the following formulas: 
EE, %




amount of “encapsulated” protein
amount of polymer
100 
Table 2.2 Encapsulation efficiency and loading capacity of nanoassemblies 
 
2.4.10 DLS and zeta potential plots: 
Dynamic light scattering (DLS) and zeta potential measurements were performed using a 
Malvern Nanozetasizer-ZS. All samples were diluted with phosphate buffer pH 7.4 to 
adjust final concentration to 1 mg/mL. 







NA-LysED 550 55 5.5
NA-LysPEG 560 56 5.6
NA-RNaseAED 558 56 5.6
NA-RNaseAPEG 553 55 5.5
NA-CytCED 637 64 6.4





Figure 2.11 Particle size analysis of protein-polymer nanoassemblies from DLS 
measurements 
 
Table 2.3 Particle size values for the nanoassemblies 
 
Sample Size, nm
Lysozyme 3.6 ± 0.4
RNase A 3.3 ± 0.2
Cytochrome C 4.3 ± 0.1
NA-EmptyED 9.7 ± 0.1
NA-EmptyPEG 9.5 ± 0.1
NA-LysED 9.7 ± 0.2
NA-LysPEG 9.4 ± 0.3
NA-RNaseAED 9.1 ± 0.1
NA-RNaseAPEG 9.5 ± 0.1
NA-CytCED 9.2 ± 0.2





Figure 2.12 Zeta potential plots for protein-polymer nanoassemblies 
 




Sample Zeta potential, mV
NA-EmptyED -7.3 ± 1.3
NA-EmptyPEG -9.2 ± 1.5 
NA-LysED -7.6 ± 0.7
NA-LysPEG -7.1 ± 0.4
NA-RNaseAED -8.2 ± 0.7
NA-RNaseAPEG -8.7 ± 0.7
NA-CytCED -6.4 ± 0.5




2.4.11 Cryo-TEM sample preparation and instrumentation 
 (a top) Cryo-EM sample preparation was done using a FEI Vitrobot MKII applying 
purified NA-Protein sample solution (20-21 mg/ml) to a c-flat holey carbon grid (hole size 
2 µm) after washing the grid in chloroform. The samples were then transferred using a 
Gatan cryo-transfer holder to a FEI TecnaiT12 TEM operating at 120 kV acceleration 
voltage. Images were acquired using standard low dose methods at 5 µm under focus. (a 
bottom) Sample preparation and HAADF imaging conditions are described under Figure 
2.15. 
 
Figure 2.13 Cryo TEM images: (a) Bright Field image of NA-CytCPEG was obtained after 
allowing a drop of sample solution to dry on a carbon coated grid and subsequent transfer 
into the TEM at room temperature mounted on a cryo-TEM holder. The sample was then 
cooled to -182 °C for observation. The bright field image shows particles in the size of 20-
30 nm, which corresponds well to the size observed after cryo-transfer sample preparation. 
The contrast is naturally not as good as after the cryo-EM sample preparation (see main 
text Figure 2a) due to the carbon support film and most likely particles have undergone 
some deformation due to drying. This sample was also used for the HAADF and EDS 
measurements at cryo-temperature (main Text Figure 2.22a bottom and Figure 2.15). Due 
to relatively high beam currents and long acquisition times necessary for EDS 
measurements it was only possible to perform these measurements on these samples since 
samples prepared through cryo-transfer are quickly destroyed during the measurements. 
The bright field image here, all HAADF images (Main text and SI) and all EDS 
measurement (SI) were done using a JEOL FEM-2200FS field emission TEM equipped 
with an Oxford 80mm2 X-Max EDS-Spectrometer. Acceleration Voltage was 200 kV and 
camera length for HAADF was 100 cm. Samples were mounted on a Gatan 636 Double 




steel holders.  (b) Bright Field image of NA-CytCPEG obtained after allowing a drop of 
sample solution to dry on a carbon coated grid and subsequently observed in a TEM at RT. 
No additional staining was performed. Compared to the sample in part (a) observed at cryo 
temperatures the sample quickly degrades under electron beam exposure and forms ring 
like structures where the average diameter of the inner dark ring is in the range of 10-30 
nm. Interestingly, individual NA-CytCPEG particles in aggregates each form a single ring 
allowing to identify the number of NA-CytCPEG particles within an aggregate (see 
calculation and Figure 2.16 for # of proteins per particle). The imaging was done using a 
JEOL JEM-2000FX TEM operating at 200kV acceleration voltage. 
 
 
Figure 2.14 Room temperature TEM images: for NA-Protein samples (samples were drop-
casted on a carbon coated grid and dried at room temperature before subjecting room 
temperature TEM study. For all samples, a mixture of individual as well as clustered 
particles were observed because of drying on TEM grids. This is also in agreement with 





Figure 2.15 Energy Dispersive X-Ray Spectroscopy (EDS) analyses and High Angle 
Annular Dark Field Microscopy (HAADF, inset) images at cryo temperature (-178 °C) for 
NA-CytCPEG. Figure 2.15 insets shows HAADF images of individual nano-assemblies. For 
HAADF and EDS analysis, samples were transferred using a Gatan 636 Double Tilt Cryo-
Holder with Beryllium cradle to avoid any contamination from external matal sources. The 
whole assembly has a diameter of ~20 nm and the bright spots in the range of ~2-3 nm is 
caused by the Fe-content of discrete CytC protein molecules.32 EDS analysis confirmed the 
presence of Fe inside (a, c) the nanoassemblies and none in the outer space (c). As expected, 
we did not observe any bright spots of Fe in NA-EmptyPEG particle (d, inset) and EDS 
confirms the absence of Fe in it(d). 
 
2.4.12 Estimation of approximate number of proteins per particle: 
Example for NA-LysED: 
Diameter of nanoassembly, D = 9.7 nm, radius, R = 4.85 nm 
Volume of each particle, VPPC = (4/3)πR3 = (4/3) π(4.85)3 nm3 = 477.6 × 10-21 cm3 
Again, for lysozyme, diameter of protein, d = 3.6 nm, radius, r = 1.8 nm 




Assuming that maximum sphere packing efficiency to be ~74%, number of lysozyme per 
nanoassembly to be = (477.6 × 10-21/ 24.4 × 10-21) × (0.74) = 14 
Based on Carl Friedrich Gauss theory on close packing of sphere in space: highest average 
packing density is given by π/3√ 2 ≈ 0.74 
The results for all other nanoassemblies are summarized below: 
 
Table 2.5 Theoretically calculated number of proteins per nanoassembly based on size 
 
 
Figure 2.16 HAADF images of different NA-CytCPEG particles. The bright spots with a 
diameter of 2-3 nm are caused by the Fe-content of the Cyt C. This allows to identify and 










approximately count number of CytC proteins per particle through Image J software (see 
discussions in Figure 2.13b), approx. # of proteins are reported in the inset, scale bar: 20 
nm. 
 
2.4.13 Enzymatic degradation (trypsin digest) study 
 Polymer-protein conjugate solutions and native proteins (lysozyme, RNase A and 
cytochrome C) were subjected to enzymatic degradation study to evaluate the stealth power 
of polymeric nanoassemblies to encapsulate and protect the sensitive cargos from protease 
mediated cleavage. Sample solutions were prepared with polymer-protein complexes (with 
final protein concentration of 0.39 mg/mL based on previous protein analysis) in NaHCO3 
buffer (pH=8.0). The concentrations of native proteins in each control sample were also 
kept identical for comparison purpose. After that 10% acetonitrile was added to each 
sample to denature the protein and incubated at 50 ºC for 45 minutes. For RNase A, samples 
were treated with 15% AcOH and incubated at 90 ºC for 4 h. After hydrolysis, samples 
were freeze-dried and finally added 10% acetonitrile and 90% NaHCO3 buffer of pH 8.0. 
Finally, all samples were digested with trypsin from porcine pancreas at a ratio of 1:25 
(trypsin:protein) at 37 ºC for 17 h. After digestion samples were collected by centrifugation 
and subjected to MALDI-MS analysis. The matrix was prepared with a solvent mixture of 
acetonitrile, water and trifluoroacetic acid (with a ratio 50:47.5:2.5) containing 10 mg/mL 
α-cyano-hydroxycinnamic acid. The matrix and digested samples were mixed at 1:1 ratio 





Figure 2.17 Trypsin digest for ED and PEG-crosslinked polymer-protein nanoassemblies 
 















































































































m/z Start End Sequence
1045 135 143 (K)GTDVQAWIR(G)
1428 52 63 (K)FESNFNTQATNR(N)
1676 116 130 (K)IVSDGNGMNAWVAWR(N)






m/z Start End Sequence
1151 1 10 (-)MPAPATTYER(I)
1547 85 98 (K)LWSSLTLLGSYKGK(N)
1662 1 14 (-)MPAPATTYERIVYK(N)
1685 26 41 (R)LEFQDGGVGLTAAQFK(Q)
m/z Start End Sequence
1168 29 39 (K)TGPNLHGLFGR(K)
1478 89 100 (K)KTEREDLIAYLK(K)
1478 90 101 (K)TEREDLIAYLKK(A)
1598 40 54 (R)KTGQAPGFTYTDANK(N)

















2.4.14 Assessment of serum stability of NA-LysPEG, NA-RNaseAPEG and NA-CytCPEG 
nanoassemblies 
To the stability of nanoassemblies in serum is considered to be an important criterion to 
perform as an efficient delivery vehicle. The serum stability of the PPCs were performed 
by monitoring the changes in particle size through DLS.33 All samples were incubated with 
differential amounts of serum (0%, 10%, 25% and 50%) for 6 h at 37 ºC before subjecting 
to DLS measurements. Conjugates were found to quite stable with negligible shifts in the 
particle sizes confirming no protein adsorption leading to aggregation and biofouling. 
 
Figure 2.18 Particle size analysis of nanoassemblies in presence of serum 
 
2.4.15 Lysine residues in proteins 
 
Figure 2.19 Lysine residues in Lysozyme (#6), RNase A (#10) and Cytochrome C (#19) 
 








NA-LysPEG 9.4 ± 0.3 7.5 ± 0.4 7.2 ± 0.6 7.4 ± 0.4
NA-RNaseAPEG 9.5 ± 0.1 8.4 ± 0.6 7.5 ± 0.2 7.0 ± 0.1























2.4.16 SDS-PAGE for protein-polymer conjugation and release studies: 
 30 µL of different samples containing NA-EmptyED, NA-EmptyPEG, NA-LysED, 
NA-LysPEG, NA-RNaseAED, NA-RNaseAPEG, NA-CytCED and NA-CytCPEG were mixed 
with 10 µL of loading buffer (DTT free) and 25 µL of each sample was loaded on 
acrylamide gel. For release experiment, identical protein-polymer conjugate samples were 
treated with 10 mM DTT and incubated at 37 ºC for 4 h before subjecting to acrylamide 
gel electrophoresis. To calculate the amount of released protein from each sample, standard 
curves were generated from the known concentrations of pure protein samples loaded into 
the gel lanes. The gel image analysis and quantification were performed with Bio-Rad 
Image LabTM software. 
 
Figure 2.20 SDS-PAGE for encapsulation analysis with nanoassemblies containing Lys 
and RNaseA 
 
2.4.17 Release kinetics of proteins from the protein-polymer nanoassemblies:  
 To monitor the release kinetics of proteins (lysozyme, RNase A and cytochrome 
C), 30 µL of NA-LysED, NA-LysPEG, NA-RNaseAED, NA-RNaseAPEG, NA-CytCED and 
NA-CytCPEG samples were incubated at 37 ºC with requisite amounts of 10 mM DTT for 




immediately frozen at -20 ºC. Finally, all samples were subjected to SDS-PAGE analysis 
to quantify the amount of released proteins. 
 
Figure 2.21 Release kinetics of proteins from the nanoassemblies by SDS-PAGE at 
disulfide of polymer to DTT ratio 1:1. 
 
Figure 2.22 Release kinetics of proteins from the PPCs by SDS-PAGE at disulfide of 






Figure 2.23 Release kinetics of proteins from the nanoassemblies: (a, b) Plot of 
concentration of protein released (µM) vs. time; (c, d) Normalized plot of 
released/encapsulated protein vs. time. Although the concentration/amount of released 
proteins are approximately same for both RNase A and Cyt C, the normalized plots (moles 
of released/encapsulated protein vs. time) differentiates the protein release behavior more 
clearly and the released protein amounts for each can be correlated with their lysine 
content. 
 
2.4.18 Activity assays: 
 To measure the activity of released proteins from different polymer-protein 
conjugates, first samples were treated with 10 mM DTT and incubated at 37 °C for 4 h. 
Identical samples were subjected to 50 µM DTT mimicking extra-cellular reducing 
environment and incubated under similar condition. SpectraMax® M5 spectrophotometer 
(Molecular Devices) was utilized for evaluating all activities through absorbance and 






a. For lysozyme: 
 The EnzChek® Lysozyme Assay Kit (Thermo-Fisher Scientific) was used to check 
the lysozyme activity on a substrate based on Micrococcus lysodeikticus cell walls which 
was labeled with fluorescein to such an extent that the fluorescence is quenched. Due to 
lysozyme’s enzymatic activity, the mucopolysaccharide cell walls of the labelled 
microorganism containing β-(1-4)-glucosidic linkages between N-acetylmuramic acid and 
N-acetyl-D-glucosamine residues were hydrolysed releasing proportional amount of 
fluorescein. To perform the assay, 20 µL sample was mixed with 20 µL prepared substrate 
solution and subjected to fluorescence measurement (Ex/Em: 494/518 nm) over 1h with 
SpectraMax® M5 spectrophotometer. 
b. For RNase A: 
 RNaseAlert® activity kit (Thermo-Fisher Scientific) was used to check the activity 
of released RNase A for all samples. RNase A cleaves the oligonucleotide substrate of the 
assay consisting a fluorophore and a quencher present at two extreme ends, thus releasing 
the fluorophore which can be detected and quantified with a fluorometer. For a typical 
kinetic experiment, the substrate was mixed with 5 µL test buffer, 35 µL nuclease free 
water and 10 µL sample (diluted X10,000 from DTT experiment). 40 µL of the prepared 
sample mixture was transferred to a black 96-well plate and immediately measured for 
fluorescence (Ex/Em: 490/520 nm) with SpectraMax® M5 spectrophotometer over a 30 
min time course.  
c. For cytochrome C: 
 The peroxidase activity of cytochrome C was determined by examining the 




Cytochrome C catalyzes the reduction of H2O2 to water which is coupled with one-electron 
oxidation of chromogenic ABTS forming a brilliant blue-green ABTS radical cation. The 
assay kinetics can be monitored by observing the changes in absorbance spectra of the 
radical cation at 418 nm. Before subjecting to activity measurement, DTT treated samples 
were washed thoroughly with PBS buffer of pH 7.4 to remove DTT and other byproducts. 
The test solution was prepared by mixing 100 µL sample solution with 400 µL H2O2 (25 
mM) and 500 µL ABTS (1 mg/mL). Absorbance spectra were recorded for all samples at 
418 nm for a time course of 5 min using SpectraMax® M5 spectrophotometer. 
 
Table 2.7 Abbreviations used in activity assay plots 
 
Sample Details Sample Details
Protein_DTT 0.05 mM Native protein treated with 
0.05 mM DTT
NA-ProteinPEG 0.05 mM Protein encapsulated PEG-
crosslinked nanoassemblies
treated with 0.05 mM DTT
Protein_DTT 10 mM Native protein treated with 
10 mM DTT
NA-ProteinED 10 mM Protein encapsulated ED-
crosslinked nanoassemblies
treated with 10 mM DTT
NA-EmptyED Empty ED-crosslinked
nanoassemblies treated 
with 10 mM DTT
NA-ProteinPEG 10 mM Protein encapsulated PEG-
crosslinked nanoassemblies
treated with 10 mM DTT
NA-EmptyPEG Empty PEG-crosslinked
nanoassemblies treated 
with 10 mM DTT
Blank Only phosphate buffer, pH 
7.4
NA-ProteinED 0.05 mM Protein encapsulated ED-
crosslinked nanoassemblies





Figure 2.24 Activity of released proteins from nanoassemblies containing (a-b) Lysozyme; 
(c-d) RNase A. 
 
2.4.19 Circular dichroism (CD) spectra:  
 CD spectra of the released and native protein samples were recorded on JASCO J-
1500 spectrophotometer. In a typical experiment, NA-protein sample was incubated with 
requisite amount of DTT for 24 h. After that, the sample was dialyzed against PBS buffer 
pH 7.4 with a membrane MWCO 20 kDa for 2 days to separate the polymer. Finally, the 
purified sample was concentrated with Amicon Ultra Centrifugal Filters MWCO 3K and 




the spectra, 200 µL protein solution was injected into a quartz cuvette of 1-mm path length, 
equilibrated at 25 ºC for 10 min and scanned from 190 to 250 nm (scan rate: 20 nm/min, 
interval: 0.2 nm, average of three spectra). 
 
 
Figure 2.25 CD spectra of native proteins and polymer-protein nanoassemblies. 
 
2.4.20 MALDI-MS spectra for the released proteins: 
 MALDI-MS analyses were performed with Bruker Autoflex III time-of-flight mass 
spectrometer. All mass spectra were acquired in the reflectron mode with an average of 
500 laser shots at ~60% optimized power.   
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Figure 2.26 Comparison of MALDI-MS spectra of the native proteins and released 





Figure 2.27 MALDI-MS spectra of the NA-ProteinPEG nanoassemblies. 
 
2.4.21 Labeling of proteins with Rhodamine B: 
 To perform the cell-uptake studies, fluorescence-labelled proteins (lysozyme, 
RNase A and cytochrome C) were prepared with Rhodamine B isothiocyanate (RB). In a 
typical labelling procedure, proteins (4 mg) were dissolved separately in 2 mL of 0.1 M 
NaHCO3 buffer (pH 8.5) and stirred for 15 min at 4 ºC. RB (5 eq. of each protein, 10 
mg/mL in DMSO) was added dropwise to each protein solution and stirred at 4 ºC for 2 h 
protected from light. The RB-labelled-proteins were purified by extensive dialysis with 50 
mM Tris pH 7.4 and 50 mM NaCl mixture to remove excess RB and concentrated using 3 
kDa Amicon Ultra Centrifugal Filters. Protein concentrations in each labelled conjugate 
were calculated using UV-Vis spectroscopy. The molar ratio of RB and labelled lysozyme, 
RNase A and cytochrome C were estimated to be 0.62, 0.43 and 0.63, respectively. All 
labelled polymer-protein conjugates were prepared with the RB-labelled proteins 





2.4.22 Cell culture: 
 Human cervical carcinoma (HeLa) cells were cultured in T75 cell culture flask 
containing Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12) in a 
humidified incubator with 5% CO2 at 37 °C. Culture media was supplemented with 10% 
fetal bovine serum (FBS), 1% L-glutamine and 1% antibiotic-antimycotic (100 units/mL 
of penicillin, 100 µg/mL of streptomycin, and 0.25 µg/mL of Amphotericin B).  
2.4.22.1 Cellular uptake studies for protein delivery and endosomal escape:  
 Cell internalization studies were performed with HeLa cells seeded at 100,000 
cells/mL in glass-bottomed petri-dishes and cultured for 1 day at 37°C in a 5% CO2 
incubator. Prior to delivery cells were washed three times with PBS buffer and incubated 
with 1 mL media containing 6 µL polymer-Rhodamine B-protein conjugate or Rhodamine 
B-protein conjugate (protein concentration 1 mg/mL) at 37 °C for 4 h. After that, cell 
nucleus was stained with Hoechst 33342 (8 µM) and finally the media was replaced with 
fresh stock and incubated for another 1 h before subjecting to CLSM analysis. In addition, 
to study the endosomal escape of the labelled proteins, HeLa cells were incubated with 
labelled nanoassemblies for 4 and 24 h. After that it was stained with LysoTracker® Green 
to label endosomes/lysosomes and studied the co-localization of red and green fluorescence 







Figure 2.28 Negligible uptake for HeLa cells incubated with only proteins, cell nucleus 
was stained with Hoechst 33342, scale bar: 50 µm. 
 
 
Figure 2.29 Cellular internalization with ED-crosslinked nanoassemblies, cell nucleus was 




Figure 2.30 (a) Depth profiling for NA-CytCPEG dosed nanoassemblies: pseudo-colored 
consecutive slices through z-axis and (b) z-stack orthogonal projection from CLSM 
experiment showing localization of cytochrome C inside HeLa cells. 
 
Figure 2.31 (a) Time course of uptake for NA-CytCPEG, (b) Fluorescence intensity 
measurement from the red channel by Image J software at different time points of uptake 
experiment, expressed as Corrected total cell fluorescence, CTCF = Integrated Density - 





Figure 2.32 Endosomal escape studies by co-localization of LysoTracker Green and 
Rhodamine B tagged protein; co-localization of dyes after 4 h incubation confirms 
existence in the endosomes and after 24 h distinct red fluorescence confirms release of 
proteins into the cytosol from endosomes. Scale bar: 10 µm. 
 
2.4.22.2 Cell viability with alamarBlue® assay: 
 HeLa cells were seeded into 96-well tissue culture plates at a density of 5000 
cells/well/100 µL sample and incubated at 37 °C. After 24 h, culture media was replaced 
and cells were treated with different concentrations of protein-polymer conjugates and 
control protein samples (0.1 mg/mL to 2 mg/mL NA-ProteinPEG concentration; for naked 
protein concentration is matched with the encapsulated one in the NA-Protein sample and 
can be calculated from encapsulation efficacies, 2 mg/mL of NA-CytCPEG refers to 126 
µg/mL of cytochrome C) in 100 µL media. All samples were incubated for 6 h at 37 °C, 
then the media was replaced and incubated for another 66 h at 37 °C. Afterwards media 
was replaced, washed with PBS buffer for three times and each well was treated with 100 
µL 10% alamarBlue in media with serum. Finally, samples were incubated for 1 h and 
subjected to fluorescence measurement with SpectraMax® M5 at 560 nm excitation/590 
nm emission wavelength in a black 96-well flat-bottomed plate. 
2.4.22.3 Study of apoptosis with NA-CytCPEG nanoassembly: 
 HeLa cells were seeded at 40,000 cells/mL density in glass-bottomed petri-dishes 




PBS buffer and incubated with 1 mL media containing NA-CytCPEG conjugate (2 mg/mL) 
at 37 °C for 4 h. After that, the media was replaced and cells were incubated for another 
68 h. To detect the apoptotic cells, each sample was treated with CellEvent™ Caspase-3/7 
Red Detection Reagent (10 µM) and hoechst 33342 (8 µM) to stain the nucleus by 
incubating for 30 min before subjecting to CLSM analysis. The apoptosis assay reagent 
consists of a DEVD peptide attached to a nucleic acid-binding cy5-dye. When bound with 
the peptide, the dye becomes intrinsically non-fluorescent as the DEVD peptide retards the 
DNA-binding ability of the dye. Once caspase-3/7 enzymes are activated in apoptotic cells 
by the delivery of cytochrome C, the DEVD peptide is cleaved by those and enable the dye 
to bind to DNA to produce a bright, fluorogenic response. Co-localization of blue (hoechst) 
and red (cy5) channels was studied to check the nuclei of the apoptotic cells. 
 
Figure 2.33 Detection of activated caspase-3/7 after 72 h in control HeLa cells treated with 
NA-EmptyPEG sample; scale bar: 10 µm, no co-localization of hoechst and cy5-tagged 
assay reagent was observed in the nucleus. 
 
2.4.22.4 Encapsulation, release and cellular internalization studies with eGFP  
 To check the robustness of the polymeric delivery system, we investigated the 
encapsulation and release properties of eGFP that has higher MW and lower pI (MW ~27 
kDa, pI 5.5) compared to lysozyme, RNase A and cytochrome C (MW between 12-15 kDa 
and pI >8.5). eGFP was encapsulated within polymer matrix by the reactive coupling 




subsequently released with the aid of redox-stimuli DTT (see section ‘SDS-PAGE for 
protein-polymer conjugation and release studies’, Figure 2.31). NA-eGFPPEG assemblies 
were subjected to cellular uptake studies with HeLa cells (dosage 2 mg/mL, see previous 
‘cellular uptake studies for protein delivery’ section) and imaged using confocal 
microscope. Evenly distributed green fluorescence of delivered eGFP (Figure 2.35) 
demonstrates successful delivery of the protein into HeLa cells.35 
 




Figure 2.35 Cellular internalization with NA-eGFPPEG nanoassemblies, cell nucleus was 
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A SYMBIOTIC SELF-ASSEMBLY STRATEGY TOWARDS LIPID-ENCASED 
CROSSLINKED POLYMER NANOPARTICLE FOR EFFICIENT GENE SILENCING 
Adapted with permission from: Dutta, K.; Davide, B.; Ribbe, A. E.; Dominique, A.; Mager, J.; 
Giovanni, P. M.; Thayumanavan, S. “Symbiotic Self-Assembly Strategy toward Lipid-Encased 
Cross-Linked Polymer Nanoparticles for Efficient Gene Silencing” ACS Appl. Mater. Interfaces 
2019, 11, 24971−24983. Copyright © 2019 American Chemical Society 
 
3.1 Introduction 
 Self-assembly that relies on non-covalent intermolecular interactions, comprising single or 
multi-component molecular building blocks, plays a fundamentally important role in many 
biological processes and in the development of novel functional materials.1-2 However, designing 
and assembling multiple molecular entities to generate a predictable and controlled supramolecular 
assembly have considerable challenges; but if achieved, this can propel the design of materials 
with functional capabilities that are currently not attainable. With this in mind, we have designed 
a new three-component self-assembling system, where the parts are interdependent in the 
formation of the nanoassembly. In addition to demonstrating the formation and the characterization 
of such an assembly, the utility of such a nanostructure in addressing current toxicity and cellular 
delivery challenges involving small interfering RNA (siRNA) molecules has been investigated. 
 Although discovery of siRNA, a potential gene silencing agent, has created attractive 
opportunities targeting a wide array of diseases,3-5 RNAi technology has produced only one drug 
approved for clinical use.6 Poor cellular internalization, serum instability, rapid clearance, severe 
cytotoxicity and potential immunological flare-ups have been identified as the critical barriers for 
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such promising technology.7-12 Potential solutions like, chemically modified siRNAs and viral 
vectors have yet to overcome issues owing to cytotoxicity, stability, immunogenicity and reduced 
silencing ability upon structural modifications.7, 13-14 Interestingly, non-viral approaches, based on 
electrostatic complexation of nucleic acids using cationic lipids, peptides, nanoparticles, or 
polymers, have the potential to resolve the major reported issues.15-20 However, the key obstacle 
in these carrier-based delivery systems is the adverse side effects originated from the cationic 
charge mediated alteration in membrane potentials of cellular organelles and non-specific 
interactions with negatively charged serum proteins.13, 21-22 
 To address this, two interesting approaches, viz. charge-masking strategies23-24 and 
spherical nucleic acids25 have been reported wherein cationic charges are masked and negatively 
charged nucleic acids are decorated on surfaces, respectively. In addition to the non-cationic 
surface display, the degradable cationic blocks offer opportunities to mitigate toxicity issues 
associated with cationic polymers as well.26-29 Mimicking viral mechanism of cellular entry, 
another polymeric delivery agent, virus-inspired polymer for endosomal release, is developed with 
a hydrophilic cationic block and an endosomolytic peptide displayed only under acidic pH.30 In a 
significant departure from the conventional approaches, direct decoration of a high density of 
nucleic acids themselves as surface functionalities on nanoparticles and polymers have produced 
negatively charged nanostructures with good cellular internalization and gene silencing 
capabilities.25, 31 Natural green tea catechin condensed siRNA-cationic polymer nanoparticles and 
fluorinated oligoethylenimine nanocomplexes have also shown encouraging outcomes for siRNA 
delivery.32-33 Despite these advances, there still exists a need for RNAi-based therapeutic 




 Inspired by this, we envisaged that a possible solution to all these delicate and 
overwhelming challenges would be a noncationic approach wherein the cationic charge is 
irreversibly removed after encapsulation of siRNA without compromising stability and activity of 
the nucleic acid. To this end, we designed a unique and well-defined ‘symbiotic self-assembly’ 
approach to efficiently self-assemble a polymer, lipids, and the nucleic acid to form stable lipid 
decorated siRNA-polymer (L-siP) nanoassemblies (Scheme 3.1). We term this as symbiotic self-
 
Scheme 3.1 Symbiotic self-assembly strategy to construct L-siP nanoassembly and its key 
molecular components. 
 
assembly, because none of these three components would form the nanostructures by themselves 
under the required conditions, but they produce well-defined assemblies when brought together in 
a sequence. We outline the design hypothesis, self-assembly, and their utility in effectively 
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delivering siRNA molecules inside cells, using four different siRNAs in different cell lines. The 
system has been designed such that: (i) the high binding affinity results in efficient capture of 
siRNAs inside the assemblies; (ii) although electrostatics is utilized to capture the siRNAs, the 
residual assembly is non-cationic due to an in situ crosslinking protocol that removes the cationic 
charge on the polymer, yet incarcerates the siRNA; (iii) the surface charge of the assemblies is 
non-cationic; and (iv) the siRNA can be released using a trigger that corresponds to the operational 
environment of the cargo.  
3.2 Results and discussion 
 The self-assembly process was envisioned in three key steps. First, a cationic amphiphilic 
polymer would be utilized to electrostatically capture the siRNA (Scheme 3.1, Figure 3.1a-b). Note 
that electrostatic interaction energy is governed by Coulomb’s law (E=q1.q2/4πor), where 
represents the dielectric constant of the medium. In this case, the ionic interaction between the 
polymer and the siRNA can be significantly enhanced in low dielectric media. The hydrophobic 
alkyl chain in the amphiphilic random copolymer facilitates the complexation between the polymer 
and the siRNA in an organic-rich solvent medium, where the electrostatic interactions are expected 
to be strong. However, the medium is not completely non-aqueous, as polyelectrolyte interactions 
are entropically driven34 and it is important to accommodate the critical counterion dissociation 
that facilitates the interaction between these two macromolecules. Second, while we utilize the 
cationic charge to bind the siRNA with high affinity, we are interested in eliminating the cationic 
charge in the system since this has been implicated in many complications in non-viral carriers.13, 
21-22 Therefore, we utilize a cationic functional group that can be triggered to concurrently self-
crosslink and release the cationic functionality (Scheme 3.1, Figure 3.1b-c). Such a process 
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switches the driving force for retaining the siRNA within the assembly, from an electrostatic one 
to a combination of physical incarceration (due to crosslinking) and solvophobic forces (due to the 
 
 
Figure 3.1 (a) Synthesis of p(PDSMA-co-DodecylMA) polymer (PPDS/DD) and post-
polymerization modification to install cationic charge yielding ⊕PPDS/DD polymer; (b) Reaction 
scheme for preparation of non-cationic L-siP nanoparticles via disulfide based crosslinking; (c) 
Schematic representation of differentially crosslinked polymer-siRNA assemblies; (d) 1H NMR 
spectra of ⊕PPDS/DD polymer treated with different amounts of DTT for crosslinking in 




unfavorable organic-rich medium for the highly charged siRNA). Finally, the resultant complex 
from this process is relatively apolar with lipophilic alkyl chains on their surface; this complex 
therefore is not amenable for distribution in aqueous media. We utilize this incompatibility to 
achieve a hydrophobic force driven coating of charge-neutral lipids in aqueous medium. The 
concentration of the lipids in this step is such that it does not exhibit self-assembly by itself, but 
does so on the surface of the existing hydrophobic exterior of the polymer-siRNA complex. This 
symbiotic self-assembly, where the organization of each of these components into the assembly is 
dependent on the presence of other components in the system, is thus achieved in three convenient 
steps.  
3.2.1 Synthesis, characterization and crosslinking study of cationic PDS-Dodecyl polymer 
(⊕PPDS/DD)  
 To achieve the desired self-assembly, a cationic random co-polymer PDS-Dodecyl 
polymer (⊕PPDS/DD) was targeted (Figure 3.1a). This copolymer was synthesized via RAFT 
polymerization of pyridyl disulfide methacrylate and dodecyl methacrylate monomers (molar ratio 
9:1, Figure 3.1) to obtain p(PDSMA-co-DodecylMA) polymer (PPDS/DD; MW =14.5 kDa; Đ: 1.3). 
The nitrogens in the PDSMA side-chain were quantitatively methylated using methyl triflate to 
achieve the ⊕PPDS/DD polymer (Figure 3.1). All polymers were characterized with 1H, 13C & 1H-
15N NMR, GPC and FT-IR spectroscopy. Methylation of the PPDS/DD polymer was confirmed from 
the chemical shift and integration of pyridinium ring protons in the final ⊕PPDS/DD polymer. To 
further confirm the synthesis of the ⊕PPDS/DD polymer, two-dimensional heteronuclear correlation 
NMR experiments (1H-15N HMBC) were performed with the synthesized polymers and 1-
methylpyridine-2-thione molecule, released after crosslinking with 1,4-dithiothreitol (DTT, 
reported in equivalents). A clear shift of 15N NMR band for ⊕PPDS/DD polymer, in addition to 
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appearance of a new correlation band corresponding to methylated nitrogen, confirms successful 
installation of cationic charge in the ⊕PPDS/DD polymer. Further, 1H NMR spectra for differentially 
crosslinked samples in presence of different amounts of DTT showed the disappearance of the 
methylated-PDS units with the concurrent appearance of the peaks that correspond to the small 
molecule byproduct of the crosslinking reaction, N-methylpyridothione (Figure 3.1d). These 
experiments were carried with the polymer by itself without self-assembling the polymer through 
electrostatic complexation with siRNA, for characterization purposes. Note that complete 
crosslinking was achieved at 1 equiv DTT (2 times excess than required) which could be attributed 
to suppressed reactivity owing to steric barriers.  
3.2.2 ‘Symbiotic self-assembly’ to create L-siP nanoassemblies 
 The first step of proposed self-assembly (Scheme 3.1) involves electrostatic complexation 
between ⊕PPDS/DD polymer with naked siRNA in acetone:water mixture (70:30 v/v). In addition 
to reducing the dielectric constant of the media35 to facilitate greater Coulombic interaction, the 
choice of solvent mixture is also optimized for the solubility of both ⊕PPDS/DD polymer & siRNA. 
The amphiphilicity of ⊕PPDS/DD polymer, governed by the ratio of cationic PDS and dodecyl 
moieties, was also found to affect the solubility of such complexes. We found that 90:10 ratio 
polymer exhibited better solubility and complexation capability, compared to that of the initially 
attempted 70:30 ratio polymer. All subsequent complexation experiments were conducted with the 
90:10 ratio polymer in the acetone:water co-solvent system. To further analyze whether the 
observed interaction between the polymer and the siRNA is indeed based on electrostatics, we 
conducted molecular dynamics (MD) simulations of a coarse-grained (CG) molecular model of 
this system (see experimental for details about the model) in the acetone:water 70:30 mixture. 
Simulations show that while the cationic polymers and the oligonucleotides are held together, 
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removal of cationic charge in the polymer detaches the oligonucleotides from the polymer chain. 
This supports the idea that the self-assembly process is controlled by electrostatic interactions (see 
experimental). 
 The next step in our self-assembly involves structurally reinforcing the complex through a 
chemical crosslinking reaction, which concurrently also releases the cationic charge from the 
polymer. This crosslinking step was executed using DTT, where the rapid thiol-disulfide exchange 
reaction between DTT and the methylated-PDS unit affords a thiol moiety on the polymer side 
chain, along with a stable small molecule byproduct, viz. N-methylpyridine-2-thione. The thiol 
moiety on the polymer chain can subsequently react with other methylated-PDS units within the 
complex to generate crosslinks. Note that this crosslinking step helps to shed positive charge, while 
also stitching the polymer chains to cage siRNA, thus preventing the loss of siRNA that is 
electrostatically encapsulated in the first step. More details on the effect of crosslinking density is 
provided in the next section.  
 Note that the complexation and crosslinking steps were conducted in an organic rich 
(acetone-water) media. In order for using this complex to deliver the siRNA molecule to cells, this 
complex must be in an aqueous media. To achieve this, the complex was coated with lipids in 
aqueous phase. Since the crosslinked polymer-siRNA complex was achieved in an organic solvent, 
we envisaged that the surface of the complex is apolar and would therefore be viable for coating 
with lipid molecules.  Accordingly, we used a combination of a zwitterionic lipid (DOPE) and a 
PEGylated lipid (DSPE PEG-2000), because of their fusogenic and solubilization abilities 
respectively.9,36-37 Briefly, a mixture of DOPE and DSPE PEG-2000 lipids was initially dissolved 
in water at a concentration much below their critical aggregation concentrations.38 The crosslinked 




Figure 3.2 Effect of N/P ratio & cross-linking on encapsulation stability & siRNA release: (a) 
Variation of N/P for uncrosslinked particles; (b) Effect of variation of cross-linking measured by 
the DTT feed amount at higher N/P ratio on encapsulation & siRNA release; (c) DLS size 
distribution and (d) correlation diagram for N/P 15 nanoassemblies at different cross-linking; (e) 
Lipid coated nanoassembly constructed with CG-MD simulation: snapshot of the equilibrated L-
siP15/1 (cut in half on the major diameter to clearly see the interior). Polymer is shown in transparent 
green, the dsDNA in yellow and the polymer outer layer is transparent grey (inset: exterior of the 
NA, where lipids are shown in grey); (f) Radial distribution functions g(r) providing the relative 





v/v) for the self-assembly of lipids on its surface (see experimental for details) to produce the final 
lipid-polymer-siRNA (L-siP) nanoassembly (Scheme 3.1). Interestingly, the overall self-assembly 
process is considered symbiotic, because the lipids are used at concentrations well below their 
CACs and yet it self-assembles on the surface of the polymer-siRNA complex, which in itself 
required functional complementarity for its formation.  
3.2.3  Effect of N/P and crosslinking on complexation and triggered release of siRNA from 
L-siP  
 The relative ratio of complementary charges (N/P) is often used, with number of positively 
charged nitrogens (N) in the polymer to the number of negatively charged phosphate moieties (P) 
in the nucleic acid as the measure, to evaluate the complexation efficiency. To understand the 
effect of this ratio on complexation, we systematically varied the amount of polymer to investigate 
the construction of L-siP assemblies at different N/P ratios (Figure 3.2). All particles were coated 
with DOPE and PEG-lipids to make them hydrophilic and stable in aqueous medium. The siRNA 
encapsulation was evaluated with agarose gel retardation assay (Figure 3.2a-b). First, 
complexation was studied at different N/P ratios without any crosslinking. At low polymer 
concentrations (N/P of 2.5 and 5), the complexation was found to be inefficient as noted from the 
significant presence of free siRNA in the gel. At N/P 7.5 and above, the siRNA encapsulation was 
found to be efficient (Figure 3.2a). In addition to the encapsulation efficiency, it is also necessary 
that we release the encapsulated siRNA molecules in the presence of a biologically relevant 
intracellular trigger.39-40 Therefore, the release of siRNA from these assemblies were assessed in 
the presence of a redox-stimulus at a concentration that is similar to that found in the cytosol (10 
mM glutathione, GSH). In the presence of this stimulus, the siRNA release was found to be 
significant in the N/P 7.5 complex, but was significantly lower at higher N/P ratios (Figure 3.2a). 
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However, dynamic light scattering (DLS) measurements revealed non-uniform, bimodal and broad 
particle size distributions with poor correlation coefficients for all uncrosslinked nanoassemblies 
(see experimental) suggesting unstable nanoparticle formations. 
 The study of uncrosslinked complexes above provides an initial insight into the optimal 
N/P ratios. Note however that in our final complex, the positive charges will be removed through 
crosslinking. Therefore, the efficiency of siRNA encapsulation in this scenario might be very 
different as the balance between weakening of the complexation due to charge removal and 
strengthening the incarceration due to crosslinking would play an important role. To evaluate this 
balance, we studied the effect of crosslinking towards the formation of L-siP particles at different 
N/P ratios (Figure 3.2b). Upon increasing crosslinking degree, leakage of siRNA was evident from 
the assemblies formed at N/P 7.5 and 10.  At higher N/P ratios (starting from N/P 15), in 
combination with higher crosslinking (0.25 equiv DTT onwards), the siRNA encapsulation was 
found to be stable (Figure 3.2b), as evident from narrow particle size distributions with excellent 
correlation coefficients. However, the release of siRNA was found to be crosslinking dependent, 
where the maximum release was obtained between 0.25-1 equiv of DTT crosslinking. This can be 
attributed to the critical balance of positive charge and crosslinking degree in L-siP 
nanoassemblies. At lower crosslinking degree (0-0.1 equiv DTT), residual cationic charge left after 
DTT treatment becomes the dominating factor and is able to hold back the siRNA tightly in the 
nanoassemblies. While at higher crosslinking degree (2 equiv DTT), siRNAs might be deeply 
buried and shielded inside the nanoassembly preventing adequate exposure to external reducing 
release environment. Evidently, at even higher N/P 25, where the polymeric burden was more, 
negligible release of siRNA was observed for similar reasons (Figure 3.2b). Based on these 
observations, a threshold of N/P 15 was thus considered as an efficient L-siP system for both 
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siRNA encapsulation and release (also see later for quantification). As L-siP nanoassemblies 
contain lipids, the zeta potential values were found to be negative (-30 to -40 mV, see 
experimental) as an effect of efficient coating of DOPE and PEG- lipids.41-42  
 To further understand the complexation and release process, we also carried out CG-MD 
simulations (see experimental). In our models, to mimic the crosslinking process, we introduced -
SS- groups in the polymer assembly, while cleaving the positively charged functionalities, 
assuming that crosslinking has occurred.  When we introduced the crosslinking in the equilibrated 
N/P 7.5 model system, we could clearly observe leakage of the oligos from the polymer (see 
experimental). Next, we built a molecular model for the more promising N/P 15 L-siP system 
(Figure 3.2d and 3.2e). We started from an N/P 15 polymer-oligo network that was spontaneously 
formed in 70:30 acetone:water (v/v) via CG-MD simulation (details are available in the 
Computational Methods in experimental). Then, we introduced a 100% crosslinking by adding a 
suitable number of DTT molecules in the system. To be sure to form a single aggregate in the 
center of the simulation box (useful for successful steps) following compaction due to crosslinking, 
we used a recently optimized simulation technique that push the system toward a single 
aggregation center.43 The DTT molecules selectively and strongly interacted with the -SS- groups 
in the polymer during this CG-MD simulation, while after coordination the cationic groups of the 
polymer involved in the process have been cleaved. Next, we added DOPE lipid molecules and 
replaced the solvent consistently with the experiments (water/organic=20, v/v). We then 
equilibrated the L-siP model nanoparticle via CG-MD simulation, which provided us with an 
insight into the structure of this assembly at a resolution <5 Å (Figure 3.2d). The lipid layer 




Figure 3.3 (a) CG-MD simulation snapshots (taken after 4 µs) showing how the oligo release 
proceeds at different degrees of de-crosslinking: no decrosslinking, 90% of crosslinking removed 
and complete de-crosslinking; (b) Quantification of the different release behaviors as the number 
of contacts between oligo and polymer as a function of simulation time (initial number of contacts 
normalized to 1); (c) Ribogreen assay to quantify encapsulated & released siRNA from L-siP15/1; 
Summary of encapsulation (d) and release profiles (e) at different N/P & crosslinking ratios 




in the polymer matrix (green). From the equilibrated phase CG-MD trajectory we computed the 
radial distribution functions of the polymer, lipid and oligonucleotides (g(r): relative probability 
to find these in space) as a function of the distance from the center of the nanoparticle (Figure 
3.2e). The superposition of the cyan and purple curves in Figure 3.2e indicates that the polymer 
and the oligos are uniformly mixed in the core of the assembly while the lipids cover it and 
constitute the shell of the nanoassembly, which resulted well stable L-siP in such experimental 
conditions. 
 Starting from this equilibrated crosslinked L-siP model, we further probed the 
nanoassembly to understand the effect of crosslinking on stabilization and release of 
oligonucleotides. Upon deleting the lipid shell, we explored the release of encapsulated 
oligonucleotides as a function of the de-crosslinking ratio. The polymer-oligo complex remains 
stable in 100% DTT, i.e., fully crosslinked condition (Figure 3.3a). However, at 90% de-
crosslinking (90% of DTT molecules eliminated from the model) we observed partial release of 
oligoes from the assembly, which completely disassembled under complete removal of DTT (0% 
DTT). Figure 3.3b quantifies these observations, showing the number of contacts between the 
polymer and the guest oligos over time calculated with respect to the initially equilibrated 
nanoassembly.  
 We further experimentally confirmed the encapsulation and release of siRNA from the L-
siP nanoparticle via RiboGreen assay for the promising N/P 15 case (Figure 3.3c, see 
experimental).44 Under the encapsulated state, siRNA is significantly inaccessible to the assay 
reagent showing no apparent fluorescence signal generation. However, the amount of siRNA, once 
released from the assembly under reducing conditions, the fluorescent signal generation was found 
to be dependent on the crosslink density. These observations further support the results obtained 
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from the agarose gel retardation study above (Figure 3.2a-b). The degree of siRNA encapsulation 
and release obtained from agarose gel studies is summarized in Figure 3.3d and 3.3e.  
To further understand the fate of siRNA during encapsulation and release steps, we also 
performed 31P NMR experiments to monitor the processes (see experimental). A 
phosphorothioate-modified siRNA (PTsi, δ ~53 ppm) is utilized to distinguish it from the 
 
Figure 3.4 Cryo-TEM images of L-siP particles at N/P 15 (a) without crosslinking & (b) with 
cross-linking (DTT-1 equiv), scale: 50 nm; (c) N-STORM confocal microscopy images of single 
L-siP15/1 particle, red: cy3-siRNA, green: carboxyfluorescein labelled DSPE-PEG lipid that coats 




phosphorus in phosphate groups of DOPE and DSPE-PEG lipids (δ ~0 ppm).45-46 Once 
encapsulated the mobility of the siRNA inside the polymer cage will be significantly impaired 
compared to its situation in bulk solvent. As a result, the 31P band at δ ~54 ppm (for PTsi) is 
completely eliminated after the formation of L-siP nanoassembly, whereas it reappears upon 
subjecting it with the release condition (with 10 mM GSH & Triton X-100, see experimental).45 
This evidence further supports the results obtained from agarose gel retardation and RiboGreen 
assay studies (Figure 3.2a-b, 3.3c). Evidently, to reduce the quantity of polymer in the L-siP 
assembly construction with suitable high crosslinking degree (in context of reducing cytotoxicity 
by shedding cationic charge), we chose the L-siP assembly (L-siP15/1) constructed under N/P 15 
with crosslinking using 1 equiv of DTT (we choose excess DTT to ensure complete removal of 
cationic charge as discussed in Figure 3.1d) as the desired candidate for further cellular 
experiments. 
3.2.4 Cryo-TEM and N-STORM confocal imaging of L-siP nanoassembly  
 Prior to evaluating the intracellular delivery of siRNA using these nanoassemblies, we 
further characterized the nanoassemblies via cryo-TEM and N-STORM confocal fluorescence 
microscopy (Figure 3.4). Cryo-TEM studies were performed for both the N/P 15 uncrosslinked 
and crosslinked samples. Images of the uncrosslinked assembly (Figure 3.4a) clearly show a fractal 
morphology consisting loose aggregates, whereas crosslinked L-siP15/1 nanoassembly (Figure 
3.4b) showed uniform spherical assemblies with an average size of ~100 nm. These results are in 
accordance with our earlier DLS observations (Figure 3.2b-c). To further characterize the particle 
construction, we prepared L-siP15/1 nanoassembly utilizing carboxy-fluorescein labelled DSPE 
PEG-2000 lipid and cy3-labelled siRNA. As per our symbiotic self-assembly hypothesis, polymer 




Figure 3.5 siRNA delivery in MDA-MB-231 cell line: (a) Cellular uptake of cy3-labelled siRNA 
(4 h incubation), scale: 20 µm; (b) Quantification of uptake with flow cytometry (4 h incubation); 
(c) Mechanism of siRNA transfection in presence and absence of endocytic inhibitors; (d) 
Endosomal colocalization of red cy3-siRNA and Lysotracker blue (pseudo-colored as green) after 
4 h and escape after 24 h incubation, scale: 20 µm; (e) Calcein assay showing efficient escape of 
calcein from endosome and localization in cytosol in presence of L-siP15/1 NA, scale: 10 µm; (f) 
Cellular viability and (g) LDH cytotoxicity assay for empty L-siP, L-siP nanoassemblies with 
different siRNA concentrations (25, 50, 100, 200 & 500 nM) at N/P 15 and Lipofectamine (LF)-
siRNA complexes (with fixed 100 nM siRNA) at 2, 5 and 10 µg/mL LF concentrations; Student’s 
t-test (compared L-siP/siNC sample bearing 100 nM siRNA with L-siP/Empty and LF samples): 
***p<0.001, **p<0.01, *p<0.05, ns (non-significant)>0.05. 
 
surrounding the electrostatic polymer-siRNA complex. The N-STORM images in Figure 3.4c 
clearly demonstrate the L-siP nanoassembly design with red cy3-siRNA comprising the inner part 
and green lipid layer encapsulating it externally. Interestingly, color-coded intensity profile 
defined by the electron scattering cross-section across the particles also matches the N-STORM 
measurements (Figure 3.4c & see experimental). 
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3.2.5 Cellular uptake and intracellular distribution 
 To test the ability of L-siP15/1 towards intracellular delivery of siRNA, we prepared these 
nanoassemblies using cy3-labelled siRNA and investigated their cellular distribution in three 
different cancer cell lines, viz. mammary gland/breast cancer cell line MDA-MB-231, cervical 
cancer cell line HeLa and a prostate cancer cell line DU-145 (Figure 3.5, for MDA-MB-231 and 
see experimental for HeLa & DU-145). As shown in Figure 3.5a, a clear distribution of red 
fluorescence in the cytosolic region confirms efficient transfection of cy3-siRNA nanoassembly 
(Figure 3.5b for flow cytometry quantification). The transfection efficacy was also evaluated in 
HeLa and DU-145 cells though confocal laser scanning microscopy (CLSM) (see experimental) 
and flow cytometry (see experimental). A quantitative comparison reveals the following order of 
uptake potency in different cell lines: MDA-MB-231>HeLa>DU-145.  
 Next, we probed the cellular uptake mechanism via utilizing different inhibitors for 
endocytic pathways in the above-mentioned cell lines through flow cytometry with cy3-siRNA 
containing L-siP15/1 nanoassembly (Figure 3.5c & see experimental). EIPA and hyperosmolar 
sucrose, inhibitors for macropinocytosis and clathrin-dependent endocytosis, respectively were 
found to have a striking effect on uptake in MDA-MB-231 and HeLa cells, whereas the effect of 
nystatin, an inhibitor for caveolae-mediated endocytosis, was found to be comparatively 
reduced.47-49 These results show that the major cellular internalization proceed through 
macropinocytosis and clathrin-dependent pathways for MDA-MB-231 and HeLa cell lines. In 
contrary, DU-145 cells only showed a significant decrease in fluorescence intensity when 
incubated in presence of EIPA suggesting macropinocytosis being the exclusive choice of uptake 
pathway (see experimental). 
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 To evaluate the intracellular distribution of delivered cy3-siRNA through L-siP15/1 
assembly over time, we performed CLSM of MDA-MB-231 cells in presence of endo/lysosomal 
stain, lysotracker blue (pseudo-colored in green in Figure 3.5d). After 4 hours of incubation, the 
red fluorescence from cy3-siRNA was observed to be co-localized with lysotracker blue (Figure 
3.5d), indicating that the nanoassemblies are located in endo/lysosomal compartments. 
Interestingly, this co-localization diminishes significantly after 24 h incubation, as indicated by 
clear separation of red (cy3-siRNA) and blue (pseudo-colored in green for lysotracker stain) 
channels suggesting endosomal disruption and release of siRNA into the cytosol. A quantitative 
comparison is reflected in the decrease in co-localization ratio from 0.65 (4 h) to a lower value 
0.34 (24 h). The probable reason for such facile intracellular release of siRNA cargo could be 
explained from the fusogenicity of DOPE lipid, employed in decorating the L-siP nanoassembly, 
through attachment and fusion with anionic endosomal membrane.7  
 To further investigate whether endosomal disruption is indeed facilitated by L-siP 
nanoassemblies, we performed calcein green assay (Figure 3.5e and see experimental). Calcein, a 
membrane-impermeable dye, shows punctate green fluorescence above its self-quenching 
concentration when entrapped in endo-lysosomal compartments.50 However, the green 
fluorescence changes to a bright diffused pattern (dequenched state), if calcein can be released in 
cytosol after successful escape from endosomes mediated by delivery agents. As shown in Figure 
3.5e & see experimental, the punctate green fluorescence of calcein in control cells confirms the 
endosomal entrapment, whereas a diffused fluorescence is observed for L-siP15/1 nanoassembly 





3.2.6 Evaluation of cytotoxicity and nuclease stability for L-siP15/1  
 Stability of the siRNA-polyion based electrostatic complex is mostly guided by the overall 
high cationic charge which eventually compromises the safety of the delivery agent increasing 
cytotoxicity. To evaluate the safety feature of L-siP15/1 nanoassembly, we evaluated cellular 
viability and plasma membrane integrity in MDA-MB-231 (Figure 3.5f-g), HeLa and DU-145 (see 
experimental) cell lines. L-siP/siNC nanoassembly (siNC: negative control siRNA) showed ~86% 
cellular viability even at 200 nM siRNA concentration (with comparable polymer amount for N/P 
15), whereas viability reduces to ~42% for lipofectamine-siRNA sample (LF-siNC) at an identical 
concentration (Figure 3.5e). Cytotoxicity study in HeLa and DU-145 cells also demonstrate a high 
cellular viability compared to lipofectamine (see experimental).  
Next, we were interested in checking the integrity of the plasma membrane through lactate 
dehydrogenase (LDH) assay.51-52 The compromised cell membrane would release cytosolic LDH 
enzyme into cell culture media which, in turn, can be quantified through an absorbance-based 
assay.51-52 Figure 3.5g shows a minimal to no membrane damage mediated by L-siP assemblies 
even at a significantly high dosage (200 or 500 nM siRNA). In comparison, LF-siNC samples 
showed ~3 to 7-fold increase in membrane damage compared to untreated cells (Figure 3.5g, see 
experimental). These results demonstrate significantly less cytotoxicity of the designed L-siP 
nanoassembly desirable for a safe delivery agent. As L-siP nanoassembly comprises biocompatible 
DOPE/PEG-based lipids and methacrylate-derived polymers, it will be prone to slow hydrolytic 
and enzymatic degradation under in vivo conditions with significantly less probability of systemic 
accumulation.53-54 
One of the bottlenecks of RNAi based technology is the limited stability of naked siRNA 




Figure 3.6 eGFP silencing with L-siP15/1: Confocal microscopy images (a) for eGFP silencing and 
flow cytometry data (b) for quantification of eGFP fluorescence in HeLaeGFP cells; scale: 20 µm; 
Student’s t-test: ***p<0.001, **p<0.01, *p<0.05, ns (non-significant)>0.05. 
 
Thus, a critical requirement for an efficient delivery agent is to provide end-to-end protection till 
the cargo is delivered in the intracellular space. To this goal, we investigated the stability of the 
encapsulated siRNA in the presence of RNase A and 10% fetal bovine serum.56-57 After incubation 
at different time interval with RNase A and serum, the L-siP/siNC nanoassemblies were subjected 
to redox-triggered release condition (10 mM GSH) and evaluated in agarose gel retardation assay. 
L-siP nanoassembly is efficient in protecting siRNA even after 24 h of incubation, whereas the 
unprotected naked siRNA is completely degraded within 4 h of incubation in presence of RNase 
A and serum (see experimental).    
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3.2.7 Gene silencing efficacy and retrieval of cytotoxicity mediated through PLK1 & MDR1 
siRNAs  
 Finally, we were interested in checking the efficacy of the L-siP15/1 assembly in silencing 
specific gene activity. To this end, HeLaeGFP and DU-145eGFP cells, stably expressing eGFP, were 
treated with L-siP15/1 nanoassembly containing 50, 100 and 200 nM GFP-siRNA. The reduction of 
green fluorescent intensity was evaluated through CLSM and flow cytometry (Figure 3.6, see 
experimental). CLSM images, shown in Figure 3.6a (see experimental), reveals a clear decrease 
in green fluorescence intensity for both HeLaeGFP and DU-145eGFP cells upon treatment of L-siP15/1 
nanoassembly. Further, the GFP expression (quantified through flow cytometry, Figure 3.6b & see 
experimental) was decreased to 43% at 200 nM siRNA concentration (L-siP/siGFP) in HeLaeGFP 
cells in comparison to ~84% for negative control siRNA (L-siP/siNC) treated cells. A similar trend 
was also observed in DU-145eGFP cells where L-siP/siGFP and L-siP/siNC treated cells showed 
50% and 110% eGFP expression, respectively. Lipofectamine RNAiMAX-eGFP siRNA complex 
(LF-siGFP), evaluated as positive controls, exhibited reduction of eGFP expression up to 61% and 
33% for HeLaeGFP and DU-145eGFP cells, respectively at similar siRNA concentrations.  
Encouraged by these results, we further tested the gene knock-down efficacy of the L-
siP15/1 nanoassemblies towards two other gene types, PLK1 and MDR1, through evaluation of 
mRNA transcription levels by quantitative real-time polymerase chain reaction (qRT-PCR) and 
protein expressions by western blot analysis (Figure 3.7). PLK1, a critical controller of mitosis, is 
found to be overexpressed in many cancer cells, leading to faster tumor progression.58 On the other 
hand, MDR1 gene in multi-drug resistant cells upregulates the expression of drug transporter 
proteins, like P-glycoprotein (P-gp).59 Although various small molecule inhibitors for PLK1 and 




Figure 3.7 Gene silencing studies: qRT-PCR (a, b) and western blot (c, d) analysis for (a, c) PLK1 
and (b, d) MDR1; Cellular viability mediated by knock-down of (e) PLK1 gene and (f) MDR1 
gene (after treatment of doxorubicin for MDR1). Uptake comparison of doxorubicin via confocal 
microscopy (g) in untreated and L-siP/siMDR1 treated cells; orthogonal view is for L-siP+Dox 
sample; scale: 10 µm; Student’s t-test: ***p<0.001, **p<0.01, *p<0.05, ns (non-significant)>0.05. 
 
its specificity, much reduced toxicity and wide applicability in multiple cancer cells. We separately 
constructed L-siP assemblies based on PLK1- & MDR1-siRNA and evaluated the gene knock-
down efficacy in MDA-MB-231 and NCI-ADR/RES cell lines, respectively. qRT-PCR studies 
showed efficient silencing of both PLK1 and MDR1 genes as evident by the reduced relative gene 
expression levels of ~12-18% in cells treated with L-siP nanoassemblies containing PLK1 and 
MDR1 siRNAs (Figure 3.7a and 3.7b, at 50 or 100 nM siRNA concentrations). Moreover, western 
blot analyses (Figure 3.7c, 3.7d and see experimental) revealed that PLK1 and P-gp protein 
expressions were reduced to ~25% and ~31% (~24% and 51% for lipofectamine), respectively 
compared to untreated cells. 
 To further demonstrate the consequence of L-siP nanoassembly mediated siRNA delivery 
and gene silencing, cellular viability studies were conducted on both PLK1 and MDR1 transfected 
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MDA-MB-231 and NCI-ADR/RES cell lines, respectively. For PLK1 compromised cells (Figure 
3.7e), viability was reduced to ~47% for L-siP nanoassembly (~51% for lipofectamine positive 
control). Similarly, when treated with anti-cancer drug -doxorubicin (Dox), MDR1 depleted NCI-
ADR/RES cells showed mere ~31% viability compared to ~73% and ~35% for free Dox and 
lipofectamine transfected positive control cells, respectively (Figure 3.7f).60 Moreover, CLSM 
images (Figure 3.7g) confirm significantly higher red fluorescence intensity in cells from Dox 
suggesting efficient penetration of the drug in L-siP nanoassembly (MDR1-siRNA) treated cells, 
whereas a rather subdued red fluorescence is observed for only free drug-treated cells. 
3.3 Summary 
 In summary, we report a unique siRNA encapsulation and intracellular delivery approach 
by developing a new symbiotic self-assembly strategy of a polymer, siRNA and lipid molecules. 
In this approach, the initial complexation with the siRNA is made possible through classical 
electrostatic interactions. The key feature here is that this interaction was carried out in a relatively 
apolar media that not only enhances the binding affinity between the polymer and the siRNA, but 
also facilitates the retention of siRNA within the in situ generated polymer ‘cage’. Note that the 
electrostatic complex is converted to a physically incarcerating capsule through a crosslinking 
reaction, which concurrently removes the positive charge in the polymer. As the positive charges 
are being removed, but before the crosslinking reinforcement is fully in place, the siRNA 
molecules could escape the complex. However, the siRNA remains stably encapsulated, because 
the bulk environment of this in situ crosslinking reaction is apolar and incompatible. This structure 
is then finally camouflaged by the coating of a zwitterionic lipid that also imparts biocompatibility 
and endosomolytic ability. We call this process symbiotic, because each of these components 
require the other components in the solution in order to provide the final self-assembled structure. 
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We have rigorously characterized each of the steps in the self-assembly process, nanoassembly 
formation, lipid coverage, cellular internalization and cytosolic release using both experimental 
and computational modeling approaches. Efficient gene-silencing mediated by the designed 
nanoassembly provides evidence for successful integration and leverage of the built-in molecular 
features. We have shown that this self-assembly strategy offers several advantages: (i) reduction 
of cytotoxicity from cationic charge-based delivery vectors; (ii) tunability in crosslinking degree 
affecting siRNA binding and release efficacy; (iii) a biologically relevant trigger for siRNA 
release; (iv) efficient cargo protection from degradation by nucleases; and (v) integrated utility of 
the useful features of lipids (biocompatible surface & tuning endosomal escape) and designer 
polymers (structural integrity, multivalent interaction & protection). We anticipate that the strategy 
reported herein could potentially serve as a safe platform and aid in the development of RNAi 
based therapeutics.  
3.4 Experimental 
3.4.1 Materials & characterizations 
 Dodecyl methacrylate, 2,2′- dithiodipyridine, 4-cyano-4-
(phenylcarbonothioylthio)pentanoic acid, D, L-dithiothreitol (DTT), Glutathione were obtained 
from Sigma-Aldrich, USA and were used without further purification unless otherwise mentioned. 
2,2′-azobis-(2-methylpropionitrile) (AIBN) was procured from Sigma-Aldrich, USA and purified 
by recrystallization before usage. Methyl trifluoromethanesulfonate was procured from Matrix 
Scientific, USA. 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (18:1 (Δ9-Cis) PE: DOPE) and 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] 
(ammonium salt, DSPE-PEG2000) lipids were procured from Avanti Polar Lipids. Silencer™ 
Negative Control No. 1 siRNA (Catalog #: AM4611, proprietary sequence not provided), 
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Silencer™ Cy™3-labeled Negative Control No. 1 siRNA (Catalog #: AM4621, proprietary 
sequence not provided), Silencer™ GFP (eGFP) siRNA (Catalog #: AM4626, proprietary 
sequence not provided) and MDR1/ABCB1-siRNA (sense: 5’-GCUUAACACCCGACUUACAtt-
3’, antisense: 5’-UGUAAGUCGGGUGUUAAGCtc-3’) were procured from Thermo-Fisher 
Scientific. PLK1-siRNA was obtained from Qiagen, USA (sense: 5’-
CGGGCAAGAUUGUGCCUAATT-3’, antisense: 5’-UUAGGCACAAUCUUGCCCGCG-3’). 
Lipofectamine RNAiMAX, LysoTracker™ Blue DND-22, were obtained from Thermo-Fisher 
Scientific. Phosphorothioate siRNA (PTsi) was obtained from Dharmacon (sense: 
A*U*G*U*A*U*U*G*G*C*C*U*G*U*A*U*U*A*G, antisense: C*U*A*A*U*A*C*A*G*G 
*C*C*A*A*U*A*C*A*U; * denotes phosphorothioate modifications). 
3.4.2 Synthesis of random co-polymer for complexation with siRNA 
3.4.2.1 Synthesis of p(PDSMA-co-DodecylMA) polymer (PPDS/DD) 
 Pyridyl disulfide ethyl methacrylate (PDSMA) was synthesized using previously reported 
procedure. Reversible Addition-Fragmentation chain Transfer (RAFT) polymerization was 
utilized to synthesize p(PDSMA-co-DodecylMA) Polymer. In a typical procedure, PDSMA (0.903 
g, 3.5 mmol), dodecyl methacrylate and chain transfer agent 4-cyano-4-
(phenylcarbonothioylthio)pentanoic acid were taken in a 25 mL Schlenk flask and dissolved in 2 
mL dry THF. To this mixture, 1.1 mg (0.007 mmol) AIBN, dissolved in 1 mL dry THF, was added. 
The solution was mixed for 5 min, the flask was subjected to three freeze-pump-thaw cycles and 
purged with argon. Finally, the sealed flask was transferred to a preheated oil-bath and the 
polymerization was carried out at 70 °C for 24 h. After that, the Schlenk flask was cooled down to 
quench the reaction and THF was evaporated. The reaction mixture was purified by precipitating 
in diethyl ether for three times and finally dried in vacuo for overnight at room temperature. Yield: 
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78%, GPC (THF) Mn: 14.5 kDa, Đ: 1.3; 1H NMR (400 MHz, CDCl3): δ ppm 4.24−4.09, 3.87, 
3.65−3.53, 3.37, 2.95-2.90, 1.93-1.84, 1.04-0.89; 13C NMR (100 MHz, CDCl3): δ ppm 177.4, 
177.07, 176.34, 159.69, 159.56, 159.5, 149.87, 137.31, 121.07, 120.01, 119.96, 62.84, 54.47, 
45.34, 45.28, 45.00, 32.06, 31.71, 29.80, 29.50, 29.18, 25.41, 22.83, 14.25, 11.56.  
3.4.2.2 Synthesis of cationic-PDS-dodecyl polymer (⊕PPDS/DD) 
In a 20 mL glass vial, 0.75 g of PPDS/DD polymer was weighed and dissolved in 5 mL DCM. The 
solution was cooled in ice for 10 min and after that methyl trifluoromethanesulfonate (0.73 g, 4.4 
mmol) was added to it dropwise. The mixture was stirred at 4 °C overnight, the solvent was dried 
and precipitated in diethyl ether three times to purify. The polymer was dried overnight in vacuo 
at room temperature. Yield: 75%, calculated Mn: ~22 kDa; 1H NMR (400 MHz, CDCl3): δ ppm 
4.24−4.09, 3.87, 3.65−3.53, 3.37, 2.95-2.90, 1.93-1.84, 1.04-0.89; 13C NMR (100 MHz, CDCl3): 
δ ppm 177.33, 159.3, 159.13, 147.57, 144.35, 125.51, 124.03, 122.05, 115.7, 62.51, 45.7, 45.13, 
44.86, 37.1, 36.97, 31.73, 31.35, 29.43, 22.4, 19.08, 16.95, 13.02. 
3.4.3 Characterization of polymers 
(a) Gel permeation chromatography (GPC) 
GPC of PPDS/DD polymer was performed in Agilent 1260 LC instrument with a refractive index 
detector using THF as the eluent and molecular weights were calculated against poly(methyl 
methacrylate, PMMA) standards. 
(b) 1H, 13C, 1H-15N & 31P NMR 
1H, 13C and 31P NMR spectra of the samples were recorded on a Bruker NMR spectrometer (400.13 




Figure 3.8 1H NMR spectra of (a) PPDS/DD and (b) ⊕PPDS/DD polymers. 
Multiple Bond Correlation, HMBC) correlation spectra were acquired on Bruker NMR 
spectrometer (500.13 MHz for 1H, 50.68 MHz for 15N).  
Molar ratio between the PDSMA and DodecylMA monomers for PPDS/DD polymer was calculated 
from the ratio of the integrations of -CH2 protons adjacent to the methacrylate monomers 
(PDSMA, δ 4.21 and DocecylMA, δ 3.9 with x:y= 9:1). 
(c) FT-IR spectra 
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FT-IR spectra of the polymers was recorded on a Bruker Alpha FT-IR (ATR) spectrometer from 
3500 cm−1 - 400 cm−1 range. 
 
Figure 3.9 1H-15N HMBC spectra of 1-methylpyridine-2-thione, PPDS/DD and ⊕PPDS/DD polymers. 
The absence of some correlation peaks with ring protons for the ⊕PPDS/DD polymer can be 
attributed to the short T2 (spin-spin) relaxation which can be approximately calculated as, 
T2≈1/(πδ1/2), where δ is peak width at half height. For macromolecules like polymers, signals 
from protons with short T2 often do not survive the 2D pulses that keep magnetization along xy 
plane. This also suggests slower molecular reorientation of cationic pyridine ring protons 








































Figure 3.10 Gel permeation chromatography of PPDS/DD polymer. 
 
Figure 3.11 FT-IR spectra of PPDS/DD and ⊕PPDS/DD polymers. A band at 1617 cm-1 is observed 
for N-methylated pyridinium polymer (⊕PPDS/DD) characteristic of C=N vibration related to 
quaternary nitrogen atom in the ring. This band is absent in the PPDS/DD polymer. The pyridine ring 
low intensity band (PPDS/DD polymer) at 1485 cm-1 due to conjugated C=C and C=N bonds become 
stronger in the ⊕PPDS/DD polymer spectra. C=O stretching at 1718/1722 cm-1 is used as calibration 
peak for both polymers. 
 
3.4.4 Study of siRNA encapsulation with varying dosages of ⊕PPDS/DD polymer (at different 
N/P ratios) 
3.4.4.1 Preparation of L-siP nanoassembly without crosslinking 
 To study the effect of N/P ratio on complexation, two different sets of solutions were 
prepared containing siRNA and ⊕PPDS/DD in a mixed solvent system (acetone:water=70:30). In 




































































first set, a fixed amount of siRNA (2 µg) was dosed in acetone/water solvent mixtures (70:30) to 
get 50 µL identical solutions. In another set, different amounts ⊕PPDS/DD polymer solution (2 
mg/mL in acetone:water= 70:30) were diluted with same mixed solvent system to achieve another 
50 µL solutions. Afterwards, the polymer solutions were added to the fixed amount siRNA 
solutions (containing 2 µg siRNA) to finally achieve N/P ratios of 5, 7.5, 10, 15, 20 and 25. All 
these mixed solutions were incubated for 2h in an orbital shaker at 20 °C to facilitate complexation. 
Meanwhile, mixed lipid solutions were prepared in 2 mL water containing 20% wt./wt. DOPE & 
10 mol% DSPE-PEG (based on ⊕PPDS/DD polymer) and stirred for 30 min. Next, each of 100 µL 
nanoassembly solutions, after 2 h complexation period, was added to an aqueous pool of lipid 
mixture and stirred for 3 h at 20 °C. In this step, the glass vials were kept open to facilitate the 
evaporation of organic solvents and maturation/hardening of the nanoassemblies. Finally, the 
solutions were filtered through Amicon Ultra Centrifugal Filters MWCO 10 kDa to remove 
remaining organic solvents, purify and concentrate the solutions. The final volume of L-siP 
nanoassembly solutions was adjusted to 100 μL with nuclease-free deionized water.  
3.4.4.2 Preparation of L-siP nanoassembly with crosslinking 
 Crosslinking of L-siP nanoassemblies were achieved by introducing DTT solutions after 
the complexation step. Different amounts of DTT (0.1, 0.25, 0.5, 1 and 2 equivalents with respect 
to PDS moiety in ⊕PPDS/DD polymer) dissolved in acetone/water (70:30) mix solvent were added 
to the siRNA-polymer mixtures after 2 h complexation step. Each solution was incubated in an 
orbital shaker at 20 °C for another 2 h. After that all solutions were subjected to lipid locating step. 
3.4.5 Agarose-gel retardation assay for proof of complexation & siRNA release 
3.4.5.1 Encapsulation study 
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 20 µL samples (with different N/P ratios and varying crosslinking) were mixed with 4 µL 
of gel loading buffer and loaded into 2% agarose gel made in TAE buffer containing EtBr. Samples 
were run in horizontal electrophoresis system at 110 V for 1 h and subjected to imaging analysis 
with NuGenius gel imager system (Syngene).  
3.4.5.2 Release study 
 20 µL sample was mixed with 1 µL Triton-x (0.1 g/mL) and sonicated for 5 min. Next, 250 
mM glutathione solution was added to it and the pH was adjusted to ~7-8 with 1 N NaOH solution 
(final glutathione concentration was 10 mM). The mixture was incubated for 6 h at 37 °C and 
subjected to agarose gel electrophoresis and visualization method as described above. 
3.4.6 MD-simulations: modelling for encapsulation & release 
 Construction of coarse-grained (CG) models, simulation parameters, features of N/P 7.5 
and 15 systems, DTT crosslinking, Construction of complete L-siP nanoassembly and release 
simulations of siRNA are described in detail in Supporting Information. Here, we have decided to 
use dsDNA as our CG models are based on the MARTINI force field, for which reliable dsDNA 
parameters are already available in literature. However, our choice is justified also by the fact that, 
at the level of precision of our CG models, the difference between dsDNA and siRNA is likely to 
be negligible, given the electrostatic nature of self-assembly in this system and the fact that the 
charges would be the same in molecules of same lengths. 
3.4.7 MD-simulation details about modelling for encapsulation & release 
CG models – The CG model for the cationic PDS-Dodecyl polymer (⊕PPDS/DD) has been built 
based on the popular MARTINI force field.  The CG structure has been mapped from an all atom 
(AA) structure of the polymer, while the appropriate CG MARTINI beads have been selected to 
preserve the different hydrophobicity of the mapped chemical groups.  Experiments have been 
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conducted using double strand dsRNA fragments, which are rigid charged molecules. For 
convenience, the CG simulations have been conducted using rigid 20-bp dsDNA segments of the 
same length instead of RNA, given the availability of a reliable MARTINI model for DNA (using 
dsDNA instead of dsRNA make little difference in our models, as the aggregation is controlled by 
electrostatic interactions and that can be both thought of as rigid charged cylindrical molecules). 
DTT has been mapped consistently on an AA model. The DTT CG model is composed of four CG 
beads – two central SP2 beads plus two terminal SC5 beads. The interaction between the DTT 
terminal SC5 beads and the first SC5 bead of the PDSMA chains has been then artificially strongly 
enhanced, to mimic the effect of DTT crosslinking ((i) strong selective spontaneous coordination 
and (ii) formation of stable bonds). 
 
Figure 3.12 Coarse grained (CG) representation of the cationic-PDS-Dodecyl polymer 
(⊕PPDS/DD). The CG MARTINI beads used in the model are indicated in the figure. SQ0 beads are 
charged (+1e). When modelling crosslinking, (i) the interaction of the first SC5 bead of the 
PDSMA chain with DTT has been artificially augmented to observe the spontaneous formation of 
stable (not breakable) bonds, and (ii) the side groups coordinated to DTT have been then detached 





Figure 3.13 CG-MD simulations at N/P 7.5 ratio showing the leakage of oligonuclueotides from 
the polymers following to crosslinking (insertion of DTT molecules). (a) The self-assembled 
system before DTT insertion appears as a quite loose network, kept together mainly by electrostatic 
interactions. When DTT crosslinking happens, polymers undergo compaction and the guest 
nucleotides detach form the polymer chains due to the loss of electrostatic interactions. (b) 
Quantification of the leakage: number of polymer-polymer and polymer-dsDNA contacts as a 
function of the CG-MD simulation time after the insertion of DTT.       
Simulation parameters – All simulations have been performed with the GROMACS molecular 
dynamics suite, patched with the PLUMED plugin. In production runs, we used the MD integrator 
with a time step of 20 fs, the v-rescale thermostat with a time constant of 2 ps and the Parrinello-
Rahman barostat with a time constant of 8 ps. 
Aggregation in N/P 7.5 and N/P 15 systems – We built the two systems by inserting 6 (or 12) 
dsDNA chains in a simulation box containing the same amount (58) of cationic polymer chains, a 
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70:30 acetone:water mixture and monovalent counterions to ensure charge neutrality of the system. 
In both systems, we observed spontaneous aggregation between the dsDNA fragments and the 
cationic polymer chains, led by the electrostatic interaction between their oppositely charged 
groups. The final aggregates in 70:30 acetone:water appeared as quite loose and not very dense), 
consistent with experimental observations of the systems before the insertion of DTT. 
DTT crosslinking – The effect of crosslinking has been mimicked in two steps: (i) the insertion of 
DTT molecules that selectively bind to the S-S groups of the polymers and (ii) the cleavage of 
positively charged groups of the polymers. For (i), we first imposed an artificially strong 
interaction between the terminal DTT CG beads and the first SC5 beads in the side charged groups 
of the polymer) – this allowed us to model the spontaneous coordination of DTT to those side 
groups that are really accessible by DTT molecules. Then (ii), the side charged groups coordinated 
to DTT have been detached from the rest of the polymer (deletion of the explicit bonds), and the 
SQ0 bead has been turned neutral, consistent with the experimental process. 
Creation of the L-siP nanoparticle for the N/P 15 system – To create a model of the L-siP 
nanoparticle, we started from the self-assembled polymer-dsDNA system at N/P 15 and introduced 
a 100% crosslinking as described above. We replaced the 70:30 acetone:water mixture with a 
(more polar) 20:1 water:acetone solvent mixture, coherent with the experiments, and introduced 
in the system enough DOPE lipids to cover the assembled aggregate surface. In order to obtain a 
single aggregate at the center of the simulation box, we used a recently optimized simulation 
technique (involving the use of PLUMED plugin) that drives the spontaneous assembly of self-
assembling molecules toward a single aggregation center (instead of forming multiple nuclei, 
which slow down the aggregation process).  The system has been then equilibrated for 4 µs of CG-
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MD simulation. The radial distribution functions of Figure 3.2f have been calculated with the gmx 
rdf tool of the GROMACS suite and normalized to have the same integral.     
Release simulations – To model the release of dsDNA fragments at different crosslinking 
conditions, we started from the equilibrated L-siP nanoparticle at N/P 15 ratio and 100% of 
crosslinking (1 equiv DTT). We removed the DOPE lipid molecules and performed 3 different 
simulations: one keeping all coordinated DTT in the system (100% crosslinking), one removing 
90% of the DTT molecules (thus, effectively simulating a residual 10% crosslinking condition) 
and a last one removing all the DTT (0% residual crosslinking). The dsDNA release has been 
quantified by monitoring the number of contacts between the polymer and the guest oligos in time 
during the CG-MD run calculated with gmx mindist and normalized dividing by the initial value 
(corresponding to the equilibrated L-siP nanoparticle). 
3.4.8 Visualization of L-siP nanoassembly with N-STORM confocal microscope 
 For N-STORM imaging, cy3-labelled siRNA loaded L-siP nanoassemblies were prepared 
and the outer lipid layer of the nanoassembly was incorporated with carboxyfluorescein labelled 
PEG-lipid (18:0 PEG2000 PE CF). The particles were first deposited on a L-lysine coated 35 mm 
glass bottomed petri-dish and incubated at room temperature for 15 min. Next, excess solution was 
withdrawn and gently washed with nuclease free water to remove loosely bound particles. Finally, 
imaging buffers (5% m/v glucose, 0.1 M MEA, 1 mg/mL glucose oxidase and catalase) were added 
to the wet petri-dish and transferred to NIKON confocal/N-STORM set-up for imaging (100X 
TIRF objective, excitation at 488 & 561 nm).   
3.4.9 Measurement of DLS and Zeta-potentials for L-siP nanoassemblies 
Dynamic light scattering (DLS) and zeta potential measurements were performed using a Malvern 
Nanozetasizer-ZS. Prepared L-siP nanoassembly and control samples were diluted with Milli-Q 
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water (50 µL sample added to 850 µL water) before subjected to particle size and zeta potential 
measurements. 
 




Figure 3.15 Zeta potential measurements for (a) uncrosslinked samples at different N/P ratios; (b) 
for L-siP15/1 with varying crosslinking; (c) lipids and mixture of (lipids + ⊕PPDS/DD). At higher 
N/P ratio and crosslinking density zeta potential decrease upto ~10 mV. Note that the zeta potential 
is not expected to show a significant change as the lipds layers are surrounding the particles in all 
cases which shows negative zeta potentials.  
 
3.4.10 Encapsulation efficiency and loading capacity 
 As in N/P 15 with 1 equiv. DTT crosslinking condition, there was no unencapsulated siRNA 
band observed in agarose gel electrophoresis, the encapsulation efficacy for L-siP15/1 
nanoassembly was 100%. 
The loading capacity for L-siP15/1 nanoassembly is calculated based on the following formula: 
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LC for L-siP15/1 nanoassembly was found to be (2 µg*100/27 µg=) 7.4%. 
 
Figure 3.16 31P NMR spectra indicating peaks from phosphorothioate-siRNA (PTsi, δ 53.56- 
55.97 ppm) and lipids (δ ~0 ppm). For crosslinked ⊕PPDS/DD + PTsi and final L-siP (with PTsi & 
Lipid) samples, no 31P peak from siRNA is observed due to complexation, whereas peak from 
lipid coating is visible. Once PTsi is released from L-siP nanoassembly, it becomes visible again 
in 31P NMR. 
 
Figure 3.17 Color-coded intensity profiling of a single L-siP15/1 nanoassembly showing a dense 





L-siP (with PTsi & Lipid)




3.4.11 Cryo-TEM study of L-siP nanoassemblies-N/P 15- crosslinked (1 equiv DTT) & 
uncrosslinked 
 Cryo Transmission Electron Microscopy was performed using FEI (Fisher Scientific) Tecnai 
T12 instrument operated at 120 kV using a Gatan 636 cryo-transfer holder. Imaging was done 
under low dose conditions. Samples were prepared using a FEI (Fisher Scientific) Vitrobot MKII 
using liquid ethane. Lacey Carbon on 200 mesh Copper Grids were glow discharged for 30 s prior 
usage. 
3.4.12 Quantification of siRNA encapsulation & release for L-siP nanoassembly through 
Quant-iT™ RiboGreen assay 
To generate a standard curve of free siRNA, different concentrations of negative control siRNA 
solutions were prepared in nuclease-free water as per the manufacturer’s protocol. L-siP 
nanoassemblies encapsulated with negative control siRNA with differential crosslinking density 
were diluted with TE buffer and mixed with RiboGreen reagent in a black 96 well plate. Another 
set of L-siP nanoassemblies were subjected to glutathione mediated release condition at first; then 
mixed with buffer and RiboGreen reagent. Samples were incubated at room temperature for 5 min 
and then subjected to fluorescence measurements in SpectraMax® M5 fluorescence microplate 
reader (excitation: 480 nm, emission: 520 nm). 
3.4.13 Cell culture  
 HeLa (cervical cancer), DU 145 (prostate cancer) , MDA-MB-231 (mammary gland/breast 
cancer), NCI/ADR-RES (derived from the ovarian cell line OVCAR-8/Adriamycin (Doxorubicin 
or Dox) resistant, procured from NCI, Frederick), HeLaeGFP and DU 145eGFP (eGFP transfected) 
cell lines were cultured in 100 mm cell culture petri-dish containing Dulbecco’s Modified Eagle 
Medium/Nutrient Mixture F-12 (DMEM/F12) in a humidified incubator with 5% CO2 at 37 °C. 
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Culture media was supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine and 1% 
antibiotic-antimycotic (100 units/mL of penicillin, 100 μg/mL of streptomycin, and 0.25 μg/mL of 
Amphotericin B). 
3.4.14 Cellular internalization, endosomal escape and L-siP nanoassembly stability studies 
 
Figure 3.18 Cellular uptake of cy3-labelled siRNA in HeLa, DU-145 and MDA-MB-231 cell 





3.4.14.1 Cellular internalization studies 
(a) Confocal microscopy 
 HeLa, DU 145 and MDA-MB-231 cell lines were seeded at 1×10
5 cells/mL density (1 mL) 
in 35 mm glass-bottomed petri-dishes and cultured for 3 days at 37°C and 5% CO2 incubator for 
proper adhesion. Afterwards cells were washed three times with PBS buffer and incubated with L-
siP nanoassemblies containing 100 nM cy3-siRNA in 1 mL serum-free media at 37 °C for 4 h. 
Next, the media was removed, washed three times with PBS and incubated with NucBlue™ Live 
ReadyProbes™ reagent in FBS containing media for 1 h to stain cell nucleus. Live cell imaging 
was performed using Nikon Spectral A1+ confocal microscope. All images were analyzed with 
Nikon NIS-Elements software. 
(b) Flow cytometry for uptake quantification 
 HeLa, DU 145 and MDA-MB-231 cell lines were seeded at 1×10
5 cells/mL density (1 mL) 
in 12 well plate and cultured for 1 day at 37°C and 5% CO2 incubator. Next, cells were washed 
three times with PBS buffer and incubated with L-siP nanoassemblies containing 100 nM cy3-
siRNA in 1 mL serum-free media at 37 °C for 4 h. Next, cells were washed with cold PBS and 
trypsinized (0.25% trypsin-EDTA solution) for 10 min to remove non-internalized samples from 
cell surface and de-touch from well plate. Cells were pelleted by centrifugation, washed two times 
with cold PBS and finally re-suspended with 500 µL cold PBS for flow cytometry analysis in BD 
LSRFortessa™ instrument. Data analyses was performed with FlowJo software to obtain 
fluorescence intensities of cell samples.   
(c) Mechanism of cellular uptake 
HeLa, DU 145 and MDA-MB-231 cell lines were seeded at 1.2×105 cells/mL density (1 mL) in 




Figure 3.19 Quantification of cellular uptake and mechanism of siRNA transfection in presence 
and absence of endocytic inhibitors for Hela, DU-145 and MDA-MB-231 cell lines through flow 
cytometry (a, c: bar graph; b, d: histogram plots).  
 
with PBS and pre-incubated with EIPA (100 µM, macro-pinocytosis pathway), Nystatin (30 µM, 
caveolin pathway) and Hyper-osmolar sucrose (45 mM, clathrine pathway) in serum-free media 
for 1 h at 37°C. After pre-incubation step, cells were co-incubated for another 1 h with L-siP 
nanoassemblies loaded with cy3-siRNA (50 nM, 1 mL serum-free media) and different inhibitors 
with final concentrations mentioned above. Untreated and L-siP-cy3-siRNA treated cells without 
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any inhibitor were used as negative and positive controls, respectively. Next, cells were harvested 
as described before for flow cytometry analysis. 
3.4.14.2 Endosomal escape  
 MDA-MB-231 cells were seeded at 1.5×10
5 cells/mL density (1 mL) in 35 mm glass-
bottomed petri-dishes and cultured for 1 day at 37°C and 5% CO2 incubator.  
 
Figure 3.20 Calcein assay for MDA-MB-231 cells: z projection (with 2 µm increment) and 
orthogonal view, scale: 20 µm. 
 
(a) Colocalization of Lysotracker Blue-cy3 siRNA  
 To study the endosomal escape, cells were washed with PBS three times and incubated 
with 100 nM cy3-siRNA L-siP nanoassemblies for 4 h in serum-free media. Next, one set of 
samples was subjected to confocal imaging after endosome staining and the other set was 
incubated for 24 h in complete media before subjecting to endosome staining and confocal 
microscopy. Lysotracker blue was used to stain endosomes as per manufacturer’s protocol. Live 
cell imaging was performed using Nikon Spectral A1+ confocal microscope. To improve visibility, 
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Lysotracker Blue stain in the images was pseud-colored with green and colocalization with red 
cy3-siRNA was studied. All images were analyzed with Nikon NIS-Elements 4.0 software.  
(b) Calcein assay 
 Cells were transfected with negative control siRNA loaded L-siP nanoassembly (100 nM 
siRNA) and 100 µM calcein for 8 h in serum-free media. Next, those were washed three times 
with PBS and incubated with complete media for another 2 h. A control set of cells was generated 
with only calcein treatment (without L-siP). Before subjecting to CLSM study, cell nucleus was 
stained with NucBlue™ Live ReadyProbes™ reagent. Cells were imaged with Nikon Spinning 
Disk Confocal Microscope (excitation 488 nm laser) and data was analysed with Nikon NIS-
Elements software. 
3.4.14.3 Stability of L-siP nanoassembly in presence of RNase A and serum 
 To test the L-siP nanoassemblies stability in presence of RNase A, 15 µL of L-siP 
nanoassembly solution (N/P 15, 1 equiv DTT crosslinked) was mixed with 1 uL RNase A solution 
(50 µg/mL) or serum (10% v/v) and incubated at 37 °C for different time intervals. After that, 2 
µL of EDTA (0.5 M) and 2 µL SDS (100 mM) were added to it and heated at 60 °C for 5 min. 
Afterwards, samples were subjected to glutathione (10 mM) based release conditions and finally 
loaded into 2% agarose gel (EtBr stained) to check the band intensity. For control, equal amount 




Figure 3.21 Stability assessment of siRNA (Naked or L-siP15/1) in presence of RNase A and 10% 
Serum at 37 °C. 
 
Figure 3.22 Cellular viability of (a) HeLa and (b) DU-145 cells in presence of L-siP nanoassembly 
at different loaded concentrations of siRNA; L-siP/Empty: crosslinked nanoassembly without 
siRNA (with same polymer concentrations as in L-siP/siNC); siNC: negative control siRNA; LF: 
Lipofectamine; Student’s t-test: ***p<0.001, **p<0.01, *p<0.05, ns (non-significant)>0.05. 
 
Figure 3.23 Cytotoxicity measured by LDH assay in (a) HeLa and (b) DU-145 cells in presence 
of L-siP nanoassembly at different loaded concentrations of siRNA; L-siP/Empty: crosslinked 
































































































































negative control siRNA; LF: Lipofectamine; Student’s t-test: ***p<0.001, **p<0.01, *p<0.05, ns 
(non-significant)>0.05. 
 
Figure 3.24 Comparison of cytotoxicity measured by (a) cellular viability and (b) 
LDH assay in MDA-MB-231, HeLa and DU-145 cells in presence of L-siP 
nanoassembly (empty, cross-linked nanoassembly without siRNA) and 
Lipofectamine RNAiMAX at different concentrations of polymer and lipofectamine 
(1, 2, 4, 8 and 10 µg/mL, which corresponds to 25, 50, 100, 200 and 500 nM siRNA 
incorporated L-siP in Figure 5.5f-g). 
 
3.4.15 Toxicity studies of L-siP nanoassemblies in HeLa/DU-145/MDA-MB-231 cell lines 
3.4.15.1 AlamarBlue assay for cellular viability 
 HeLa, DU 145 and MDA-MB-231 cells were seeded (7.5 ×10
3
 cells in 0.1 mL per well) 
into 96-well tissue culture plates and incubated at 37 °C. After 24 h, cell culture media was 
replaced with serum-free media containing L-siP nanoassemblies bearing different concentrations 
of negative control siRNA (25, 50, 100, 200 and 500 nM). Identical control crosslinked 
nanoassemblies devoid of any siRNA, L-siP(empty), were also tested for toxicity. Lipofectamine® 
RNAiMAX was complexed at different dosages (2, 5 and 10 µg/mL) with negative control siRNA 
(at 100 nM) and compared with other samples. After 24 h incubation, media was replaced with 


























































































































































with PBS for three times and each well was treated with 100 μL 10% alamarBlue in complete 
media. Finally, cells were incubated for 1 h at 37 °C and solutions were transferred to black 96-
well flat-bottomed plate for fluorescence measurement with SpectraMax® M5 microplate reader 
(excitation: 560 nm, emission: 590 nm). 
3.4.15.2 LDH cytotoxicity assay for membrane damage studies 
 For LDH assay, all cells were incubated with L-siP nanoassembliess for 24 h and then subjected 
to Pierce LDH cytotoxicity assay.61 50 µL of media was collected from 96 well cell culture plate 
and transferred to another 96 well plate. To that solution 50 µL LDH reaction mixture was added 
and incubated at room temperature for 30 min. Next, 50 µL stop solution was added to each well 
and subjected to absorbance measurements with SpectraMax® M5 microplate reader at 490 nm 
and 680 nm (cytotoxicity was calculated based on absorbance, A= A490-A680). 
3.4.16 Gene silencing studies 
 
Figure 3.25 eGFP silencing with L-siP15/1 in DU-145eGFP cells: (a) Confocal microscopy 
images and (b) flow cytometry data for quantification of eGFP fluorescence, respectively; scale: 
20 µm; Student’s t-test: ***p<0.001, **p<0.01, *p<0.05, ns (non-significant)>0.05. 
 
3.4.16.1 Knockdown of GFP in GFP-transfected HeLa & DU-145 cell lines through flow 
cytometry & confocal microscopy 
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 To study the gene silencing, GFP-transfected HeLa and DU-145 cells were plated in 12 
well plate (5× 104 cells in each well) and incubated for 24 h at 37 °C. After that cells were 
transfected with GFP-siRNA loaded L-siP nanoassemblies (50, 100 & 200 nM siRNA 
concentrations) and incubated for 24 h. Next, media was replaced with fresh one and incubated for 
another 24 h at 37 °C. Finally, cells were trypsinized, pelleted by centrifugation and washed two 
times with PBS followed by suspension in 500 µL PBS. Flow cytometry was performed with this 
cell suspension in a BD LSRFortessa™ instrument (excitation wavelength: 488 nm, FITC channel) 
to check the reduction in GFP fluorescence intensity. FlowJo version 10 software was used to 
analyze data and obtain fluorescence intensities of the samples.  
For confocal microscopy analyses for GFP-silencing, 1×10
5 cells were plated in 35 mm glass-
bottomed petri-dishes and incubated for 3 days at 37°C and 5% CO2 incubator for proper adhesion. 
Afterwards cells were transfected with L-siP-GFP-siRNA nanoassemblies, incubated for 24 h, 
washed and subjected to further 24 h incubation before subjecting to washed three times with PBS 
buffer and incubated with L-siP nanoassemblies containing 100 nM cy3-siRNA in 1 mL serum-
free media at 37 °C for 24 h. Next, the media was removed, washed three times with PBS and 
incubated with NucBlue™ Live ReadyProbes™ reagent in FBS containing media for 1 h to stain 
cell nucleus. Live cell imaging was performed using Nikon Spinning Disk confocal microscope. 
All images were analyzed with Nikon NIS-Elements software.  
3.4.16.2 Knockdown of PLK1 in MDA-MB-231 and MDR1 in NCI-ADR/RES cell lines 
through qPCR & western blot studies 
 1.5 × 105 cells were plated in 6 well tissue culture plate, incubated for 24 h at 37 °C- 5% 
CO2 atmosphere and then transfected with L-siP nanoassemblies containing PLK1 and MDR1 
siRNA (at 50 & 100 nM siRNA concentration) for MDA-MB-231 & NCI-ADR/RES cells, 
128 
 
respectively. Control samples containing L-siP nanoassemblies without siRNA, untreated cells and 
only siRNA treated cells were subjected to similar conditions. After transfection (24 h), media was 
changed and incubated at 37 °C- 5% CO2 atmosphere for another 24 h. 
qPCR studies 
Finally, cells were washed and total RNA was isolated by RNA extraction kit (High Pure RNA 
Isolation Kit, Roche) according to manufacturer’s protocol. Isolated RNAs were checked for purity 
and concentrations by measuring absorbances at 260/280 nm. 
Next, cDNA synthesis was performed with iScript cDNA synthesis kit (Bio-Rad Laboratories) 
from the isolated RNA. After that, RT-PCR was performed using the synthesized cDNA, PerfeCTa 
MultiPlex qPCR SuperMix (Low ROX) and Taqman probes for PLK1, MDR1 and control β-actin 
genes in Mx3005P qPCR System (Stratagene/Agilent). Target gene expression levels were 
normalized and reported as fold increase compared to β-actin using the ΔΔCT method. 
Western blot analyses 
To isolate total proteins, cells were washed with cold PBS buffer once and scraped to de-touch 
from the plate and transferred with cold PBS to an eppendorf tube. Afterwards, cells were 
pelletized by centrifugation, washed with cold PBS twice to remove proteins from media. Next, 
RIPA lysis buffer containing protease/phosphatase inhibitor mix was added to the cell pellet 
keeping it in ice and incubated for 15 min, followed by 3×30 s sonication to ensure complete lysis 
of cells. Finally, lysed cells were centrifuged at 14000 rpm - 4 °C to collect soluble protein extracts 
and quantified with 660 nm protein assay. 
Western blot analyses were performed to identify PLK1 and MDR1/P-gp protein levels in cells. 
Rabbit monoclonal antibodies (PLK1, MDR1/ABCB1 & β-Actin mAbs, Cell Signaling) were used 
to detect target proteins and loading control. HRP-linked anti-rabbit IgG was used as secondary 
129 
 
antibody and proteins bands were detected by enhanced chemiluminescence (ECL) reagent 
(Luminol, coumaric acid and H2O2). 
3.4.17  Cellular viability post-PLK1 and MDR1 knockdown  
 MDA-MB-231 and NCI/ADR-RES cells were seeded at a density of 5×103 cells/well/100 
µL in 96-well tissue culture plate. After 24 h incubation, media well removed and treated with L-
siP nanoassemblies loaded with PLK1 siRNA (for MDA-MB-231 cells) and MDR1 siRNA (for 
NCI/ADR-RES) at final siRNA concentration of 100 nM in serum-free media. Control sets of 
samples were also subjected to identical conditions. After 24 h incubation, media was replaced 
with fresh complete one and incubated for another 48 h.   
For PLK1 siRNA treated samples, cells were subjected to alamarBlue assay (as described in 
manuscript). For MDR1-siRNA treated samples, media was removed, treated with 10 µM 
doxorubicin in complete media and incubated for another 48 h. After that cells were subjected to 
alamarBlue assay (as described in manuscript). 
3.4.18 Uptake of doxorubicin in NCI/ADR-RES cells after MDR1 knockdown  
 NCI/ADR-RES cells were seeded at 1×10
5 cells/mL density (1 mL) in 35 mm glass-
bottomed petri-dishes and cultured for 3 days at 37°C and 5% CO2 incubator for proper adhesion. 
Afterwards, media was removed, treated with L-siP nanoassemblies loaded with MDR1-siRNA 
(final siRNA concentration: 100 nM) in serum-free media and incubated for 24 h. Next, media was 
replaced with fresh complete one and incubated for another 48 h. After that, cells were treated with 
10 µM doxorubicin and incubated for 4 h. Finally, media was removed, cells were washed with 
PBS and nucleus was stained with NucBlue™ Live ReadyProbes™ reagent before subjecting to 
confocal microscopy by Nikon Spectral A1+ confocal microscope. All images were analyzed with 




‘L-siP’: ‘Lipid decorated siRNA-Polymer’ nano-assembly; siNC: siRNA-Negative Control; LF: 
























1. Whitesides, G. M.; Mathias, J. P.; Seto, C. T. "Molecular Self-Assembly and Nanochemistry: 
A Chemical Strategy for the Synthesis of Nanostructures" Science 1991, 254 (5036), 1312-1319. 
2. Zhang, S. G. "Fabrication of Novel Biomaterials through Molecular Self-Assembly" Nat. 
Biotechnol. 2003, 21 (10), 1171-1178. 
3. Zimmermann, T. S.; Lee, A. C. H.; Akinc, A.; Bramlage, B.; Bumcrot, D.; Fedoruk, M. N.; 
Harborth, J.; Heyes, J. A.; Jeffs, L. B.; John, M.; Judge, A. D.; Lam, K.; McClintock, K.; Nechev, 
L. V.; Palmer, L. R.; Racie, T.; Rohl, I.; Seiffert, S.; Shanmugam, S.; Sood, V.; Soutschek, J.; 
Toudjarska, I.; Wheat, A. J.; Yaworski, E.; Zedalis, W.; Koteliansky, V.; Manoharan, M.; 
Vornlocher, H. P.; MacLachlan, I. "RNAi-Mediated Gene Silencing in Non-Human Primates" 
Nature 2006, 441 (7089), 111-114. 
4. Li, J.; Wu, C.; Wang, W.; He, Y.; Elkayam, E.; Joshua-Tor, L.; Hammond, P. T. "Structurally 
Modulated Codelivery of siRNA and Argonaute 2 for Enhanced RNA Interference" Proc. Natl. 
Acad. Sci. U. S. A. 2018, 115 (12), E2696-E2705. 
5. Biswas, A.; Chakraborty, K.; Dutta, C.; Mukherjee, S.; Gayen, P.; Jan, S.; Mallick, A. M.; 
Bhattacharyya, D.; Roy, R. S. "Engineered Histidine-Enriched Facial Lipopeptides for Enhanced 
Intracellular Delivery of Functional siRNA to Triple Negative Breast Cancer Cells" ACS Appl. 
Mater. Interfaces 2019, 11 (5), 4719-4736. 
6. "A Triumph of Perseverance over Interference" Nat. Biotechnol. 2018, 36, 775. 
7. Nguyen, J.; Szoka, F. C. "Nucleic Acid Delivery: The Missing Pieces of the Puzzle?" Acc. Chem. 
Res. 2012, 45 (7), 1153-1162. 
8. Wang, J.; Lu, Z.; Wientjes, M. G.; Au, J. L. S. "Delivery of siRNA Therapeutics: Barriers and 
Carriers" Aaps J. 2010, 12 (4), 492-503. 
132 
 
9. Gallas, A.; Alexander, C.; Davies, M. C.; Puri, S.; Allen, S. "Chemistry and Formulations for 
siRNA Therapeutics" Chem. Soc. Rev. 2013, 42 (20), 7983-7997. 
10. Majumder, P.; Bhunia, S.; Chaudhuri, A. "A Lipid-Based Cell Penetrating Nano-Assembly for 
RNAi-Mediated Anti-Angiogenic Cancer Therapy" Chem. Commun. 2018, 54 (12), 1489-1492. 
11. Roy, R.; Jerry, D. J.; Thayumanavan, S. "Virus-Inspired Approach to Nonviral Gene Delivery 
Vehicles" Biomacromolecules 2009, 10 (8), 2189-2193. 
12. Zheng, M.; Pavan, G. M.; Neeb, M.; Schaper, A. K.; Danani, A.; Klebe, G.; Merkel, O. M.; 
Kissel, T. "Targeting the Blind Spot of Polycationic Nanocarrier-Based siRNA Delivery" ACS 
Nano 2012, 6 (11), 9447-9454. 
13. Xue, H. Y.; Liu, S. M.; Wong, H. L. "Nanotoxicity: A Key Obstacle to Clinical Translation of 
siRNA-Based Nanomedicine" Nanomedicine (London, U. K.) 2014, 9 (2), 295-312. 
14. Wang, Y.; Xiao, H.; Fang, J.; Yu, X. S.; Su, Z. W.; Cheng, D.; Shuai, X. T. "Construction of 
Negatively Charged and Environment-Sensitive Nanomedicine for Tumor-Targeted Efficient 
siRNA Delivery" Chem. Commun. 2016, 52 (6), 1194-1197. 
15. Wagner, E. "Polymers for siRNA Delivery: Inspired by Viruses to Be Targeted, Dynamic, and 
Precise" Acc. Chem. Res. 2012, 45 (7), 1005-1013. 
16. Tai, W.; Gao, X. "Functional Peptides for siRNA Delivery" Adv. Drug Delivery Rev. 2017, 
110-111, 157-168. 
17. Dunn, S. S.; Tian, S.; Blake, S.; Wang, J.; Galloway, A. L.; Murphy, A.; Pohlhaus, P. D.; 
Rolland, J. P.; Napier, M. E.; DeSimone, J. M. "Reductively Responsive siRNA-Conjugated 
Hydrogel Nanoparticles for Gene Silencing" J. Am. Chem. Soc. 2012, 134 (17), 7423-7430. 
133 
 
18. Freyer, J. L.; Brucks, S. D.; Campos, L. M. "Fully Charged: Maximizing the Potential of 
Cationic Polyelectrolytes in Applications Ranging from Membranes to Gene Delivery through 
Rational Design" J. Polym. Sci., Part A: Polym. Chem. 2017, 55 (19), 3167-3174. 
19. Ripoll, M.; Neuberg, P.; Kichler, A.; Tounsi, N.; Wagner, A.; Remy, J. S. "pH-Responsive 
Nanometric Polydiacetylenic Micelles Allow for Efficient Intracellular siRNA Delivery" ACS 
Appl. Mater. Interfaces 2016, 8 (45), 30665-30670. 
20. Shen, S. D.; Gu, T.; Mao, D. S.; Xiao, X. Z.; Yuan, P.; Yu, M. H.; Xia, L. Y.; Ji, Q.; Meng, L.; 
Song, W.; Yu, C. Z.; Lu, G. Z. "Synthesis of Nonspherical Mesoporous Silica Ellipsoids with 
Tunable Aspect Ratios for Magnetic Assisted Assembly and Gene Delivery" Chem. Mater. 2012, 
24 (1), 230-235. 
21. Lv, H.; Zhang, S.; Wang, B.; Cui, S.; Yan, J. "Toxicity of Cationic Lipids and Cationic 
Polymers in Gene Delivery" J. Controlled Release 2006, 114 (1), 100-9. 
22. Hunter, A. C. "Molecular Hurdles in Polyfectin Design and Mechanistic Background to 
Polycation Induced Cytotoxicity" Adv. Drug Delivery Rev. 2006, 58 (14), 1523-1531. 
23. Takae, S.; Miyata, K.; Oba, M.; Ishii, T.; Nishiyama, N.; Itaka, K.; Yamasaki, Y.; Koyama, 
H.; Kataoka, K. "PEG-Detachable Polyplex Micelles Based on Disulfide-Linked Block Catiomers 
as Bioresponsive Nonviral Gene Vectors" J. Am. Chem. Soc. 2008, 130 (18), 6001-6009. 
24. Sizovs, A.; Xue, L.; Tolstyka, Z. P.; Ingle, N. P.; Wu, Y. Y.; Cortez, M.; Reineke, T. M. 
"Poly(Trehalose): Sugar-Coated Nanocomplexes Promote Stabilization and Effective Polyplex-
Mediated siRNA Delivery" J. Am. Chem. Soc. 2013, 135 (41), 15417-15424. 
25. Rosi, N. L.; Giljohann, D. A.; Thaxton, C. S.; Lytton-Jean, A. K.; Han, M. S.; Mirkin, C. A. 
"Oligonucleotide-Modified Gold Nanoparticles for Intracellular Gene Regulation" Science 2006, 
312 (5776), 1027-1030. 
134 
 
26. Cohen, J. A.; Beaudette, T. T.; Cohen, J. L.; Brooders, K. E.; Bachelder, E. M.; Frechet, J. M. 
J. "Acetal-Modified Dextran Microparticles with Controlled Degradation Kinetics and Surface 
Functionality for Gene Delivery in Phagocytic and Non-Phagocytic Cells" Adv. Mater. 2010, 22 
(32), 3593-3597. 
27. Samarajeewa, S.; Ibricevic, A.; Gunsten, S. P.; Shrestha, R.; Elsabahy, M.; Brody, S. L.; 
Wooley, K. L. "Degradable Cationic Shell Cross-Linked Knedel-Like Nanoparticles: Synthesis, 
Degradation, Nucleic Acid Binding, and in Vitro Evaluation" Biomacromolecules 2013, 14 (4), 
1018-1027. 
28. McKinlay, C. J.; Vargas, J. R.; Blake, T. R.; Hardy, J. W.; Kanada, M.; Contag, C. H.; Wender, 
P. A.; Waymouth, R. M. "Charge-Altering Releasable Transporters (Carts) for the Delivery and 
Release of mRNA in Living Animals" Proc. Natl. Acad. Sci. U. S. A. 2017, 114 (4), E448-E456. 
29. Geng, Z. S.; Garren, M.; Finno, M. G. "Thiabicyclononane-Based Hyperbranched Polycations 
for Low-Dose Oligonucleotide Delivery" Chem. Mater. 2018, 30 (22), 8164-8169. 
30. Cheng, Y. L.; Yumul, R. C.; Pun, S. H. "Virus-Inspired Polymer for Efficient in Vitro and in 
Vivo Gene Delivery" Angew. Chem., Int. Ed. 2016, 55 (39), 12013-12017. 
31. Lu, X.; Jia, F.; Tan, X.; Wang, D.; Cao, X.; Zheng, J.; Zhang, K. "Effective Antisense Gene 
Regulation Via Noncationic, Polyethylene Glycol Brushes" J. Am. Chem. Soc. 2016, 138 (29), 
9097-9100. 
32. Shen, W.; Wang, Q.; Shen, Y.; Gao, X.; Li, L.; Yan, Y.; Wang, H.; Cheng, Y. "Green Tea 
Catechin Dramatically Promotes RNAi Mediated by Low-Molecular-Weight Polymers" ACS 
Cent. Sci. 2018, 4 (10), 1326-1333. 
33. Zhang, T.; Huang, Y.; Ma, X.; Gong, N.; Liu, X.; Liu, L.; Ye, X.; Hu, B.; Li, C.; Tian, J. H.; 
Magrini, A.; Zhang, J.; Guo, W.; Xing, J. F.; Bottini, M.; Liang, X. J. "Fluorinated 
135 
 
Oligoethylenimine Nanoassemblies for Efficient siRNA-Mediated Gene Silencing in Serum-
Containing Media by Effective Endosomal Escape" Nano Lett. 2018, 18 (10), 6301-6311. 
34. Bucur, C. B.; Sui, Z.; Schlenoff, J. B. "Ideal Mixing in Polyelectrolyte Complexes and 
Multilayers: Entropy Driven Assembly" J. Am. Chem. Soc. 2006, 128 (42), 13690-13691. 
35. Akerlof, G. "Dielectric Constants of Some Organic Solvent-Water Mixtures at Various 
Temperatures" J. Am. Chem. Soc. 1932, 54, 4125-4139. 
36. Dominska, M.; Dykxhoorn, D. M. "Breaking Down the Barriers: siRNA Delivery and 
Endosome Escape" J. Cell Sci. 2010, 123 (8), 1183-1189. 
37. Zhu, X.; Xu, Y.; Solis, L. M.; Tao, W.; Wang, L.; Behrens, C.; Xu, X.; Zhao, L.; Liu, D.; Wu, 
J.; Zhang, N.; Wistuba, II; Farokhzad, O. C.; Zetter, B. R.; Shi, J. "Long-Circulating siRNA 
Nanoparticles for Validating Prohibitin1-Targeted Non-Small Cell Lung Cancer Treatment" Proc. 
Natl. Acad. Sci. U. S. A. 2015, 112 (25), 7779-7784. 
38. Shi, J.; Xiao, Z.; Votruba, A. R.; Vilos, C.; Farokhzad, O. C. "Differentially Charged Hollow 
Core/Shell Lipid-Polymer-Lipid Hybrid Nanoparticles for Small Interfering RNA Delivery" 
Angew. Chem., Int. Ed. 2011, 50 (31), 7027-7031. 
39. Dutta, K.; Hu, D.; Zhao, B.; Ribbe, A. E.; Zhuang, J.; Thayumanavan, S. "Templated Self-
Assembly of a Covalent Polymer Network for Intracellular Protein Delivery and Traceless 
Release" J. Am. Chem. Soc. 2017, 139 (16), 5676-5679. 
40. Ghosh, S.; Basu, S.; Thayumanavan, S. "Simultaneous and Reversible Functionalization of 
Copolymers for Biological Applications" Macromolecules 2006, 39 (17), 5595-5597. 
41. Garbuzenko, O.; Zalipsky, S.; Qazen, M.; Barenholz, Y. "Electrostatics of Pegylated Micelles 




42. Meyer, O.; Kirpotin, D.; Hong, K. L.; Sternberg, B.; Park, J. W.; Woodle, M. C.; 
Papahadjopoulos, D. "Cationic Liposomes Coated with Polyethylene Glycol as Carriers for 
Oligonucleotides" J. Cell Biol. 1998, 273 (25), 15621-15627. 
43. Bochicchio, D.; Pavan, G. M. "Effect of Concentration on the Supramolecular Polymerization 
Mechanism Via Implicit-Solvent Coarse-Grained Simulations of Water-Soluble 1,3,5-
Benzenetricarboxamide" J. Phys. Chem. Lett. 2017, 8 (16), 3813-3819. 
44. Buyens, K.; Lucas, B.; Raemdonck, K.; Braeckmans, K.; Vercammen, J.; Hendrix, J.; 
Engelborghs, Y.; De Smedt, S. C.; Sanders, N. N. "A Fast and Sensitive Method for Measuring 
the Integrity of siRNA-Carrier Complexes in Full Human Serum" J. Controlled Release 2008, 126 
(1), 67-76. 
45. Leung, A. K. K.; Hafez, I. M.; Baoukina, S.; Belliveau, N. M.; Zhigaltsev, I. V.; Afshinmanesh, 
E.; Tieleman, D. P.; Hansen, C. L.; Hope, M. J.; Cullis, P. R. "Lipid Nanoparticles Containing 
siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core" J. 
Phys. Chem. C 2012, 116 (34), 18440–18450. 
46. Viger-Gravel, J.; Schantz, A.; Pinon, A. C.; Rossini, A. J.; Schantz, S.; Emsley, L. "Structure 
of Lipid Nanoparticles Containing siRNA or mRNA by Dynamic Nuclear Polarization-Enhanced 
Nmr Spectroscopy" J. Phys. Chem. B 2018, 122 (7), 2073-2081. 
47. Majumder, P.; Baxa, U.; Walsh, S. T. R.; Schneider, J. P. "Design of a Multicompartment 
Hydrogel That Facilitates Time-Resolved Delivery of Combination Therapy and Synergized 
Killing of Glioblastoma" Angew. Chem., Int. Ed. 2018, 57 (46), 15040-15044. 
48. Chen, Y.; Wang, S.; Lu, X.; Zhang, H.; Fu, Y.; Luo, Y. "Cholesterol Sequestration by Nystatin 
Enhances the Uptake and Activity of Endostatin in Endothelium Via Regulating Distinct 
Endocytic Pathways" Blood 2011, 117 (23), 6392-6403. 
137 
 
49. Koivusalo, M.; Welch, C.; Hayashi, H.; Scott, C. C.; Kim, M.; Alexander, T.; Touret, N.; Hahn, 
K. M.; Grinstein, S. "Amiloride Inhibits Macropinocytosis by Lowering Submembranous pH and 
Preventing Rac1 and Cdc42 Signaling" J. Cell Biol. 2010, 188 (4), 547-563. 
50. Ren, K.; Liu, Y.; Wu, J.; Zhang, Y.; Zhu, J.; Yang, M.; Ju, H. "A DNA Dual Lock-and-Key 
Strategy for Cell-Subtype-Specific siRNA Delivery" Nat. Commun. 2016, 7, 13580. 
51. Zeller, S.; Choi, C. S.; Uchil, P. D.; Ban, H. S.; Siefert, A.; Fahmy, T. M.; Mothes, W.; Lee, S. 
K.; Kumar, P. "Attachment of Cell-Binding Ligands to Arginine-Rich Cell-Penetrating Peptides 
Enables Cytosolic Translocation of Complexed siRNA" Chem. Biol. 2015, 22 (1), 50-62. 
52. Convertine, A. J.; Benoit, D. S.; Duvall, C. L.; Hoffman, A. S.; Stayton, P. S. "Development 
of a Novel Endosomolytic Diblock Copolymer for siRNA Delivery" J. Controlled Release 2009, 
133 (3), 221-229. 
53. van Hoogevest, P. "Review - an Update on the Use of Oral Phospholipid Excipients" Eur. J. 
Pharm. Sci. 2017, 108, 1-12. 
54. Doskocilova, D.; Mikes, F.; Pecka, J.; Kriz, J. "Compositional Microstructure of Polymer 
Prepared by Partial Hydrolysis of Isotactic Poly(Methyl Methacrylate)" Makromol. Chem. 1992, 
193 (10), 2529-2538. 
55. Shi, B.; Abrams, M. "Technologies for Investigating the Physiological Barriers to Efficient 
Lipid Nanoparticle-siRNA Delivery" J. Histochem. Cytochem. 2013, 61 (6), 407-420. 
56. Jafari, M.; Xu, W.; Pan, R.; Sweeting, C. M.; Karunaratne, D. N.; Chen, P. "Serum Stability 
and Physicochemical Characterization of a Novel Amphipathic Peptide C6m1 for siRNA 
Delivery" PLoS One 2014, 9 (5), e97797. 
138 
 
57. Wang, H. X.; Chen, W.; Xie, H. Y.; Wei, X. Y.; Yin, S. Y.; Zhou, L.; Xu, X.; Zheng, S. S. 
"Biocompatible, Chimeric Peptide-Condensed Supramolecular Nanoparticles for Tumor Cell-
Specific siRNA Delivery and Gene Silencing" Chem. Commun. 2014, 50 (58), 7806-7809. 
58. Jiang, Y.; Tang, R.; Duncan, B.; Jiang, Z.; Yan, B.; Mout, R.; Rotello, V. M. "Direct Cytosolic 
Delivery of siRNA Using Nanoparticle-Stabilized Nanocapsules" Angew. Chem., Int. Ed. 2015, 
54 (2), 506-510. 
59. Xiong, X. B.; Lavasanifar, A. "Traceable Multifunctional Micellar Nanocarriers for Cancer-
Targeted Co-Delivery of Mdr-1 siRNA and Doxorubicin" ACS Nano 2011, 5 (6), 5202-5213. 
60. Zhang, C. G.; Zhu, W. J.; Liu, Y.; Yuan, Z. Q.; Yang, S. D.; Chen, W. L.; Li, J. Z.; Zhou, X. 
F.; Liu, C.; Zhang, X. N. "Novel Polymer Micelle Mediated Co-Delivery of Doxorubicin and P-
Glycoprotein siRNA for Reversal of Multidrug Resistance and Synergistic Tumor Therapy" Sci. 
Rep. 2016, 6, 23859. 
61. Korzeniewski, C.; Callewaert, D. M. "An Enzyme-Release Assay for Natural Cytotoxicity" J. 










A STRUCTURE-ACTIVITY STUDY TO MODULATE REACTIVE SIDE CHAINS 
OF A SELF-IMMOLATIVE POLYMER FOR OPTIMAL PROTEIN 
CONJUGATION 
Adapted in parts from the manuscript under review: Dutta, K; Kanjilal, P. Das, R.; 
Medeiros, J.; Thayumanavan, S. “Synergistic Interplay of Covalent and Non-Covalent 




 Controlled polymerization and post-modification techniques have provided many 
impressive examples of creating functional polymers for utilization in catalysis, sensing, 
tissue-engineering and controlled drug delivery.1-10 Amongst these, activated ester 
polymers have gained significant attention for providing enormous flexibility in 
bioconjugation processes to install a desired functionality, which was otherwise impaired 
due to the structural instability of sensitive biomolecules under harsh reaction conditions.1, 
11-15 Inspired by this, we had designed a self-immolative polymer containing activated 
carbonate moieties and reported a covalent self-assembly approach for encapsulation of 
functional proteins through the reactive side chains.16 Lysines, an abundant surface 
functionality in majority of proteins,16-17 have been utilized as conjugation handles for 
reaction with the activated carbonate moieties to form self-assembled nanostructures. Due 
to the presence of reactive side-chain functionalities that are responsive to redox stimuli, 
the encapsulated proteins could be released in a ‘traceless’ manner with retention of its 
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catalytic activity.18-19 Understanding the potential of the newly developed polymer 
platform, we envisaged the utilization of such reactive covalent self-assembly approach for 
conjugation of functional antibody through the conveniently available lysines present on 
the surface of antibodies. However, slow macromolecular reaction kinetics owing to high 
pKa of lysine amines,20 incomplete reactivity of activated carbonate groups with lysines,16 
and competitive hydrolytic degradation of polymer were found to be major hurdles in the 
successful extension of this approach for conjugation of larger biomacromolecules, such 
as antibodies (~150 kDa).  
 
Figure 4.1 Schematic representation of activated carbonate containing self-immolative 
polymers tested for lysine conjugation 
 
 In this chapter, we have synthesized various activated carbonates containing self-
immolative polymers and studied the kinetics of aminolysis vs. hydrolysis in presence of a 
small molecule lysine analogue (Figure 4.1). Down-selected activated carbonate polymer 
with higher degree of aminolysis and low hydrolysis is utilized to test encapsulation and 




4.2 Results and discussion 
4.2.1 Synthesis of activated carbonate-containing monomers and polymers for protein 
conjugation 
 While the reaction between amines and various activated ester moieties are well-
established, including for bioconjugation, such an understanding does not exist for 
activated carbonates.1, 11-12, 21 Note that utilization of an activated carbonate, instead of the 
classical activated ester, is critical for reversibility in polymer-protein conjugation through 
surface lysines. We also envisaged that the resultant carbamate linker would impart 
hydrolytic stability of the covalent connection, and provide potential biocompatibility due 
to resemblance to the biologically abundant amide moiety. Stable conjugation with 
reversible features is critical for a versatile assembly that can translocate the protein across 
a cellular membrane and release the protein cargo in its native form without any remnants 
of polymer.13, 22 To address this, we incorporated a disulfide bond for redox-mediated 
cleavage at the β-position of the carbonate moiety in the polymer chain. Upon cleavage of 
the disulfide owing to the presence of higher intracellular glutathione concentration, the 
self-immolative mechanism will kick-in to release the attached protein tracelessly in its 
pristine form (Figure 4.2).18 Although we have successfully demonstrated encapsulation of 
proteins with p-nitrophenyl-carbonate, this functionality falls short of the ability to 
encapsulate larger proteins, such as antibodies, likely due to low reactivity and competitive 
hydrolysis issues. We surmised that identifying a reactive functionality that is biased 







Figure 4.2 (a) Schematic of the designed random copolymers for evaluating protein 
conjugation; (b) General reaction scheme for the synthesis of activated ester containing 
monomers; (c) General reaction scheme for polymerization to achieve random copolymers 
of PEG and activated ester monomers; and (d) Activated carbonate polymer mediated 
protein conjugation and ‘traceless’ release. 
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 To this end, we synthesized a library of random copolymers containing six potential 
activated carbonate candidates, viz., nitrophenyl (NPC, previously reported), 
pentafluorophenyl (PFP), trichlorophenyl (TCL), hexafluoropropanol (CF3), 
trimethylaminophenyl (NMe3) carbonate moieties (Figure 4.2). The polymers were 
synthesized via RAFT polymerization technique using carbonate methacrylate and PEG 
methacrylate monomers (Figure 4.2, see experimental section for detailed synthetic 
procedures). Post-polymerization modification of a PEG-hydroxyethylene disulfide 
polymer was utilized to synthesize NHS carbonate ester polymer (see experimental 
section).16 All monomers and polymers were characterized by NMR (1H, 13C and 19F NMR 
(as required)) and gel permeation chromatography. The ratio between the carbonate and 
PEG groups (~2:8) were evaluated from 1H NMR. 
4.2.2 Comparison of aminolysis vs. hydrolysis and efficacy studies  
 To test the designed polymers for conjugation efficacy and degradation kinetics, 
we first investigated the aminolysis reaction in the presence of a protected small molecule 
lysine analogue (Figure 4.3). Kinetic studies of the desired aminolysis and the competitive 
hydrolytic degradation were performed by reacting polymers with the lysine analog in 
phosphate buffer (pH 8.5, previously optimized for protein conjugation).16 For TCL-, CF3-
, NMe3-, and NPC-polymers, both aminolysis and hydrolysis rates were found to be very 
slow. Aminolysis rates for PFP- and NHS-polymers were found to be much faster. 
However, with the NHS-polymer, this increase in rate of aminolysis was also accompanied 
by an increase in the rate of hydrolysis. Considering that we require fast aminolysis rates, 
combined with a significant bias towards aminolysis relative to hydrolysis rates, we 




Figure 4.3 Kinetics studies with synthesized activated ester containing polymers to 
examine extent of aminolysis and hydrolysis reactions. 
 To investigate the translation of our findings with small molecules on to protein-
polymer conjugation, we investigated the reactions of NPC-, PFP-, and NHS-polymers 
with a model protein, horseradish peroxidase (HRP). Percentage encapsulation of proteins, 
as evident from the SDS-PAGE analysis, was found to follow the following order: PFP 
(48%) > NHS (18%) > NPC (11%) (Figure 4.4a). Importantly, to ‘shrink-wrap’ the protein 
cargo after conjugation, a crosslinking reaction is employed to better protect it from 
degrading environmental conditions. However, residual activated ester group analyses 
revealed only ~9% remaining groups for NHS-polymer leaving little room for crosslinking 










Figure 4.4 (b) SDS-PAGE analyses for studying HRP encapsulation percentage with the 
NPC, PFP and NHS-polymers (PFP:48%, NHS: 18% and NPC:11%); (c) Measurements 
of residual activated carbonate ester moieties left after protein conjugation that can be 
utilized for crosslinking reaction; (d) SDS-PAGE analyses to show similar encapsulation 
percentage with Cyt C for the NPC, PFP and NHS-polymers (PFP:54%, NHS: 22% and 
NPC:18%). 
bioconjugation efficacy (PFP:54%, NHS: 22% and NPC:18%) for another protein 
cytochrome C (Figure 4.4c). These studies further confirm that the PFP-polymer is the 
appropriate down-selected candidate for protein conjugation. 
4.3 Summary  
 In summary, we demonstrated a versatile strategy for encapsulation of proteins 
using an activated carbonate polymer platform. Towards developing a fundamental 
understanding in the activated carbonate chemistry for protein conjugation, we first 
developed the structure-reactivity relationship by synthesizing and testing several activated 
carbonate-bearing polymers for their reactivity in aminolysis vs. hydrolysis. PFP-polymer 
not only provided faster aminolysis rate along with slower hydrolysis, this also enabled to 
utilize the left-over reactive carbonate functionalities for enforcing secondary-crosslinking 
to secure the nanoparticle formation. Based on the kinetics studies with small molecule 
lysine analogue, we chose PFP-carbonate as the preferred functionality for encapsulating 
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proteins. We tested the protein conjugation efficacy and redox-mediated release of the 
proteins thereafter via SDS-PAGE analyses. This polymer platform is expected to provide 
beneficial effect in protein conjugation and would be tested and improved for encapsulation 
of larger proteins and antibodies. 
4.4 Experimental 
4.4.1 Materials 
2-Hydroxyethyl disulfide, methacryloyl chloride, bis(trichloromethyl) carbonate 
(triphosgene), 4-nitrophenol, 2,4,5-trichlorophenol, N-hydroxysuccinimide and 
1,1,1,3,3,3-hexafluoro-2-propanol were procured from Sigma-Aldrich and were used 
without further purification unless otherwise mentioned. 4-(Dimethylamino)phenol was 
purchased from Combi-Blocks, USA. Polyethylene glycol monomethyl ether methacrylate 
(PEGMA; MW 500), 4-cyano-4-(phenylcarbonothioylthio)pentanoic acid, 4-Cyano-4-
[(dodecylsulfanylthiocarbonyl)sulfanyl] pentanoic acid (chain transfer agents), D,L-
dithiothreitol (DTT), bis(pentafluorophenyl) carbonate and N,N′-disuccinimidyl carbonate 
were also procured from Sigma-Aldrich. 2,2′-azobis-(2-methylpropionitrile) (AIBN) was 
purchased from Sigma-Aldrich, USA and purified by recrystallization in methanol. All 
protein samples, e.g., peroxidase from horseradish and cytochrome C were purchased from 
Sigma-Aldrich. 
4.4.2 Synthesis of activated ester containing monomers and polymers 
4.4.2.1 Synthesis of methacrylate monomer of 2-hydroxyethyl disulfide  
 
 4 g (26 mmol, 1 equiv) of 2-hydroxyethyl disulfide was weighed in a 250 mL 
round-bottom flask and was dissolved in 75 mL dry THF. 5.4 mL (3.9 g, 39 mmol, 1.5 
equiv) of triethylamine was added to the solution and stirred for 5 min. The mixture was 
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cooled in ice bath for 10 min. 2.5 mL (26 mmol, 1 equiv) of methacryloyl chloride 
dissolved in 75 mL DCM was added to the reaction flask through a dropping funnel over 
a period of 30 min. After complete addition, the ice bath was removed, and the reaction 
was continued for another 12 h under argon. After that the solvent was evaporated in a 
rotary evaporator. The reaction mixture was dissolved in ethyl acetate (50 mL), washed 
with distilled water (3×50 mL), saturated NaCl solution (1×50 mL) and finally dried over 
Na2SO4. The organic layer was collected and purified by flash column chromatography 
using hexane/ethyl acetate (75:25 v/v). Yield: 76%. 1H NMR (400 MHz, CDCl3) (δ ppm):  
6.13-6.14 (dd, 1H), 5.59-5.6 (t, 1H), 4.41-4.43 (t, 2H), 3.87-3.91 (q, 2H), 2.96-2.99 (t, 2H), 
2.87-2.90 (t, 2H), 2.06-2.09 (t, 1H), 1.95 (t, 3H). 13C NMR (100 MHz, CDCl3) (δ ppm): 
167.24, 136.02, 126.11, 62.61, 60.20, 41.69, 36.99, 18.29. ESI-MS (m/z) for C8H14O3S2 
expected [M]+: 222.04, obtained: [M+Na]+: 245.02.   
4.4.2.2 General synthesis of methacrylate activated ester monomers  
 In a typical procedure, 500 mg (2.25 mmol, 3 equiv) of 2-hydroxylethyl disulfide 
methacrylate was taken in a 20 mL glass vial and dissolved in 7.5 mL of dry THF. 275 mg 
(2.25 mmol, 3 equiv) of 4-dimethylaminopyridine (DMAP) was added to the solution and 
stirred for 10 min to dissolve. The reaction vial was stoppered and purged with argon. 227 
mg (0.75 mmol, 1 equiv, purity: 98%) of triphosgene dissolved in 5 mL of dry THF was 
added to the vial in a dropwise manner. The reaction was stirred for 5 h. After that 
calculated amount of DMAP (see specific examples below) was added to the vial. Finally, 
phenols/alcohols for corresponding activated esters were added (dissolved in 2.5 mL dry 
THF, see specific examples below) to the reaction mixture dropwise and stirred for 12 h. 
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The reaction mixture was filtered to remove the salt, THF was dried in a rotary evaporator 
and the mixture was purified with column chromatography (DCM: hexane 90:10). 
Nitrophenyl carbonate methacrylate monomer (NPC-monomer):  
 
 Amount of chemicals used as par the general synthetic procedure described above: 
4-nitrophenol: 344 mg (2.47 mmol) and DMAP: 302 mg (2.47 mmol), Yield: 56%. 1H 
NMR (400 MHz, CDCl3) (δ ppm): 8.27-8.30 (m, 2H), 7.26-7.41 (m, 2H), 6.13-6.14 (dd, 
1H), 5.59-5.60 (t, 1H), 4.53-4.57 (t, 2H), 4.42-4.45 (t, 2H), 3.00-3.06 (m, 4H), 1.94-1.95 
(dd, 3H).  13C NMR (100 MHz, CDCl3) (δ ppm):167.13, 155.40, 152.32, 145.50, 135.99, 
126.10, 125.35, 121.79, 66.79, 62.46, 37.23, 36.81, 18.29. ESI-MS (m/z) for C15H11NO7S2 
expected [M]+: 387.04, obtained: [M+Na]+: 410.03.    
Pentafluorophenyl carbonate methacrylate monomer (PFP-monomer):  
 
 Amount of chemicals used as par the general synthetic procedure described above: 
Pentafluorophenol (PFP): 455 mg (2.47 mmol), and DMAP: 302 mg (2.47 mmol), Yield: 
49%. 1H NMR (400 MHz, CDCl3) (δ ppm): 6.13-6.14 (d, 1H), 5.59-5.60 (m, 1H), 4.56-
4.60 (td, 2H), 4.41-4.45 (td, 2H), 2.99-3.06 (ddd, 4H), 1.95-1.96 (d, 3H). 13C NMR (100 
MHz, CDCl3) (δ ppm): 167.13, 151.14, 142.46, 141.14, 140.12, 138.61, 136.65, 136.00, 
126.11, 126.08, 68.03, 62.76, 62.40, 42.20, 40.44, 37.41, 37.33, 37.16, 36.46, 30.94, 30.64, 
29.71, 25.48, 24.79,18.30, 18.27. 19F NMR (376 MHz, CDCl3) (δ ppm): -152.84-152.79, -
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156.94-156.83, -161.63-161.51. ESI-MS (m/z) for C15H13F5O5S2 expected [M]+: 432.01, 
obtained: [M+Na]+: 455.00. 
Trichlorophenyl carbonate methacrylate monomer (TCL-monomer): 
 
 Amount of chemicals used as par the general synthetic procedure described above: 
2,4,5-trichlorophenol: 488 mg (2.47 mmol) and DMAP: 302 mg (2.47 mmol), Yield: 89%. 
1H NMR (400 MHz, CDCl3) (δ ppm): 7.56 (s, 1H), 7.4 (s, 1H), 6.13-6.14 (dd, 1H), 5.59-
5.60 (t, 1H), 4.53-4.56 (t, 2H), (4.41-4.43 (t, 2H), 2.99-3.05 (dt, 4H), 1.95 (dd, 3H). 13C 
NMR (100 MHz, CDCl3) (δ ppm): 167.12, 151.91, 145.78, 135.99, 131.64, 131.21, 131.09, 
126.09, 124.91, 67.16, 62.46, 37.28, 36.70, 18.29. ESI-MS (m/z) for C15H15Cl3O5S2 
expected [M]+: 445.75, obtained: [M+Na]+: 468.93.   
Hexafluoropropanol carbonate methacrylate monomer (CF3-monomer):  
 
 Amount of chemicals used as par the general synthetic procedure described above: 
1,1,1,3,3,3-hexafluoro-2-propanol: 415 mg (2.47 mmol) and DMAP: 302 mg (2.47 mmol), 
Yield: 48%. 1H NMR (400 MHz, CDCl3) (δ ppm): 6.13-6.14 (dq, 1H), 5.60 (q, 1H), 5.53-
5.60 (m, 1H), 4.52-4.56 (t, 2H), 4.40-4.43 (t, 2H), 2.97-3.02 (td, 4H), 1.95-1.96 (dd, 3H). 
13C NMR (100 MHz, CDCl3) (δ ppm): 167.13, 152.70, 136.00, 126.08, 121.57, 118.76, 
71.10, 70.75, 70.41, 70.06, 69.71, 67.97, 62.38, 37.31, 36.39, 18.26. 19F NMR (376 MHz, 
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CDCl3) (δ ppm): -73.49. ESI-MS (m/z) for C12H14F6Cl3O5S2 expected [M]+: 416.02, 
obtained: [M+Na]+: 439.01.   
Dimethylamino carbonate methacrylate monomer (NMe2-monomer):  
 
 Amount of chemicals used as par the general synthetic procedure described above- 
4-(Dimethylamino)phenol: 429 mg (2.47 mmol) and DMAP: 302 mg (2.47 mmol), Yield: 
53%. 1H NMR (400 MHz, DMSO-d6) (δ ppm): 7.01-7.03 (d, 2H), 6.70-6.72 (d, 2H), 6.05-
6.06 (dd, 1H), 5.70-5.71 (t, 1H), 4.32-4.41 (m, 4H), 3.04-3.09 (m, 4H), 2.88 (s, 6H), 1.88-
1.89 (d, 3H). 13C NMR (100 MHz, DMSO-d6) (δ ppm): 166.84, 166.82, 154.03, 149.13, 
141.93, 136.13, 126.61, 126.58, 121.84, 113.16, 66.27, 65.77, 62.68, 62.65, 40.90, 40.68, 
40.63, 40.42, 40.21, 40.01, 36.81, 36.74, 36.73, 18.43, 18.40. ESI-MS (m/z) for 
C17H23NO5S2 expected [M]+: 385.1, obtained: [M+Na]+: 408.09.   
4.4.2.3 General synthesis of random copolymers 
 PEGMA, methacrylate activated ester monomer, 4-Cyano-4-
[(dodecylsulfanylthiocarbonyl)sulfanyl] pentanoic acid (RAFT agent) were weighed in a 4 
mL glass vial (amount of reagents taken are listed below) and dissolved in 200 μL dioxane. 
Next, AIBN solution in dioxane was added to this solution. Total volume of solvent 
(dioxane) was 0.3 mL. To prepare for polymerization, the glass vial was purged with argon 
and stoppered. After that, the vial was subjected to four freeze-pump-thaw cycles, sealed 
completely and transferred to an oil bath preheated at 80 °C. The polymerization was 
continued for 48 h and then quenched by cooling down with cold water. The solvent was 
evaporated, and the product was first precipitated in hexane. The final product was 
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collected after redissolving in DCM and precipitating in diethyl ether two times. Finally, 
the polymer was dried overnight under high vacuum.  
NPC polymer:  
 
Amount of chemicals used as par the general synthetic 
procedure described above: PEGMA: 258 mg (0.52 mmol), 
NPC monomer: 50 mg (0.13 mmol), RAFT: 4.1 mg (0.0102 
mmol), AIBN: 0.34 mg (0.0021 mmol). Yield: 88%. GPC 
(THF), Mn: 21 kDa, Đ: 1.3. 1H NMR (400 MHz, CDCl3) (δ 
ppm): 8.30, 8.28, 7.44, 7.42, 7.41, 4.57, 4.55, 4.54, 4.22, 4.07, 3.65, 3.64, 3.61, 3.55, 3.54, 
3.54, 3.53, 3.37, 3.06, 3.04, 2.95, 1.94, 1.82, 1.01, 0.88, 0.87, 0.85. 13C NMR (100 MHz, 
CDCl3) (δ ppm): 155.46, 152.30, 145.50, 125.41, 121.97, 71.95, 70.62, 70.58, 70.54, 68.60, 
68.47, 66.83, 59.05, 36.65, 31.91, 29.65, 29.34, 22.69, 14.15. From 1H NMR, the molar 
ratio of the repeating units was determined by integrating the methylene protons next to 
the methacrylate ester groups in the activated carbonate and PEG monomeric units (x:y ≈ 
0.2:0.8). 
PFP polymer:  
Amount of chemicals used as par the general synthetic 
procedure described above: PEGMA: 232 mg (0.46 mmol), 
PFP monomer: 50 mg (0.12 mmol), RAFT: 3.7 mg (0.0092 
mmol), AIBN: 0.30 mg (0.0018 mmol). Yield: 96%. GPC 
(THF), Mn: 22 kDa, Đ: 1.2. 1H NMR (400 MHz, CDCl3) (δ 
ppm): 4.60, 4.58, 4.23, 4.22, 4.08, 3.81, 3.71, 3.67, 3.67, 3.65, 3.64, 3.64, 3.63, 3.62, 3.59, 


















3.55, 3.55, 3.54, 3.53, 3.37, 3.06, 2.95, 1.87, 1.76, 1.25, 1.02, 0.89, 0.87, 0.86, 0.86. 13C 
NMR (100 MHz, CDCl3) (δ ppm): 177.25, 151.22, 72.08, 70.75, 70.72, 70.67, 70.58, 
68.73, 68.60, 68.27, 63.94, 59.17, 45.29, 44.99, 36.48. 19F NMR (376 MHz, CDCl3) (δ 
ppm): -152.96, -157.12, -161.74. From 1H NMR, the molar ratio of the repeating units was 
determined by integrating the methylene protons next to the methacrylate ester groups in 
the activated carbonate and PEG monomeric units (x:y ≈ 0.2:0.8). 
TCL polymer:  
Amount of chemicals used as par the general synthetic 
procedure described above: PEGMA: 224 mg (0.45 mmol), 
TCL monomer: 50 mg (0.11 mmol), RAFT: 3.6 mg (0.0089 
mmol), AIBN: 0.29 mg (0.0018 mmol). Yield: 91%. GPC 
(THF), Mn: 22 kDa, Đ: 1.3. 1H NMR (400 MHz, CDCl3) (δ 
ppm): 7.60, 7.46, 7.44, 4.57, 4.56, 4.54, 4.23, 4.23, 4.08, 
3.67, 3.66, 3.65, 3.65, 3.63, 3.62, 3.56, 3.55, 3.55, 3.54, 3.38, 3.06, 2.95, 1.82, 1.81, 1.26, 
1.02, 0.89, 0.88, 0.88, 0.86, 0.85. 13C NMR (100 MHz, CDCl3) (δ ppm): 152.00, 145.98, 
131.72, 131.36, 131.14, 126.24, 125.16, 72.08, 70.75, 70.71, 70.66, 68.73, 68.60, 67.35, 
59.17, 36.69, 32.04, 29.76, 22.82. From 1H NMR, the molar ratio of the repeating units 
was determined by integrating the methylene protons next to the methacrylate ester groups 
in the activated carbonate and PEG monomeric units (x:y ≈ 0.2:0.8). 





















Amount of chemicals used as par the general synthetic 
procedure described above: PEGMA: 240 mg (0.48 mmol), 
NPC monomer: 50 mg (0.12 mmol), RAFT: 3.8 mg (0.0095 
mmol), AIBN: 0.31 mg (0.0019 mmol). Yield: 84%. GPC 
(THF), Mn: 28 kDa, Đ: 1.2. 1H NMR (400 MHz, CDCl3) (δ 
ppm): 5.66, 4.57, 4.21, 4.08, 3.65, 3.65, 3.38, 1.89, 1.79, 1.59, 1.26, 1.02, 0.88, 0.86. 13C 
NMR (100 MHz, CDCl3) (δ ppm): 71.95, 70.61, 70.58, 70.53, 68.47, 68.06, 63.81, 59.04, 
44.85, 30.94. 19F NMR (376 MHz, CDCl3) (δ ppm): -73.33. From 1H NMR, the molar ratio 
of the repeating units was determined by integrating the methylene protons next to the 
methacrylate ester groups in the activated carbonate and PEG monomeric units (x:y ≈ 
0.2:0.8). 
NMe2 polymer:  
Amount of chemicals used as par the general synthetic 
procedure described above: PEGMA: 259 mg (0.52 mmol), 
NPC monomer: 50 mg (0.13 mmol), RAFT: 4.2 mg (0.0103 
mmol), AIBN: 0.34 mg (0.0021 mmol). Yield: 95%. GPC 
(THF), Mn: 31 kDa, Đ: 1.2. 1H NMR (500 MHz, DMSO-d6) 
δ 7.06, 7.04, 6.75, 6.73, 4.45, 4.20, 4.05, 3.64, 3.46, 3.28, 
3.11, 3.03, 2.92, 1.83, 1.28, 1.19, 0.99, 0.89, 0.84. 13C NMR (100 MHz, DMSO-d6) (δ 
ppm): 152.90, 147.98, 140.86, 120.67, 111.98, 70.69, 69.20, 69.01, 65.22, 57.43. From 1H 
NMR, the molar ratio of the repeating units was determined by integrating the methylene 


















protons next to the methacrylate ester groups in the activated carbonate and PEG 
monomeric units (x:y ≈ 0.2:0.8). 
NMe3 polymer:  
 
Scheme 4.1 Methylation of NMe2-polymer to form NMe3-polymer 
 For methylation reaction, NMe2 polymer (25 mg, 0.0524 mmol) was first weighed 
in a 1.5 mL glass vial and dissolved in 400 μL DCM. Next, 296 mg (130 μL, 2.1 mmol) of 
methyl iodide was added dropwise to the solution. After 12 h of reaction, solvent was 
evaporated and the polymer was precipitated in diethyl ether three times. Finally, the 
polymer was dried overnight under high vacuum. Yield: 92%. GPC (TFE), Mn: 32 kDa, Đ: 
1.3. 1H NMR (400 MHz, DMSO-d6) (δ ppm): 8.10, 8.08, 7.58, 7.56, 4.51, 4.19, 4.06, 3.66, 
3.63, 3.56, 3.55, 3.47, 3.47, 3.46, 3.45, 3.40, 3.28, 3.14, 2.68, 2.68, 2.67, 2.56, 2.56, 2.40, 
2.40, 2.40, 1.28, 0.99, 0.89, 0.88, 0.84. 13C NMR (100 MHz, DMSO-d6) (δ ppm): 151.75, 






Scheme 4.2 Synthesis of random copolymers of NHS 
 Co-polymer of PEGMA and hydroxyethylene disulfide, was synthesize based on a 
previously reported procedure (see synthesis of p(PEGMA-co-EDSMA).16 To install the 
NHS carbonate ester group, 300 mg of p(PEGMA-co-EDSMA) polymer was weighed in a 
glass vial and dissolved in 2 mL DMF. Next, 606 mg (2.83 mmol) of proton-sponge (1,8-
Bis(dimethylamino)naphthalene) was added to the solution and stirred for 15 min to 
dissolve. After that, 724 mg (2.83 mmol) N,N′-disuccinimidyl carbonate was added to the 
reaction mixture portion-wise over 15 min. The reaction was stirred for 2 days. The product 
was precipitated with diethyl ether twice and then dialyzed to purify in DCM:MeOH (1:1) 
solvent system. Finally, the polymer was dried overnight under high vacuum. Yield: 92%. 
GPC (THF), Mn: 17 kDa, Đ: 1.2. 
1H NMR (400 MHz, CDCl3) (δ ppm): 4.59, 4.40, 4.22, 3.67, 3.65, 3.65, 3.64, 3.63, 3.62, 
3.56, 3.55, 3.54, 3.53, 3.37, 3.05, 2.96, 2.87, 1.88, 1.78, 1.72, 1.25, 1.02, 0.88, 0.88, 0.85. 
13C NMR (100 MHz, CDCl3) (δ ppm): 168.92, 151.60, 77.48, 72.09, 70.76, 70.72, 70.67, 
68.60, 63.95, 59.18, 45.01, 25.68. From 1H NMR, the molar ratio of the repeating units 
was determined by integrating the methylene protons next to the methacrylate ester groups 
in the activated carbonate and PEG monomeric units (x:y ≈ 0.2:0.8). 
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Scheme 4.3 Kinetics of aminolysis study with small molecule lysine analogue 
 To compare the kinetics of aminolysis vs. hydrolysis for different activated ester 
containing polymers in the context of protein encapsulation, we have studied the reaction 
of a protected small molecule lysine analogue, Nα-Acetyl-L-lysine methyl ester 
hydrochloride (Lys, Sigma), with all reactive carbonate ester polymers. In a typical 
procedure, ~1 mg of polymer was dissolved in 3.5 mL phosphate buffer (100 mM, pH 8.5). 
The solution is transferred to three UV-Vis cuvettes and 10 μL Lys solution (10 mg/mL) 
was added. The cuvettes were sealed, stirred with magnetic stirrers and UV-Vis 
measurements were taken at different time points over a period of 12 h. Only polymer 
solutions in phosphate buffer (100 mM, pH 8.5) without the addition of Lys reagent were 
tested to evaluate the degree of hydrolysis. For NHS and CF3-polymers, 1H NMR 
measurements were performed for kinetics analysis under identical conditions. 
4.4.4 Conjugation of proteins with NPC, PFP and NHS-polymers 
 In a typical process, the self-immolative polymers were dissolved in phosphate 
buffer (100 mM, pH 8.5) to make 10 mg/mL solution. Protein stocks (horseradish 
peroxidase, HRP and cytochrome C, Cyt C) were also prepared at 400 μg/mL concentration 
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(in phosphate buffer, 100 mM, pH 8.5). Finally, 25 μL of protein stock solution was added 
dropwise to a stirred 50 μL of polymer solution. The reaction was continued for 12 h at 
room temperature and subjected to SDS-PAGE analyses. 
4.4.5 SDS-PAGE for protein-polymer conjugation 
 40 μL of protein-polymer conjugates were mixed with 10 μL of gel loading buffer 
(DTT free) and incubated at 95 °C for 5 min. After that, 40 μL of each sample was loaded 
into the acrylamide gel and electrophoresis was continued at constant voltage (130 V) for 
45 min. To study the protein release, protein-polymer conjugate samples were treated with 
10 mM GSH, incubated at 37 ºC for 4 h and subjected to acrylamide gel electrophoresis. 
The amount of released protein from the nanoassembly was estimated via generating a 
standard curve from the known amounts of pure proteins loaded into the gel lanes. All gel 




Figure 4.5 1H NMR spectrum (400 MHz) of methacrylate monomer of 2-hydroxyethyl 



















Figure 4.6. 13C NMR spectrum (100 MHz) of methacrylate monomer of 2-hydroxyethyl 












Figure 4.8. 1H NMR spectrum (400 MHz) of NPC-monomer in CDCl3. 
 



























































Figure 4.14 ESI-MS analysis of PFP-monomer in methanol. 
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HARNESSING ELECTROSTATIC AND COVALENT CONJUGATION 
STRATEGIES FOR EFFICIENT ENCAPSULATION AND INTRACELLULAR 
DELIVERY OF ANTIBODY  
Adapted in parts from the manuscript under review: Dutta, K; Kanjilal, P. Das, R.; 
Thayumanavan, S. “Synergistic Interplay of Covalent and Non-Covalent Interactions in 
Reactive Polymer Nanoassembly Facilitates Intracellular Delivery of Antibodies” 
 
5.1 Introduction 
 Molecular self-assembly, inspired by recognition processes in nature, has formed 
the basis for many functional supramolecular architectures.1 Although these self-
assembled structures are mainly governed by weak non-covalent forces, the co-existence 
of both covalent and non-covalent interactions is also prevalent in many biological 
processes. For example, covalent modifications of histones through acetylation and 
methylation of lysines dictate their electrostatic non-covalent binding interactions with 
negatively charged DNA in the chromatin structure.2 Similarly, in synthetic chemistry the 
concept of dynamic covalent bonds, coupled with non-covalent templating, has been 
utilized to create supramolecular structures and identification of ligands for protein 
targets.3-4 In this article, we report a covalent self-assembly strategy that is templated by 
non-covalent interactions between the host and the guest molecules to address a key 
challenge in achieving robust encapsulation of complex and sensitive biomacromolecules.  
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 Intracellular targeting of “undruggable” proteins is an unresolved challenge that 
impacts many diseases with low life expectancy.5-6 Antibodies, long-standing diagnostic 
candidates in the biologics toolkit, could now serve to address this therapeutic challenge 
as it is possible to produce them at large scale for many protein targets.7-10 Unlike small-
molecule drugs, antibodies present very high specificity to its target antigens, thus offering 
therapeutic benefits with minimal side-effects. Binding to a particular epitope via the Fab 
region of antibody could turn-off the cellular activity of the protein of interest causing 
deactivation of relevant biological signaling pathways. In fact, antibody-based 
therapeutics occupy a large portion of the FDA-approved biologics.8, 11 But, these 
biologics target only the extracellular epitopes. When it comes to intracellular targets, its 
utility has been confined to diagnostics so far and for developing a fundamental 
understanding of a limited number of cellular processes. This is mainly attributed to the 
inability of antibodies to penetrate live cell membrane, owing to their large hydrophilic 
nature and entrapment in endosomal compartment.12 Although conventional strategies, 
such as electroporation and microinjection, are able to traffic antibodies inside cells, they 
are limited because of their poor efficacy and the potential for imparting severe 
cytotoxicity due to cell membrane damage.13  
 Acknowledging the therapeutics need, two key approaches targeting intracellular 
delivery of antibody have been taken: (a) physical encapsulation, and (b) electrostatic 
complexation strategies with the help of peptide, lipid, inorganic and polymer based 
nanoparticles.14-22 However, given the enormous possibility of antibody therapeutics, the 
dearth of literature for intracellular trafficking of functional antibody points to the 
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significant challenges associated with such macromolecular cargo delivery without the 
loss of biological activity.  
In this chapter, we have utilized a down-selected activated carbonate polymer with 
higher degree of aminolysis and low hydrolysis from our previous studies (Chapter 4) and 
further improved the efficacy for protein and antibody encapsulation (Figure 5.1). With 
the help of an electrostatics-aided covalent capture strategy, we demonstrate efficient 
encapsulation of large proteins, such as antibodies. Finally, we investigate the cellular 
trafficking of functional antibodies to probe cytosolic delivery and evaluated their 
biological activities in targeting specific intracellular epitopes (Figure 5.1).  
     
 
Figure 5.1 Schematic representation of an electrostatic-aided covalent self-assembly of 
polymer network using protein (antibody) as the template and its transport into the cytosol 
to deliver the cargo in functional form. 
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5.2 Results and discussion 
5.2.1 Electrostatics-aided covalent self-assembly strategy for the generation of 
polymer-protein nanoassembly 
 In addition to identifying PFP-moiety as the optimal functionality for protein 
conjugation (discussed in Chapter 4), we were interested in tuning the structural features 
further to boost the encapsulation efficacy. Protein surfaces are composed of diverse 
arrays of amino acids with different surface charges and hydrophobicity. Charged residues 
on protein surfaces play an important role in dynamic reversible interactions with other 
biomacromolecules (in protein-protein and protein-antibody complexes).23 For most 
water-soluble proteins, charges are distributed on the surfaces as a patch with an average 
size between 1-2 nm.24 We hypothesized that introducing a negatively charged group in 
the activated ester polymer backbone could help recruit protein near the vicinity of 
polymer via electrostatic interaction with positively charged patches, based on amino acid 
residues such as lysines, arginines and histidines.24-26 We hypothesized that once 
electrostatically drawn to polymer, the proximity-induced reactivity between lysine 
functionalities from the protein and the activated carbonate esters on polymer backbone 
should increase. To test this possibility, we synthesized a random copolymer consisting 
three different monomeric units, bearing PFP carbonate ester, PEG and 3-sulfopropyl 
functionalities with a compositional ratio of 2:6:2 (PAb, Figure 5.2a). Sulfonate moiety, 
having pKa ≈ −0.5,27 would remain as negatively charged at the conjugation of pH 8.5, for 
interactions with positively charged groups on protein surface. To test the effect of mere 
electrostatic interactions in protein conjugation, we also synthesized a control polymer 
consisting PEG and sulfopropyl moieties (SO3-polymer, Figure 5.2a). 
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5.2.2 Polymer-protein nanoassembly formation and characterizations 
 Before pursuing the antibody conjugation, we tested the encapsulation efficacy 
and the subsequent stimulus-mediated release of proteins with the designed random 
copolymer, PAb. Two different proteins of very different molecular weights, HRP (~44 
kDa) and β-gal (~465 kDa, with four subunits of 116.3 kDa), were chosen to form 
Figure 5.2 (a) Design of self-immolative polymer, PAb, for protein and antibody 
conjugation along with control polymers; Polymer-protein nanoassembly 
characterizations: (b, c) Dynamic light scattering measurements; and (d,e) 
Transmission electron microscopy images for NA-HRP and NA-β-gal, 
respectively along with naked proteins, scale bar:  500 nm; (f,g) SDS-PAGE 
analyses under reducing and non-reducing (with GSH) conditions to show 
efficient encapsulation and redox-mediated release with the NA-HRP and NA-β-
gal nanoassemblies, respectively. 
180 
 
polymer-protein nanoassembly. Whereas the ζ potential was measured to be similar to the 
naked protein for NA-HRP (naked HRP: -8 mV; NA-HRP: -9 mV), it was reduced 
significantly in the case of NA-β-gal (naked β-gal:-25 mV; NA-β-gal: -13 mV). Dynamic 
light scattering (DLS) measurements showed uniform distribution of nanoassemblies with 
119 and 162 nm hydrodynamic diameters for NA-HRP and NA-β-gal, respectively 
(Figure 5.2b-c), suggesting efficient shrink-wrapping with polymer network. Further 
analyses with transmission electron microscopy (TEM) revealed discrete nanoassemblies 
with distribution patterns matching with the DLS studies (Figure 5.2d-e). 
 Gel electrophoresis (SDS-PAGE) studies under non-reducing conditions showed 
no protein band, confirming that the proteins are effectively wrapped by the polymer 
(Figure 5.2f-g). Note that the encapsulation efficacies were much higher, ~91% and ~82% 
for HRP and β-gal respectively, for the PAb  polymer, compared to the corresponding PFP-
polymer without the sulfonate moieties (see Chapter 4). Interestingly, control SO3-
polymer without the PFP units also showed negligible protein encapsulation (<10%), 
suggesting that electrostatics alone is not sufficient for efficient encapsulation of proteins 
either. Thus, it is the combination of electrostatic and covalent self-assembly that offer 
efficient wrapping of proteins by the polymer. 
 Next, we investigated whether the nanoassembly can release the proteins in a 
stimuli-responsive manner. The protein bands reappeared in the gel electrophoresis 
studies, when the nanoassembly was run in the gel under reducing conditions (10 mM 
glutathione). This concentration corresponds to the typical intracellular GSH 
concentrations of the cytosol. Retaining the structure and function of the released proteins 
are critical in developing an effective encapsulation strategy. Towards this goal, we first 
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investigated the secondary structure of the released HRP and β-gal from the 
nanoassemblies. Circular dichroism spectra of the released proteins showed no apparent 
changes suggesting conservation of secondary structure of proteins releasing from the 
 
Figure 5.3 (a,b) Circular dichroism spectra of native HRP, NA-HRP and β-gal, NA-
β-gal, respectively; (c,d) Comparison of protein activity for native, encapsulated and 
released HRP and β-gal proteins (Encap and Release: NA-Protein nanoassemblies 
without and with 10 mM GSH treatment, respectively); (e,f) Intracellular uptake of 
rhodamine tagged HRP and β-gal delivered with NA-HRPRhod and NA-β-galRhod 
indicating uniform cellular distribution in HeLa cells, respectively. Scale bar: 20 μm; 
and (g,h) X-gal staining assay showing cytosolic activity of β-gal delivered through 




nanoassembly upon treatment of glutathione (Figure 5.3a-b). Similarly, in vitro activity 
studies of the released proteins revealed that the proteins activities were greatly silenced 
(6% and 5% for HRP and β-gal, respectively; Figure 5.3c-d).28-29 However, upon releasing 
from the shrink-wrapped state, both proteins regained their enzymatic activities (84% and 
87% for HRP and β-gal, respectively). Thus, both structure and functional assays show 
efficacy of the polymer shell in efficiently wrapping the protein and the recovery of 
activity of the protein upon encountering a specific environmental stimulus.  
 Finally, cellular internalization of the protein cargoes was tested for 
nanoassemblies encapsulated with rhodamine-tagged HRP and β-gal via confocal laser 
scanning microscopy (CLSM, Figure 5.3e-f). Uniform red fluorescence in HeLa and 
MDA-MB-231 cell lines suggested that the nanoassemblies were efficiently internalized 
by the cells. Furthermore, we were also interested in investigating whether the delivered 
protein is active, i.e. if the protein was unwrapped to be activated inside the cells. To this 
end, intracellular activity of delivered β-gal was tested using the x-gal assay. Generation 
of intense blue color in the cells, compared to the controls, suggests that the protein was 
not only transported across the cellular membrane to the cytosol, but that it is active inside 
the cells (Figure 5.3g-h).  
5.2.3 Extension of the encapsulation strategy to antibody and cellular delivery 
 Inspired by the results with globular proteins, we tested the ability of these 
polymers to encapsulate and deliver antibodies inside cells. A typical immunoglobulin G 
(IgG) antibody is about ~150 kDa in molecular weight and has ~82 surface lysines. The 
developed encapsulation strategy with activated ester and negatively charged sulfonate 
moieties could provide chemical and electrostatic handles for boosting the encapsulation 
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of a such large antibody. Indeed, we were able to efficiently form polymer-IgG 
nanoassemblies (NA-IgG), as evident from the absence of IgG band (at ~150 kDa) for 
 
Figure 5.4 (a) SDS-PAGE study to show efficient encapsulation of IgG inside the NA-IgG 
nanoassembly indicated by the absence of IgG band; (b) Transmission electron microscopy 
images for NA-IgG, scale bar: 500 nm; and (c) Dynamic light scattering and (d) ζ potential 
measurements for native IgG and NA-IgG nanoassembly; (e) Intracellular uptake of NA-
IgGRhod in HeLa cells, scale bar: 20 μm; (f) Mechanism of cellular uptake for NA-IgGRhod in 
presence and absence of endocytic inhibitors; (g) Endosomal colocalization and escape studies 
after incubation with NA-IgGRhod in HeLa cells at 4 and 24 h (green: lysotracker; red: 
rhodamine B-IgG; blue: nuclear stain, scale bar: 10 μm. 
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NA-IgG samples in the SDS-PAGE analysis (Figure 5.4a). TEM and DLS studies 
revealed monomodal distribution of NA-IgG samples with an average size of 94 nm and 
ζ potential was found to be -12 mV (Figure 5.4b-d).  
 Our ultimate aim is to traffic the antibody for intracellular targeting of specific 
proteins. Prior to delivering a functional antibody, we were interested in testing the 
cellular localization of a fluorophore-labelled antibody. A rhodamine labelled IgG was 
first encapsulated in the polymer nanoassembly (NA-IgGRhod) and delivered in HeLa cells. 
A uniform distribution of red fluorescence, as observed from CLSM studies, confirmed 
the intracellular access of the delivered IgG (Figure 5.4e). When tested with other cell 
lines, the transfection efficacies were found to be as follows: HeLa: 69%, MDA-MB-231: 
80% and EMT6: 91%. Cellular uptake can be governed by various pathways.30 To probe 
the cellular internalization mechanism for our nanoassemblies, we incubated cells with 
different endocytosis pathway inhibitors and checked their influence in cellular uptake of 
nanoparticle via flow cytometry.30-32 As evident from Figure 5.4f, the uptake is governed 
by the clathrin-mediated endocytosis pathway for HeLa cells, since hyperosmolar sucrose 
is a dominant uptake inhibitor. Upon being endocytosed inside the cells, the next 
important step for cytosolic access is to escape from the endosome. Time dependent 
CLSM studies with lysotracker green (an endosome/lysosome marker stain) showed 
colocalization of red (from rhodamine-labelled IgG) and green (lysotracker) channels 
after 4 h of incubation with the NA-IgG (Figure 5.4g).  escape from endosome and 
cytosolic accumulation of IgG after 24 h. Also, high cellular viability for NA-IgG samples 
across three different cell lines suggest that the designed nanoassemblies are non-toxic 
even at a high dosage of 2 mg/mL. 
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5.2.4 Intracellular trafficking of functional antibodies: anti-pAkt and anti-NPC 
antibody 
  In order to test the potential of polymeric nanoassemblies in trafficking antibody 
inside cells, it is critical to show that the antibody is able to recognize the targeted epitope 
inside the cells. To this end, we aimed to test the ability of these nanoassemblies in 
delivering two functional monoclonal antibodies, viz. anti-nuclear pore complex (anti-
Figure 5.5 (a) Schematic of cytosolic delivery for anti-NPC and anti-pAkt antibodies 
in functional forms through the polymer nanoassembly; (b) Immunostained HeLa 
cells after NA-anti-NPC delivery showing highlighted nuclear pore complex 
localized in nuclear membrane, scale: 10 μm; (c) Cellular viability study in MCF-7 
cells after delivery of NA-anti-pAkt showing dose dependent decrease in cell 
survival; (d) Detection of caspase 3/7 in MCF7 cells after NA-anti-pAkt delivery (6 
h) using a green fluorescent dye labelled caspase substrate, scale bar: 20 μm; and (e) 
Western blot analysis showing cleavage of PARP owing to the activation of caspase 
pathway in MCF-7 cells. 
186 
 
NPC) and anti-phospho-Akt (Ser473) antibody (Figure 5.5a). The epitopes for both these 
antibodies are present in the cytosol and thus analyzing these antibodies would also 
confirm the endosomal escape that we observed in our fluorescence microscopy studies. 
When delivered inside cells, anti-NPC antibody bind to the nuclear pore complex located 
on the nuclear membrane.15-16 While naked anti-NPC antibody could not penetrate cellular 
membrane efficiently and failed to locate on the nuclear membrane, NA-anti-NPC could 
traffic the antibody and successfully highlighted the nuclear pore complex of the cells. 
This is evident from the red-colored membrane of the nucleus (stained with a blue dye), 
due to the binding of the anti-NPC antibody (Figure 5.5b).  
 Gratified by this observation, we further tested the intracellular activity with 
another antibody, anti-pAkt. Protein kinase B, also known as Akt, is an intracellular signal 
transduction protein responsible for activation of nuclear factor-κB (NF-κB) and several 
other proteins in the Akt signaling pathway that are responsible for cellular growth.18, 33 It 
inhibits the key apoptotic pathway in many cancer cells and therefore blocking this could 
result in reinstating the apoptosis mechanism.33-34 With this goal in mind, we delivered 
anti-pAkt antibody with our polymer nanoassembly and were gratified to see that the 
cellular viability had reduced in a dose-dependent manner (Figure 5.5c). In addition to 
utilizing viability as an assay, we were also interested in showing that this is indeed due 
to the specific inhibition of the Akt pathway. If these results were indeed due to the 
reactivation of the targeted apoptosis pathway, we should observe the presence of caspase 
3/7 enzymes, one of the key controllers for cellular apoptosis pathways. To this end, we 
examined the presence of caspase 3/7 via immunofluorescence technique. The assay 
utilizes a caspase substrate attached to a nucleic acid binding dye that only fluoresces upon 
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substrate cleavage by active cellular caspases after binding to nuclear DNA. A clear green 
fluorescence from the detection assay localized on cellular nucleus confirmed the 
activation of caspase pathways leading to cellular apoptosis (Figure 5d). To further probe 
the apoptosis process, we studied the cleavage of poly(ADP-ribose) polymerase (PARP) 
protein via intracellularly activated caspases through western blot analyses (Figure 5.5e). 
The apoptotic activation led to cleavage of PARP (~116 kDa) into 89 and 24 kDa 
fragments with the NA-anti-pAkt sample, while naked anti-pAkt control did not show any 
discernible amount of activity. These studies demonstrate the ability of the developed 
polymeric nanoassembly system in delivering antibody cargoes into the cytosol with the 
retention of recognition function.  
5.3 Conclusions  
 In summary, we demonstrated a versatile strategy for encapsulation of large 
proteins and antibody therapeutics using an activated carbonate polymer platform. Based 
on the kinetics studies and previous investigation in protein encapsulation experiments 
(chapter 4), we chose PFP-carbonate as the preferred functionality for further 
development in encapsulating large proteins, such as antibodies. To further boost the 
conjugation efficiency, we engineered the polymer structures with electrostatic handles 
that offered higher degree of encapsulation presumably through proximity-induced 
reactivity enhancement. We show here that the electrostatics-aided covalent encapsulation 
strategy provided a robust platform to (i) capture larger antibody molecules with high 
fidelity that are found difficult to encapsulate otherwise; (ii) protect the structure and 
silence the cargo activity while in encapsulated state; (iii) enable regaining the functional 
activity of the payload upon release by the influence of an intracellular stimulus; (iv) 
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efficiently deliver the encapsulated cargo into the cytosol; and (v) ensure that the desired 
biological functions of the cargo are retained upon intracellular delivery and cytosolic 
release. We believe that the developed polymer nanoassembly system would serve as a 
generalized protein delivery platform, specifically for antibody-based intracellular drug 
targets, which is so far considered as one of the most challenging goals for the 
development of antibody therapeutics.  
5.4 Experimental 
5.4.1 Materials 
 Reagents used for polymerization- polyethylene glycol monomethyl ether 
methacrylate (PEGMA; MW 500), 4-cyano-4-(phenylcarbonothioylthio)pentanoic acid, 
4-Cyano-4-[(dodecylsulfanylthiocarbonyl)sulfanyl] pentanoic acid (chain transfer 
agents), D,L-dithiothreitol (DTT), bis(pentafluorophenyl) carbonate and N,N′-
disuccinimidyl carbonate were also procured from Sigma-Aldrich. 2,2′-azobis-(2-
methylpropionitrile) (AIBN) was purchased from Sigma-Aldrich, USA and purified by 
recrystallization in methanol. All protein samples, e.g., peroxidase from horseradish and 
β-galactosidase were purchased from Sigma-Aldrich. Anti-nuclear pore complex proteins 
antibody (Anti-NPC) and phospho-AKT1 (ser473) recombinant rabbit monoclonal 
antibody (Anti-pAkt) were purchased from abcam and Thermo Fisher Scientific, 
respectively. 
5.4.2 Synthesis of random copolymer consisting pentafluorophenyl carbonate, 




Scheme 5.1 Polymerization reaction scheme for synthesis of PAb polymer 
 PEGMA (180 mg, 0.36 mmol), PFP monomer (50 mg, 0.12 mmol), 3-sulfopropyl 
methacrylate potassium salt (29 mg, 0.12 mmol) and 4-Cyano-4-
(phenylcarbonothioylthio)pentanoic acid (2.3 mg, 0.0083 mmol, RAFT agent) were 
weighed in a 4 mL glass vial and dissolved in 1 mL DMF by stirring for 15 min. AIBN 
solution in DMF was added to this solution. Total volume of solvent (DMF) was 1.2 mL. 
To prepare for polymerization, the glass vial was purged with argon and stoppered. After 
that, the vial was subjected to four freeze-pump-thaw cycles, sealed completely and 
transferred to an oil bath preheated at 80 °C. The polymerization was continued for 48 h 
and then quenched by cooling down with cold water. The solvent was evaporated, the 
product was first precipitated in diethyl ether and purified by extensive dialysis in 
acetone:methanol (1:1). Finally, the polymer was dried overnight under high vacuum. 
Yield: 79%, GPC (TFE), Mn: 38 kDa, Đ: 1.1. From 1H NMR, the molar ratio of the 
repeating units was determined by integrating the methylene protons next to the 
methacrylate ester groups in the activated carbonate, methyl protons of PEG monomeric 
unit and the methylene protons next to the sulfonate group in sulfopropyl units (i:j:k ≈ 
0.2:0.6:0.2). 1H NMR (400 MHz, DMSO-d6) (δ ppm): 4.59, 4.15, 4.01, 3.60, 3.51, 3.45, 
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3.43, 3.43, 3.42, 3.41, 3.33, 3.24, 3.13, 2.99, 2.01, 1.99, 1.75, 1.24, 1.23, 0.95, 0.87, 0.86, 
0.85, 0.85, 0.84, 0.80, 0.80, 0.78. 13C NMR (100 MHz, DMSO-d6) (δ ppm): 149.86, 
139.20, 133.53, 129.24, 127.55, 125.32, 118.12, 114.61, 107.44, 77.28, 70.67, 69.16, 
68.97, 57.43, 47.31, 36.46, 35.15.  19F NMR (376 MHz, DMSO-d6) (δ ppm): -154.01, -
157.47, -162.27. 
 
Figure 5.6 1H NMR spectrum (400 MHz) of PFP-SO3-polymer, PAb in DMSO-d6. 
 
 



























5.4.3 Synthesis of control sulfonate polymer, SO3-polymer 
 
Scheme 5.2 Polymerization reaction scheme for the synthesis of control SO3-polymer 
 PEGMA (750 mg, 1.5 mmol), 3-sulfopropyl methacrylate potassium salt (92 mg, 
0.38 mmol) and 4-Cyano-4-(phenylcarbonothioylthio)pentanoic acid (7.8 mg, 0.028 
mmol, RAFT agent) were weighed in a 20 mL glass vial and dissolved in 2 mL 2,2,2-
trifluoroethanol (TFE) by stirring for 15 min. AIBN solution in TFE was added to this 
solution. Total volume of solvent was 2.5 mL. To prepare for polymerization, the glass 
vial was purged with argon and stoppered. After that, the vial was subjected to four freeze-
pump-thaw cycles, sealed completely and transferred to an oil bath preheated at 70 °C. 
The polymerization was continued for 24 h and then quenched by cooling down with cold 
water. The solvent was evaporated, the product was first precipitated in diethyl ether and 
purified by extensive dialysis in water. Finally, the polymer was lyophilized, and dried 
overnight under high vacuum. Yield: 92%, GPC (TFE), Mn: 28 kDa, Đ: 1.1. From 1H 
NMR, the molar ratio of the repeating units was determined by integrating the methyl 
protons of PEG monomeric units and methylene protons next to the sulfonate group in 
sulfopropyl units (j:k ≈ 0.8:0.2). 1H NMR (400 MHz, D2O) (δ ppm): 4.20, 3.81, 3.72, 3.65, 
3.65, 3.64, 3.63, 3.55, 3.41, 3.40, 2.95, 2.13, 1.95, 1.60, 1.28, 1.10, 0.93. 13C NMR (100 




Figure 5.8 1H NMR spectrum (400 MHz) of SO3-polymer in D2O. 
 
5.4.4 Encapsulation of proteins and antibody with activated ester polymer, PAb 
 
Scheme 5.3 Reaction scheme for covalent protein encapsulation aided by electrostatic 
interactions 
 
 In a typical process, the self-immolative polymer, PAb, was dissolved in phosphate 
buffer (100 mM, pH 8.5) to make 10 mg/mL solution. Protein stocks were also prepared 
in phosphate buffer (100 mM, pH 8.5, [HRP] = 400 μg/mL, [β-gal] and [IgG]= 200 
μg/mL). Finally, 25 μL of protein stock solution was added dropwise to a stirred 50 μL of 
polymer solution. The reaction was continued for 12 h at room temperature. Next, 
calculated amount of (PEO)4-bis-amine was added and stirred for another 12 h for 
crosslinking. Finally, the reaction mixture was dialyzed to purify the nanoassemblies 




















5.4.5 Measurement of DLS and Zeta-potentials 
Dynamic light scattering (DLS) and zeta potential measurements were performed 
using a Malvern Nanozetasizer-ZS instrument. All nanoassemblies and protein samples 
were diluted with PBS (pH 7.4) to adjust final concentration to 1 mg/mL. 
 
Figure 5.9 ζ potential measurements for NA-HRP and NA-β-gal samples along with the 
native proteins.  
 
5.4.6 TEM measurements 
 Bright Field TEM images were captured on a JEOL JEM- 2000FX TEM operating 
at 200kV acceleration voltage. 0.5 uL of prepared Polymer-protein assemblies were drop 
casted on a carbon coated TEM grid and dried overnight at room temperature. The sample 
was subjected to TEM analyses without any additional staining. 
5.4.7 SDS-PAGE for polymer-protein conjugation and release studies 
 40 μL of protein-polymer conjugates were mixed with 10 μL of gel loading buffer 
(DTT free) and incubated at 95 °C for 5 min. After that, 40 μL of each sample was loaded 
into the acrylamide gel and electrophoresis was continued at constant voltage (130 V) for 
45 min. To study the protein release, protein-polymer conjugate samples were treated with 
10 mM GSH, incubated at 37 ºC for 4 h and subjected to acrylamide gel electrophoresis. 




standard curve from the known amounts of pure proteins loaded into the gel lanes. All gel 
image analysis and quantification were performed with Bio-Rad Image LabTM software. 
 
Figure 5.10 SDS-PAGE of control SO3-polymer showing inefficient protein (HRP) 
conjugation. 
 
5.4.8 Activity assays for HRP and β-gal 
 To measure the activity of released proteins from the nanoassembly, polymer-
protein conjugates were treated with 10 mM glutathione (GSH) for 4 h.  
HRP (ABTS assay): 
 The enzymatic activity of HRP and Cyt C can be studied by examining the 
catalytic conversion of 2,2’-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS). 
Proteins with peroxidase activity (e.g., HRP, Cyt C) catalyze the reduction of H2O2 to 
water in presence of ABTS forming oxidized ABTS radical cation which imparts a 
brilliant blue-green color. The kinetics of the activity assay can be studied by monitoring 
the absorbance of the ABTS radical cation at 418 nm. After releasing proteins from the 
nanoassembly, samples were washed with PBS to remove traces of glutathione and other 
byproducts that might interfere with the assay reagent. Test solution was prepared in a 96 
well plate by mixing 2 μL of sample solution with 80 μL H2O2 (25 mM) and 100 μL ABTS 
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(1 mg/mL). Absorbance spectra were recorded using a SpectraMax® iD5 multiplate 
reader at 418 nm for a period of 6 min. 
β-gal (ONPG assay) 
 The activity of released β-gal protein was measured via the β-Gal Assay Kit 
reagent (Thermo Fisher Scientific). β-gal catalyzes the hydrolyses of ortho-nitrophenyl-
β-D-galactopyranoside (ONPG) substrate producing ONP anion with a bright yellow 
color (absorbance 420 nm). Test solution was prepared in a 96 well plate by adding 2 μL 
released protein sample solution, 98 μL PBS buffer and 40 μL ONPG assay reagent. The 
assay kinetics was immediately recorded over 45 min using a SpectraMax® iD5 
multiplate reader at 420 nm. 
 
Figure 5.11 Kinetic plots for activity assay studies with NA-HRP and NA-β-gal samples 
along with naked proteins and controls. Encap and Release: NA-Protein nanoassemblies 
without and with GSH treatment, respectively.  
β-gal (in HeLa cells) 
 To check the cellular activity of the β-gal trafficked inside the cytosol via the 
nanoassemblies, an intracellular activity assay (x-gal assay) was performed. HeLa cells 
were seeded (1×105 cells) in a 24 well tissue culture plate and incubated for 24 h at 37°C 
and 5% CO2 atmosphere to ensure complete adhesion. Next, cells were washed three times 
with PBS buffer and incubated with NA-β-gal nanoassemblies (protein concentration 10 




washed with PBS three times and stained with the Senescence β-Galactosidase Staining 
Kit (Cell Signaling) according to the manufacturer’s protocol. Cell were imaged with a 
light microscope to capture the development of blue color which was indicative of β-gal 
activity delivered inside cells.  
 
 
Figure 5.12 X-gal cellular assay for untreated and treated HeLa cells with polymer, β-gal 
and NA-β-gal showing nanoassembly mediated delivery of β-gal in cells in its active form.  
 
5.4.9 Circular dichroism (CD) spectra measurements 
 Polymer-protein conjugates were incubated with 10 mM glutathione (GSH) for 6 
h to release proteins from the nanoassembly. After that samples were centrifuged in 
Amicon Ultra Centrifugal Filter (MWCO 50 kDa for HRP, MWCO 200 kDa for β-gal) to 
remove residual polymers from the proteins. After that protein samples were concentrated 
in Amicon filters with MWCO 10 kDa and protein concentrations were measured with 
Pierce 660 nm Protein Assay Reagent (Thermo Fisher Scientific). Next, the protein 
samples (200 μL) were transferred to a quartz cuvette (path length: 1 mm) and measured 






5.4.10 Cell culture-general information 
 All cell lines were cultured in 100 mm cell culture petri-dish with Dulbecco’s 
Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12) in a humidified incubator 
with 5% CO2 at 37 °C. DMEM/F12 media was supplemented with 10% fetal bovine serum 
(FBS), 1% L-glutamine and 1% antibiotic-antimycotic (100 units/mL of penicillin, 100 
μg/mL of streptomycin, and 0.25 μg/mL of Amphotericin B). 
5.4.11 Cellular uptake of rhodamine tagged HRP and β-gal  
 HeLa and MDA-MB-231 cells were seeded at 1×105 cells/mL density (1 mL) in 
35 mm glass-bottomed petri-dishes. Cells were cultured for 3 days at 37°C and 5% CO2 
atmosphere to ensure complete adhesion. Next, cells were washed three times with PBS 
buffer and incubated with NA-HRPRhod and NA-β-galRhod nanoassemblies (rhodamine 
conjugated proteins, concentration 10 μg/mL) at 37 °C for 6 h in complete media. 
Afterwards, media was removed, washed with PBS three times and incubated with 
NucBlue™ Live ReadyProbes™ reagent (Thermo Fisher Scientific) in complete media 
for 1 h to stain the cell nucleus. Live cell imaging was performed using Nikon Spectral 
A1+ confocal microscope and images were analyzed with Nikon NIS-Elements 4.0 
software.  
5.4.12 Measurement of DLS and Zeta-potentials for polymer-IgG nanoassembly 
(NA-IgG) 
 Dynamic light scattering (DLS) and zeta potential measurements were performed 
using a Malvern Nanozetasizer-ZS instrument. All nanoassemblies and protein samples 




5.4.13 TEM measurements of NA-IgG  
 Bright Field TEM images were captured on a JEOL JEM- 2000FX TEM operating at 
200kV acceleration voltage. 0.5 uL of prepared Polymer-IgG assemblies were drop casted 
on a carbon coated TEM grid and dried overnight at room temperature. The sample was 
subjected to TEM analyses without any additional staining. 
5.4.14 SDS-PAGE for IgG conjugation and release studies 
 40 μL of protein-polymer conjugates were mixed with 10 μL of gel loading buffer 
(DTT free) and incubated at 95 °C for 5 min. After that, 40 μL of each sample was loaded 
into the acrylamide gel and electrophoresis was continued at constant voltage (130 V) for 
45 min. To study the protein release, protein-polymer conjugate samples were treated with 
10 mM GSH, incubated at 37 ºC for 4 h and subjected to acrylamide gel electrophoresis. 
The amount of released protein from the nanoassembly was estimated via generating a 
standard curve from the known amounts of pure proteins loaded into the gel lanes. All gel 
image analysis and quantification were performed with Bio-Rad Image LabTM software. 
5.4.15 Cellular uptake studies for polymer-IgG nano assembly (NA-IgG)  
 HeLa, MDA-MB-231 and EMT6 cells were seeded at 1×105 cells/mL density (1 
mL) in 35 mm glass-bottomed petri-dishes. Cells were cultured for 3 days at 37°C and 5% 
CO2 incubator to ensure complete adhesion. Next, cells were washed three times with PBS 
buffer and incubated with polymer-IgG nanoassemblies (rhodamine conjugated IgG, 
concentration 10 μg/mL) at 37 °C for 6 h in complete media. Afterwards, media was 
removed, washed with PBS three times and incubated with NucBlue™ Live 
ReadyProbes™ reagent (Thermo Fisher Scientific) in complete media for 1 h to stain the 
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cell nucleus. Live cell imaging was performed using Nikon Spectral A1+ confocal 
microscope and images were analyzed with Nikon NIS-Elements 4.0 software.  
5.4.16 Endocytosis mechanism studies 
 HeLa, MDA-MB-231 and EMT6 cells were seeded at 1.2×105 cells/mL density (1 
mL) in a 24 well tissue culture plate and incubated for 24 h at 37 °C. Afterwards, cells 
were washed with PBS three times and pre-incubated with EIPA (100 μM, macro-
pinocytosis pathway), Nystatin (30 μM, caveolin pathway) and hyper-osmolar sucrose (45 
mM, clathrine pathway) in serum-free media for 1 h at 37°C. Next, media was removed 
and cells were co-incubated for another 1 h in presence of polymer-IgG nanoassemblies 
(with rhodamine conjugated IgG, concentration 10 μg/mL, in 1 mL serum-free media) and 
different inhibitors (concentrations same as above). Untreated and polymer-rhodamine-
IgG treated cells without any inhibitor were used as negative and positive controls, 
respectively. Afterwards, cells were harvested by washing with cold PBS followed by 
trypsinization (0.25% trypsin-EDTA solution) for 5 min. Detached cells were collected in 
Eppendorf tubes, pelleted by centrifugation, washed two times with cold PBS and finally 
re-suspended in 400 μL cold PBS. Samples were immediately analyzed in a BD 
LSRFortessa™ flow cytometer instrument. Data analyses were performed with FlowJo 




Figure 5.13 Studies of cellular uptake mechanism (endocytosis) through flow cytometry 
after NA-IgGRhod incubation in presence and absence of endocytic inhibitors (a) MDA-
MB-231 and (b) EMT6 cell lines. 
 
5.4.17 Endosomal escape study 
 HeLa, MDA-MB-231 and EMT6 cells were seeded at 1×105 cells/mL density (1 
mL) in 35 mm glass-bottomed petri-dishes. Cells were cultured for 3 days at 37°C and 5% 
CO2 incubator to ensure complete adhesion. Next, cells were washed three times with PBS 
buffer and incubated with polymer-IgG nanoassemblies (rhodamine conjugated IgG, 
concentration 10 μg/mL) at 37 °C for 4 h in complete media. To study the endosomal 
escape, one set of samples was subjected to endosomal staining with Lysotracker Green 
(Thermo Fisher Scientific) for confocal microscopy. The other set was further incubated 
in complete media for 24 h before subjecting to endosome staining and confocal 
microscopy. Cell nucleus was stained with NucBlue™ Live ReadyProbes™ reagent 
(Thermo Fisher Scientific) and live cell imaging was performed using Nikon Spectral A1+ 
confocal microscope. All images were analyzed with Nikon NIS-Elements 4.0 software. 
5.4.18 Cell viability with alamarBlue® assay 
 HeLa, MDA-MB-231 and EMT6 cells were seeded in a 96 well tissue culture plate 




cells were treated with polymer-antibody conjugates and empty crosslinked polymers at 
different concentrations. Samples were incubated for another 24 h at 37 °C. Next, media 
was removed, cells were washed with PBS and were treated with 100 μL 10% alamarBlue 
in complete media. The well plate was incubated for 1 h at 37 °C. Finally, the reagent was 
transferred to a black 96 well flat-bottomed plate and subjected to fluorescence 
measurement in a SpectraMax® iD5 microplate reader (excitation/emission: 560/590 
nm). 
 
Figure 5.14 Cytotoxicity studies in HeLa, MDA-MB-231 and EMT6 cells after 
incubation with only polymer and NA-IgG complexes, respectively. 
 
5.4.19 Intracellular delivery of anti-NPC antibody 
 1×105 HeLa cells were plated in a 35 mm glass-bottom tissue culture plate and 
incubated at 37 °C-5% CO2 atmosphere for 24 h. After that media was removed and cells 
were transfected with polymer-antibody (Anti-NPC) conjugate (Anti-NPC concentration 
20 μg/mL) and naked Anti-NPC antibody for 24 h in complete media. After that, media 
was removed and cells were washed with PBS three times. 4% paraformaldehyde 





















were washed again two times with PBS and permeabilized with permeabilization buffer 
(1 mL, Biotium) for 10 min at room temperature. Next, cells were washed two times with 
PBS and blocked with 2% BSA solution for 1 h. After washing once with PBS, cells were 
incubated with secondary antibody (Anti-Mouse IgG H&L, Alexa Fluor® 647 
conjugated, abcam) and nuclear stain (NucBlue™ Live ReadyProbes™ reagent, Thermo 
Fisher Scientific) for 1 h at room temperature. Finally, cells were washed two times with 
PBS and subjected to confocal laser scanning microscopy using Nikon Spectral A1+ 
confocal microscope. All images were analyzed with Nikon NIS-Elements 4.0 software. 
 
Figure 5.15 (a) Additional images for NA-anti-NPC nanoassembly treated HeLa cells 
showing staining of nuclear pore complex in red; and (b) Naked Anti-NPC antibody 
treated HeLa cells showing no apparent nuclear pore complex staining. Scale bar: 10 μm. 
 
5.4.20 Cellular viability after delivery of pAkt antibody 
 MCF-7 cells were seeded in a 96 well tissue culture plate (7500 cells/100 μL) and 
incubated for 24 h at 37 °C. After that, media was replaced, and cells were treated with 
polymer-pAkt antibody conjugates, empty crosslinked polymers, and pAkt antibody and 
polymer-igG antibody conjugates at different concentrations. Further, cells were 
incubated for 24 h at 37 °C. Afterwards, media was removed, cells were washed with PBS 
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and treated with 100 μL 10% alamarBlue in complete media. The well plate was incubated 
for 1 h at 37 °C. Finally, the reagent was transferred to a black 96 well flat-bottomed plate 
and subjected to fluorescence measurement in a SpectraMax® iD5 microplate reader 
(excitation/emission: 560/590 nm). 
5.4.21 Study of apoptosis with polymer-antibody nanoassembly 
 1×105 MCF-7 cells were plated in a 24 well tissue culture plate and incubated at 
37 °C-5% CO2 atmosphere for 24 h. After that media was removed and cells were 
transfected with polymer-antibody (pAkt) conjugate (pAkt concentration 10 μg/mL), 
empty crosslinked polymer and naked pAkt antibody for 6 h in complete media. After that 
media was replaced and cells were treated with CellEvent™ Caspase-3/7 Green Detection 
Reagent (based on the manufacturer’s protocol) to identify apoptotic cells.  
 
 
Figure 5.16 Detection of caspase 3/7 for untreated and only crosslinked polymer treated 
MCF-7 cells. No green fluorescence was observed indicating absence of any apoptosis 
pathway. Scale bar: 10 μm. 
 
5.4.22 Western blot analysis for detection of PARP cleavage via activation of 
apoptosis 
 2×105 MCF-7 cells were plated in a 6 well tissue culture plate and incubated at 37 
°C-5% CO2 atmosphere for 24 h. After that media was removed and cells were transfected 
with polymer-antibody (pAkt) conjugate (pAkt concentration 10 and 20 μg/mL), empty 
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crosslinked polymer and naked pAkt antibody for 24 h in complete media. Positive control 
samples were transfected with staurosporine (at 1 and 2 μM concentrations) and incubated 
for 24 h. After transfection, media was removed, and cells were washed with ice cold PBS 
two times to prepare for isolation of total protein. Next, cells were scraped to remove from 
the plate, transferred with cold PBS in an eppendorf tube and centrifuged to pelletize. Two 
cold PBS washings were performed to remove any proteins from media. Next, RIPA lysis 
buffer (Thermo Fisher Scientific) containing protease/phosphatase inhibitor mix (Cell 
Signaling) was added to the centrifuge tubes containing cell pellets and incubated for 15 
min at room temperature. To ensure complete lysis, tubes were sonicated (3×30 s) and 
incubated at room temperature for another 15 min. Finally, lysed cells were centrifuged at 
14000 rpm at 4 °C for 30 min and collected the soluble protein fraction from the 
supernatant. The protein content was quantified with BCA assay. Western blot analysis 
was performed to quantify the amount of PARP and its cleavage due to activation of 
caspase enzymes. Target proteins and loading control were detected with rabbit 
monoclonal antibodies (PARP & β-Actin mAbs, Cell Signaling). AP-linked anti-rabbit 
IgG was used as secondary antibody and proteins bands were detected via chromogenic 
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SUMMARY AND FUTURE DIRECTIONS 
6.1. Summary of the dissertation 
 Biologics are considered to be a safer therapeutic option that can not only minimize 
toxicity and off-target effects of small molecule drugs, but those can also drug many 
‘undruggable’ targets. However, due to hydrophilicity and fragile nature of the biologic 
drugs, it is difficult to achieve efficient intracellular trafficking of those with retention of 
structural properties and functional attributes. Acknowledging the challenges, this 
dissertation discusses design strategies of stimuli-responsive polymeric delivery systems 
for the encapsulation of biologics. 
 In chapter 1, we have discussed the opportunities of biologic drugs and challenges 
associated with their intracellular delivery. Next, we describe specific hurdles associated 
with three kinds of biomacromolecules, viz., protein, nucleic acid and antibody, and state 
of the art techniques to address those. By highlighting the promises and pitfalls, we have 
established the benefits of such existing methodologies as well as the need for new 
molecular designs to address the drawbacks. 
 To this end, in chapter 2, we have introduced the design of a self-immolative 
polymer, containing activated carbonate and disulfide linkages, for covalent conjugation 
of proteins through their surface exposed lysines. The polymer-protein nanoassemblies are 
not only able to encapsulate proteins, but those can also efficiently protect the sensitive 




of reducing environment. Further, cellular studies have revealed the efficient tracking of 
proteins into the cytosol with retention of their biological activities. 
 As nucleic acids are highly negatively charged, a non-covalent self-assembly 
strategy is employed in chapter 3 comprising protein, siRNA and zwitterionic lipids acting 
symbiotically to form a stable self-assembled structure guided by electrostatic and 
hydrophobic interactions. While a synthetic cationic polymer is designed to 
electrostatically complex siRNA, we hypothesize to employ a crosslinking reaction in the 
second step to neutralize the cationic charge without any loss of siRNA from the 
nanoassembly. We have utilized these Lipid-siRNA-Polymer (L-siP) nanoassemblies to 
deliver multiple siRNAs and have assessed their efficacies in silencing multiple target 
genes. 
 In chapter 4, we have studied the structure-property relationship to improve the 
efficacy of our previously designed polymer for protein delivery, as discussed in chapter 
2. By studying a series of activated carbonate polymers for reactivity and protein 
conjugation efficiency, we have identified a candidate that shows significantly higher 
aminolysis with lysines of protein compared to undesired competitive hydrolysis. In 
chapter 5, the down-selected activated carbonate containing polymer is structurally tuned 
further to boost conjugation efficiency with larger proteins. By employing an electrostatics-
aided covalent conjugation strategy, we have showed efficient encapsulation and redox-
triggered cytosolic delivery of proteins with retention of cellular activity. We have 
extended the strategy for encapsulation of antibody drugs and have shown successful 
cytosolic delivery to recognize the target epitopes that resulted in the perturbation of 




6.2. Future directions 
6.2.1. Self-immolative ‘pro-drug’ strategy for antibody-drug-polymer conjugates 
 The ultimate goal of drug delivery is to package and transport drug without leakage 
and degradation en route to its target site. However, delivery of hydrophobic drug is 
challenging due to the aqueous insolubility, short half-life and spill-off from the delivery 
vehicles. A pro-drug concept, where the actual drug is generated in situ after getting 
released from a covalently attached molecule or delivery vehicle, can be beneficial to 
address these issues.  
 To this end, we hypothesize a covalent self-assembly strategy to encapsulate a 
suitable hydrophobic drug within a crosslinked polymer network. The self-immolative 
polymer platform that we have developed for encapsulation of protein and antibody could  
Scheme 6.1 A pro-drug approach for encapsulation of hydrophobic drug having a 
nucleophilic reactive handle for attachment with the polymer and its extension in anti-





be utilized to encapsulate and release the drug on demand with the help of redox stimulus 
(Scheme 6.1). Furthermore, this polymeric nanoparticle can also be decorated with an 
antibody for targeting purposes. The drug loading capacity can be desirably tuned with this 
approach which, in turn, can address the current bottleneck of antibody-drug conjugates 
(ADC) suffering from lower antibody drug ratio (ADR).  
 
6.2.2. Tuning HLB of host-guest assemblies for enhancing encapsulation efficiency 
 Designing a universal molecular container that can encapsulate small molecule 
actives with a wide range of logP values is one of the most challenging objectives with 
significant academic and industrial importance. If achieved, it can create enormous 
opportunities in formulation development across many technological sectors. 
 
Scheme 6.2 Modulation of hydrophilic-lipophilic balance to generate stable nanoparticles 





Inspired by previous studies from our lab and ongoing research activities, we hypothesize 
to create polymeric nanogel systems with tunable hydrophilic-lipophilic balance (HLB) 
that will be able to predictively capture small molecule actives, e.g., therapeutic drugs, 
actives for home and personal care (skin care products, detergents and beverages) and 
agricultural crop protection (herbicide,  fungicide and insecticide) formulations.  
 To this end, the homo, random and block copolymer based nanogel systems, 
developed in our lab, can be further optimized. Based on our previous observations with 
polymer nanogel based encapsulation approaches, we hypothesize that both 
microenvironmental and bulk hydrophobicity of the nanogels affect the encapsulation of 
molecules with varying logP. To test this, we can create polymer nanogels with systematic 
variation of amphiphilicity by choosing appropriate crosslinker. For example, a 
homopolymer nanogel system can be stabilized in aqueous media via crosslinking with an 
oligoethylene glycol based crosslinker (see Scheme 6.2 for details). Thus, by choosing an 
appropriate combination of polymer (homopolymer, random or block copolymer) and 
crosslinker (with varying hydrophobicity, e.g., PEG, aromatic, alkyl dithiols) systems, it 
might be possible to capture actives with a wide range of logP and stabilize in the 
crosslinked nanogels. A fundamental study, such as this, might help to design custom-made 
nanogels with high encapsulation efficacy.      
 
6.2.3. AND-gated approach for nucleic acid delivery based on ‘L-siP’ strategy 
 Delivery of therapeutics to specific diseased cells requires the drug encapsulated 
vehicle to cross several barriers before it is delivered to the actual place of action of the 




gateways in the complex biological milieu. Thus, it is often difficult to design a unique 
delivery strategy that can adapt the ongoing changes throughout the course of journey of 
the drug delivery vehicle. This can be addressed via incorporating a stimuli-responsive unit 
that can response to a specific environmental cue to release the encapsulated drug on target 
site. However, due to differential physiological conditions in the delivery pathway, a better 
strategy could be to engineer a delivery vehicle responsive towards dual stimuli where the 
resulting response from each stimulus would synergize to facilitate the desired therapeutic 
action.  
 Building on the symbiotic self-assembly strategy discussed in chapter 3, we 
hypothesize the design of a 2nd generation ‘L-siP’ nanoassembly with built-in ‘AND’ gated  
 






stimuli-responsive units, wherein two stimuli incorporated in the polymer and lipid 
structures will be sequentially processed to release the nucleic acid cargo. To this end, a 
pH responsive unit can be incorporated in the lipid structure and a redox-responsive unit 
will be present in the polymer backbone (Scheme 6.3). In the final tri-component self-
assembled nanostructure, both pH and redox-stimuli-responsive units are needed to be 
processed for an efficient cargo release. In addition, the initial electrostatic complexation 
efficacy between the polymer and the nucleic acid can also be tested with different cationic 
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